US20240025982A1 - Map kinase pathway targets for the treatment of marfan syndrome - Google Patents
Map kinase pathway targets for the treatment of marfan syndrome Download PDFInfo
- Publication number
- US20240025982A1 US20240025982A1 US18/202,066 US202318202066A US2024025982A1 US 20240025982 A1 US20240025982 A1 US 20240025982A1 US 202318202066 A US202318202066 A US 202318202066A US 2024025982 A1 US2024025982 A1 US 2024025982A1
- Authority
- US
- United States
- Prior art keywords
- mfs
- mice
- disease
- map2k6
- mmp17
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001826 Marfan syndrome Diseases 0.000 title claims abstract description 191
- 230000037361 pathway Effects 0.000 title claims description 73
- 238000011282 treatment Methods 0.000 title abstract description 24
- 108091000080 Phosphotransferase Proteins 0.000 title description 17
- 102000020233 phosphotransferase Human genes 0.000 title description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 109
- 201000010099 disease Diseases 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 57
- 208000035475 disorder Diseases 0.000 claims abstract description 39
- 108091054455 MAP kinase family Proteins 0.000 claims description 105
- 102000043136 MAP kinase family Human genes 0.000 claims description 103
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 102100033060 Mitogen-activated protein kinase kinase kinase 4 Human genes 0.000 claims description 65
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 claims description 64
- 239000003795 chemical substances by application Substances 0.000 claims description 62
- 230000000694 effects Effects 0.000 claims description 61
- 239000003112 inhibitor Substances 0.000 claims description 59
- 101001018147 Homo sapiens Mitogen-activated protein kinase kinase kinase 4 Proteins 0.000 claims description 58
- 230000011664 signaling Effects 0.000 claims description 58
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 claims description 55
- 102100030219 Matrix metalloproteinase-17 Human genes 0.000 claims description 54
- 101001011887 Homo sapiens Matrix metalloproteinase-17 Proteins 0.000 claims description 51
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 51
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 51
- 150000003384 small molecules Chemical class 0.000 claims description 20
- 208000007474 aortic aneurysm Diseases 0.000 claims description 13
- 206010014561 Emphysema Diseases 0.000 claims description 9
- 206010002329 Aneurysm Diseases 0.000 claims description 8
- GHVMTHKJUAOZJP-CGTJXYLNSA-N GI254023X Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@@H]([C@H](C)N(O)C=O)CCCC1=CC=CC=C1 GHVMTHKJUAOZJP-CGTJXYLNSA-N 0.000 claims description 6
- CVZIHNYAZLXRRS-HNNXBMFYSA-N (3s)-4-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-n-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)N1[C@@H](C(=O)NO)C(C)(C)SCC1 CVZIHNYAZLXRRS-HNNXBMFYSA-N 0.000 claims description 5
- FARMEEAGJWMFSZ-UHFFFAOYSA-N N-[2-[4-[[2-[(hydroxyamino)-oxomethyl]-4,6-dimethylphenyl]-(phenylmethyl)sulfamoyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound ONC(=O)C1=CC(C)=CC(C)=C1N(S(=O)(=O)C=1C=CC(OCCNC(=O)C=2OC3=CC=CC=C3C=2)=CC=1)CC1=CC=CC=C1 FARMEEAGJWMFSZ-UHFFFAOYSA-N 0.000 claims description 5
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 claims description 5
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 claims description 5
- 229950001858 batimastat Drugs 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 25
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 129
- 150000007523 nucleic acids Chemical class 0.000 description 48
- 150000001875 compounds Chemical class 0.000 description 46
- 230000004913 activation Effects 0.000 description 37
- 102000039446 nucleic acids Human genes 0.000 description 37
- 108020004707 nucleic acids Proteins 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 108700028369 Alleles Proteins 0.000 description 24
- 108060006698 EGF receptor Proteins 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- -1 small molecule chemical compound Chemical class 0.000 description 22
- 108091033409 CRISPR Proteins 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 19
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 239000000758 substrate Substances 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 102000001301 EGF receptor Human genes 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 239000002083 C09CA01 - Losartan Substances 0.000 description 16
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 16
- 229960004773 losartan Drugs 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 239000002924 silencing RNA Substances 0.000 description 16
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 15
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 208000025494 Aortic disease Diseases 0.000 description 14
- 210000000709 aorta Anatomy 0.000 description 14
- 210000000349 chromosome Anatomy 0.000 description 14
- 229940121647 egfr inhibitor Drugs 0.000 description 14
- 230000002786 root growth Effects 0.000 description 14
- 230000019491 signal transduction Effects 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- 101150018665 MAPK3 gene Proteins 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 239000001509 sodium citrate Substances 0.000 description 12
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 229960001433 erlotinib Drugs 0.000 description 11
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 11
- 229940038773 trisodium citrate Drugs 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 102000001253 Protein Kinase Human genes 0.000 description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
- 108091005735 TGF-beta receptors Proteins 0.000 description 10
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 108060006633 protein kinase Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 101800000733 Angiotensin-2 Proteins 0.000 description 9
- 102400000345 Angiotensin-2 Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 102100031509 Fibrillin-1 Human genes 0.000 description 9
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 9
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229950006323 angiotensin ii Drugs 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003607 modifier Substances 0.000 description 9
- 230000003472 neutralizing effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 8
- 108010075647 MAP Kinase Kinase Kinase 4 Proteins 0.000 description 8
- 230000001594 aberrant effect Effects 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 102000054766 genetic haplotypes Human genes 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- 102000053642 Catalytic RNA Human genes 0.000 description 7
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 7
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 206010023509 Kyphosis Diseases 0.000 description 7
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 7
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 7
- 108091027967 Small hairpin RNA Proteins 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 238000012230 antisense oligonucleotides Methods 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000005754 cellular signaling Effects 0.000 description 7
- 229960005395 cetuximab Drugs 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 108091092562 ribozyme Proteins 0.000 description 7
- 239000004055 small Interfering RNA Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 238000010354 CRISPR gene editing Methods 0.000 description 6
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 description 6
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 6
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 235000010419 agar Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 230000002939 deleterious effect Effects 0.000 description 6
- 238000002224 dissection Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229950010203 nimotuzumab Drugs 0.000 description 6
- 229960001972 panitumumab Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 108091007914 CDKs Proteins 0.000 description 5
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101100236411 Homo sapiens MAP3K4 gene Proteins 0.000 description 5
- 101100237840 Homo sapiens MMP17 gene Proteins 0.000 description 5
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 5
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 5
- 101150015464 MAP2K5 gene Proteins 0.000 description 5
- 101150088769 MAP2K6 gene Proteins 0.000 description 5
- 101150021038 MAP3K4 gene Proteins 0.000 description 5
- 101150020862 MKK5 gene Proteins 0.000 description 5
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 229960004891 lapatinib Drugs 0.000 description 5
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 5
- 229950008001 matuzumab Drugs 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 4
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 4
- 101710146516 Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101001014196 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 4
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 4
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 4
- 101150024075 Mapk1 gene Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 4
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 4
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 4
- 208000021642 Muscular disease Diseases 0.000 description 4
- 201000009623 Myopathy Diseases 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000000783 alginic acid Substances 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 238000002592 echocardiography Methods 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 210000004177 elastic tissue Anatomy 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- 206010039722 scoliosis Diseases 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- SYYMNUFXRFAELA-BTQNPOSSSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol;hydrobromide Chemical compound Br.N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 SYYMNUFXRFAELA-BTQNPOSSSA-N 0.000 description 3
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 3
- 206010060874 Aortic rupture Diseases 0.000 description 3
- 241001553178 Arachis glabrata Species 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 3
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 108010030229 Fibrillin-1 Proteins 0.000 description 3
- 101000976900 Homo sapiens Mitogen-activated protein kinase 14 Proteins 0.000 description 3
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 108010075656 MAP Kinase Kinase Kinase 2 Proteins 0.000 description 3
- 101150101215 Mapk8 gene Proteins 0.000 description 3
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 3
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 description 3
- 102100033058 Mitogen-activated protein kinase kinase kinase 2 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- KFHMLBXBRCITHF-UHFFFAOYSA-N PD158780 Chemical compound N1=CN=C2C=NC(NC)=CC2=C1NC1=CC=CC(Br)=C1 KFHMLBXBRCITHF-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 3
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 3
- 101000761953 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein kinase byr2 Proteins 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 206010002895 aortic dissection Diseases 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 208000018631 connective tissue disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006353 environmental stress Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 102220342429 rs750043368 Human genes 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- BUOXOWNQZVIETJ-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethanol;hydrochloride Chemical compound Cl.C=12C=C(OCCO)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 BUOXOWNQZVIETJ-UHFFFAOYSA-N 0.000 description 2
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 description 2
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 2
- 102100034134 Activin receptor type-1B Human genes 0.000 description 2
- 102100034135 Activin receptor type-1C Human genes 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 101100455868 Arabidopsis thaliana MKK2 gene Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 2
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000005461 Canertinib Substances 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 101150062966 FBN1 gene Proteins 0.000 description 2
- 241000272186 Falco columbarius Species 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101150048172 Grin2c gene Proteins 0.000 description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 2
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 2
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 description 2
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 2
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 2
- 101000976899 Homo sapiens Mitogen-activated protein kinase 15 Proteins 0.000 description 2
- 101001052477 Homo sapiens Mitogen-activated protein kinase 4 Proteins 0.000 description 2
- 101000950710 Homo sapiens Mitogen-activated protein kinase 6 Proteins 0.000 description 2
- 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- IBCXZJCWDGCXQT-UHFFFAOYSA-N LY 364947 Chemical compound C=1C=NC2=CC=CC=C2C=1C1=CNN=C1C1=CC=CC=N1 IBCXZJCWDGCXQT-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102100023483 Mitogen-activated protein kinase 15 Human genes 0.000 description 2
- 102100024189 Mitogen-activated protein kinase 4 Human genes 0.000 description 2
- 102100037801 Mitogen-activated protein kinase 6 Human genes 0.000 description 2
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 2
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 description 2
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 2
- 108700011325 Modifier Genes Proteins 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 2
- MVZGYPSXNDCANY-UHFFFAOYSA-N N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=CC=C4N=CN=3)=CC=2)Cl)=C1 MVZGYPSXNDCANY-UHFFFAOYSA-N 0.000 description 2
- 102000008950 PB1 domains Human genes 0.000 description 2
- 108050000924 PB1 domains Proteins 0.000 description 2
- ZJOKWAWPAPMNIM-UHFFFAOYSA-N PD-153035 hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 ZJOKWAWPAPMNIM-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010079855 Peptide Aptamers Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- 102000007374 Smad Proteins Human genes 0.000 description 2
- 108010007945 Smad Proteins Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 101710084191 TGF-beta receptor type-1 Proteins 0.000 description 2
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
- 229960005054 acepromazine Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000001765 aortic valve Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- ZYQXEVJIFYIBHZ-UHFFFAOYSA-N n-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide Chemical compound C=12N(CCNC(=O)CC(C)(O)C)C=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 ZYQXEVJIFYIBHZ-UHFFFAOYSA-N 0.000 description 2
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229950006299 pelitinib Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 201000003144 pneumothorax Diseases 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 210000003291 sinus of valsalva Anatomy 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- 229950008250 zalutumumab Drugs 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical class COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 1
- CSGQVNMSRKWUSH-IAGOWNOFSA-N (3r,4r)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol Chemical compound COC1=CC=CC(NC=2C3=C(CN4C[C@@H](O)[C@H](N)CC4)C=CN3N=CN=2)=C1 CSGQVNMSRKWUSH-IAGOWNOFSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 description 1
- KSMZEXLVHXZPEF-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)C=CN=C2C=C1OCC1(N)CC1 KSMZEXLVHXZPEF-UHFFFAOYSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- IOASODGEZSLHHY-UHFFFAOYSA-N 1-thia-4-azaspiro[4.5]decane;hydrochloride Chemical compound Cl.N1CCSC11CCCCC1 IOASODGEZSLHHY-UHFFFAOYSA-N 0.000 description 1
- CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 102000043279 ADAM17 Human genes 0.000 description 1
- 101150019464 ARAF gene Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 229940124618 Anlotinib Drugs 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical compound C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000031464 Cavernous Central Nervous System Hemangioma Diseases 0.000 description 1
- 102000011068 Cdc42 Human genes 0.000 description 1
- 108050001278 Cdc42 Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 101150074775 Csf1 gene Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100450350 Danio rerio helz gene Proteins 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 1
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 description 1
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 1
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000054184 GADD45 Human genes 0.000 description 1
- 101150106478 GPS1 gene Proteins 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 1
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101001137642 Homo sapiens Kinase suppressor of Ras 1 Proteins 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
- 101000591236 Homo sapiens Receptor-type tyrosine-protein phosphatase R Proteins 0.000 description 1
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 description 1
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 208000005137 Joint instability Diseases 0.000 description 1
- 102100021001 Kinase suppressor of Ras 1 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
- 108010068306 MAP Kinase Kinase 6 Proteins 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 102000011857 MAP Kinase Kinase Kinase 4 Human genes 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 101150100676 Map2k1 gene Proteins 0.000 description 1
- 101150010110 Map3k8 gene Proteins 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 102000008887 Membrane-Associated Matrix Metalloproteinases Human genes 0.000 description 1
- 108010088571 Membrane-Associated Matrix Metalloproteinases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
- 208000011682 Mitral valve disease Diseases 0.000 description 1
- 101150106019 Mmp2 gene Proteins 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 1
- 101100119832 Mus musculus Fbn1 gene Proteins 0.000 description 1
- 101100013725 Mus musculus Fzd2 gene Proteins 0.000 description 1
- 101100450352 Mus musculus Helz gene Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- APHGZZPEOCCYNO-UHFFFAOYSA-N N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(Cl)C(OC=2C=C(NC(=O)C=C)C=CC=2)=N1 APHGZZPEOCCYNO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- BTYYWOYVBXILOJ-UHFFFAOYSA-N N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide Chemical compound C12=CC(NC(=O)C#CC)=CC=C2N=CN=C1NC1=CC=CC(Br)=C1 BTYYWOYVBXILOJ-UHFFFAOYSA-N 0.000 description 1
- FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical compound C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- HTUBKQUPEREOGA-UHFFFAOYSA-N PD 168393 Chemical compound BrC1=CC=CC(NC=2C3=CC(NC(=O)C=C)=CC=C3N=CN=2)=C1 HTUBKQUPEREOGA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229940116193 Protein phosphatase inhibitor Drugs 0.000 description 1
- 206010058491 Pulmonary artery dilatation Diseases 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
- 102100034101 Receptor-type tyrosine-protein phosphatase R Human genes 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 101150022125 Rimbp2 gene Proteins 0.000 description 1
- 101150093801 SLC9A3R1 gene Proteins 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 101150059736 SRY gene Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100028948 Serine/threonine-protein kinase TAO1 Human genes 0.000 description 1
- 101710106079 Serine/threonine-protein kinase TAO1 Proteins 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 108091027076 Spiegelmer Proteins 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101150050472 Tfr2 gene Proteins 0.000 description 1
- 241000283907 Tragelaphus oryx Species 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- ITTRLTNMFYIYPA-UHFFFAOYSA-N WZ4002 Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1OC1=CC=CC(NC(=O)C=C)=C1 ITTRLTNMFYIYPA-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- MXDSJQHFFDGFDK-CYBMUJFWSA-N [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2r)-2,4-dimethylpiperazine-1-carboxylate Chemical compound C=12C=C(OC(=O)N3[C@@H](CN(C)CC3)C)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F MXDSJQHFFDGFDK-CYBMUJFWSA-N 0.000 description 1
- 230000036579 abiotic stress Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000009468 active modified atmosphere packaging Methods 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- OVDSPTSBIQCAIN-UHFFFAOYSA-N ap26113 Chemical compound COC1=CC(N2CCC(CC2)N(C)C)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O OVDSPTSBIQCAIN-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000008758 canonical signaling Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 102000007656 ets-Domain Protein Elk-1 Human genes 0.000 description 1
- 108010032461 ets-Domain Protein Elk-1 Proteins 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004398 heart morphogenesis Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000053208 human MMP17 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 108700005457 microfibrillar Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 108091006026 monomeric small GTPases Proteins 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- IQNVEOMHJHBNHC-UHFFFAOYSA-N n-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1h-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxyphenyl]prop-2-enamide Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 IQNVEOMHJHBNHC-UHFFFAOYSA-N 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- KIISCIGBPUVZBF-UHFFFAOYSA-N n-[3-[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]sulfanylphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(Cl)C(SC=2C=C(NC(=O)C=C)C=CC=2)=N1 KIISCIGBPUVZBF-UHFFFAOYSA-N 0.000 description 1
- HUFOZJXAKZVRNJ-UHFFFAOYSA-N n-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(C(F)(F)F)C=1NC1=CC=CC(NC(=O)C=C)=C1 HUFOZJXAKZVRNJ-UHFFFAOYSA-N 0.000 description 1
- BFSRTTWIPACGMI-UHFFFAOYSA-N n-[3-[[2-[4-[[1-(2-fluoroethyl)azetidin-3-yl]amino]-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C=1C=C(NC=2N=C(NC=3C=C(NC(=O)C=C)C=CC=3)C(=CN=2)C(F)(F)F)C(OC)=CC=1NC1CN(CCF)C1 BFSRTTWIPACGMI-UHFFFAOYSA-N 0.000 description 1
- ZAJXXUDARPGGOC-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C)(C)C#CC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1NC(=O)C=C ZAJXXUDARPGGOC-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000008759 noncanonical signaling Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 102000006271 p21-Activated Kinases Human genes 0.000 description 1
- 108010058266 p21-Activated Kinases Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical group OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 102000019075 protein serine/threonine/tyrosine kinase activity proteins Human genes 0.000 description 1
- 108040008258 protein serine/threonine/tyrosine kinase activity proteins Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 102200062347 rs121909354 Human genes 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- HVXKQKFEHMGHSL-QKDCVEJESA-N tesevatinib Chemical compound N1=CN=C2C=C(OC[C@@H]3C[C@@H]4CN(C)C[C@@H]4C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1F HVXKQKFEHMGHSL-QKDCVEJESA-N 0.000 description 1
- 108091008743 testicular receptors 4 Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229950006605 varlitinib Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11025—Mitogen-activated protein kinase kinase kinase (2.7.11.25), i.e. MAPKKK or MAP3K
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- Marfan syndrome is a systemic connective tissue disorder with autosomal dominant inheritance, caused by mutations in the FBN1 gene. It has cardinal features involving the ocular, skeletal and cardiovascular systems, with the major cause of mortality resulting from aortic root dilatation, dissection and rupture.
- Marfan syndrome Many of the features of Marfan syndrome are common in the general population and represent a tremendous public health burden. These include aortic aneurysm (1-2% of the population at large), mitral valve prolapse ( ⁇ 7%), emphysema (11%), scoliosis (0.5%), cataract (30%), arthritis (very common), and myopathy (many common genetic and acquired forms).
- compositions and methods for the treatment of Marfan syndrome diseases and disorders are described below.
- the instant disclosure provides a method for treating a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition involving administering to the subject an effective amount of an agent that modulates the activity of MAP kinase pathway signaling, thereby treating the subject.
- the agent that modulates the activity of MAP kinase pathway signaling is a MAP kinase pathway inhibitor.
- the agent that modulates the activity of MAP kinase pathway signaling is an inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof.
- the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof is an antisense agent or a double-stranded nucleic acid, optionally a siRNA or shRNA specific for MMP17, MAP2K6 or MAP3K4.
- the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof is specific for a nucleic acid molecule having at least a 50% sequence identity to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8.
- the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof is specific for a nucleic acid molecule set forth as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8.
- the agent that modulates the activity of MAP kinase pathway signaling is a small molecule.
- the agent that modulates the activity of MAP kinase pathway signaling comprise Batimastat, GI 254023X, GM 6001, TMI 1, WAY 170523, WX-554 or combinations thereof.
- the agent that modulates the activity of MAP kinase pathway signaling is an antibody.
- the Marfan syndrome-associated disease or disorder is a clinical condition associated with Marfan syndrome.
- the disease or disorder is an aneurysm, an aortic aneurysm, or emphysema.
- the disease or disorder is an aneurysm.
- Another aspect of the disclosure provides a method for treating a subject having Marfan syndrome or a Marfan-associated condition involving identifying a variant allele of MMP17, MAP2K6 or MAP3K4 that produces elevated expression and/or activity of a gene product of the MMP17, MAP2K6 or MAP3K4 gene; and replacing the variant allele of MMP17, MAP2K6 or MAP3K4 with an allele of MMP17, MAP2K6 or MAP3K4 that does not produce elevated expression and/or activity of a gene product of the MMP17, MAP2K6 or MAP3K4 gene, thereby treating the subject.
- the step of replacing the variant allele is performed via a CRISPR-Cas9 gene replacement process.
- the step of replacing is performed ex vivo.
- re-introduction to the subject of a cell manipulated ex vivo to perform gene replacement treats the subject.
- the variant allele of MMP17, MAP2K6 or MAP3K4 that produces elevated expression and/or activity of a gene product of the MMP17, MAP2K6 or MAP3K4 gene comprises a nucleic acid sequence having at least a 50% sequence identity to SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.
- the variant allele of MMP17, MAP2K6 or MAP3K4 that produces elevated expression and/or activity of a gene product of the MMP17, MAP2K6 or MAP3K4 gene comprise nucleic acid sequences set forth as SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.
- An additional aspect of the disclosure provides a pharmaceutical composition for the treatment of a disease or disorder characterized by aberrant MAP kinase pathway expression or activity, where the pharmaceutical composition includes an agent that modulates the activity of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof.
- a further aspect of the disclosure provides a kit for identifying a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition that includes primers specific for amplification of MMP17, MAP2K6 and/or MAP3K4; a probe oligonucleotide, optionally fluorescently labeled, that specifically detects the presence of a MMP17, MAP2K6 and/or MAP3K4 amplicon, wherein detection of elevated expression of MMP17, MAP2K6 and/or MAP3K4 identifies the subject as having or at risk of developing Marfan Syndrome or a Marfan-associated condition; and instructions for use.
- the kit further includes a pharmaceutical composition of the instant disclosure.
- Another aspect of the disclosure provides a method for identifying and treating a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition involving: isolating a sample from the subject; assessing the expression level of MMP17, MAP2K6 and/or MAP3K4 in the sample, assessing the level of activity of a gene product of MMP17, MAP2K6 and/or MAP3K4 in the sample, and/or genotyping MMP17, MAP2K6 and/or MAP3K4 in the sample; identifying elevated expression of MMP17, MAP2K6 and/or MAP3K4 in the sample, identifying elevated activity of a gene product of MMP17, MAP2K6 and/or MAP3K4 in the sample, and/or identifying a genotype of MMP17, MAP2K6 and/or MAP3K4 in the sample that causes elevated expression and/or activity of MMP17, MAP2K6 and/or MAP3K4, or of a gene product thereof
- a method for treating a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition comprises administering to the subject an effective amount of an agent that modulates the activity of MAP kinase pathway signaling and/or expression, function or activity of epidermal growth factor receptor (EGFR); thereby treating the subject.
- an agent that modulates the activity of MAP kinase pathway signaling and/or expression, function or activity of epidermal growth factor receptor (EGFR) thereby treating the subject.
- EGFR epidermal growth factor receptor
- the therapy for Marfan Syndrome or a Marfan-associated condition comprises administration of a TGF ⁇ NAb, losartan and/or an inhibitor of MMP17, MAP2K6 and/or MAP3K4, or of a gene product thereof.
- agent any small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide, or fragments thereof.
- ameliorate is meant decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease.
- alteration is meant a change (increase or decrease) in the expression levels or activity of a gene or polypeptide as detected by standard art known methods such as those described herein.
- an alteration includes a 10% change in expression levels, preferably a 25% change, more preferably a 40% change, and most preferably a 50% or greater change in expression levels.
- conjugated when used with respect to two or more moieties, means that the moieties or domains are physically associated or connected with one another, either directly or via one or more additional moieties that serve as a linking agent, to form a structure that is sufficiently stable so that the moieties remain physically associated under the conditions in which the structure is used, e.g., physiological conditions.
- the linkage can be based on genetic fusion according to the methods known in the art or can be performed by, e.g., chemical cross-linking.
- the compounds and targeting agents may be linked by a flexible linker, such as a polypeptide linker or a synthetic linker.
- the polypeptide linker can comprise plural, hydrophilic or peptide-bonded amino acids of varying lengths.
- the term “associated” will be used for the sake of brevity and is meant to include all possible methods of physically associating each compound with one or more desired molecules or agents.
- detectable label is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
- useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.
- the detectable label is associated with a composition of interest by any possible methods of physically associating each compound to a detectable label.
- disease is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include Marfan Syndrome.
- EGFR inhibitor is intended to include therapeutic agents that inhibit, downmodulate, suppress or downregulate EGFR signaling activity.
- the term is intended to include chemical compounds, such as small molecule inhibitors (e.g., small molecule tyrosine kinase inhibitors) and biologic agents, such as antibodies, interfering RNA (shRNA, siRNA), soluble receptors and the like.
- small molecule inhibitors e.g., small molecule tyrosine kinase inhibitors
- biologic agents such as antibodies, interfering RNA (shRNA, siRNA), soluble receptors and the like.
- an effective amount is meant the amount of a required to ameliorate the symptoms of a disease relative to an untreated patient.
- the effective amount of active compound(s) used to practice the present disclosure for therapeutic treatment of a disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an “effective” amount.
- the disclosure provides a number of targets that are useful for the development of highly specific drugs to treat or a disorder characterized by the methods delineated herein.
- the methods of the disclosure provide a facile means to identify therapies that are safe for use in subjects.
- the methods of the disclosure provide a route for analyzing virtually any number of compounds for effects on a disease described herein with high-volume throughput, high sensitivity, and low complexity.
- fragment is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide.
- a fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
- Hybridization means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases.
- adenine and thymine are complementary nucleobases that pair through the formation of hydrogen bonds.
- inhibitory nucleic acid is meant a double-stranded RNA, siRNA, shRNA, or antisense RNA, or a portion thereof, or a mimetic thereof, that when administered to a mammalian cell results in a decrease (e.g., by 10%, 25%, 50%, 75%, or even 90-100%) in the expression of a target gene.
- a nucleic acid inhibitor comprises at least a portion of a target nucleic acid molecule, or an ortholog thereof, or comprises at least a portion of the complementary strand of a target nucleic acid molecule.
- an inhibitory nucleic acid molecule comprises at least a portion of any or all of the nucleic acids delineated herein.
- marker any protein or polynucleotide having an alteration in expression level or activity that is associated with a disease or disorder.
- obtaining as in “obtaining an agent” includes synthesizing, purchasing, or otherwise acquiring the agent.
- Primer set means a set of oligonucleotides that may be used, for example, for PCR.
- a primer set would consist of at least 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30, 40, 50, 60, 80, 100, 200, 250, 300, 400, 500, 600, or more primers.
- reduces is meant a negative alteration of at least 10%, 25%, 50%, 75%, or 100%.
- a “reference sequence” is a defined sequence used as a basis for sequence comparison.
- a reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.
- the length of the reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids.
- the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides or any integer thereabout or therebetween.
- siRNA is meant a double stranded RNA.
- an siRNA is 18, 19, 20, 21, 22, 23 or 24 nucleotides in length and has a 2 base overhang at its 3′ end.
- These dsRNAs can be introduced to an individual cell or to a whole animal; for example, they may be introduced systemically via the bloodstream.
- Such siRNAs are used to downregulate mRNA levels or promoter activity.
- binds is meant a compound or antibody that recognizes and binds a polypeptide of the disclosure, but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes a polypeptide of the disclosure.
- Nucleic acid molecules useful in the methods of the disclosure include any nucleic acid molecule that encodes a polypeptide of the disclosure or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity. Polynucleotides having “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the disclosure include any nucleic acid molecule that encodes a polypeptide of the disclosure or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity.
- Polynucleotides having “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule.
- hybridize is meant pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency.
- complementary polynucleotide sequences e.g., a gene described herein
- stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate.
- Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and more preferably at least about 50% formamide.
- Stringent temperature conditions will ordinarily include temperatures of at least about 30° C., more preferably of at least about 37° C., and most preferably of at least about 42° C.
- Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art.
- concentration of detergent e.g., sodium dodecyl sulfate (SDS)
- SDS sodium dodecyl sulfate
- Various levels of stringency are accomplished by combining these various conditions as needed.
- hybridization will occur at 30° C. in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS.
- hybridization will occur at 37° C. in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 ⁇ g/ml denatured salmon sperm DNA (ssDNA).
- hybridization will occur at 42° C. in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 ⁇ g/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.
- wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature.
- stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate.
- Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25° C., more preferably of at least about 42° C., and even more preferably of at least about 68° C. In a preferred embodiment, wash steps will occur at 25° C.
- wash steps will occur at 42 C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS.
- wash steps will occur at 68° C. in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad.
- substantially identical is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence (for example, any one of the amino acid sequences described herein) or nucleic acid sequence (for example, any one of the nucleic acid sequences described herein).
- a reference amino acid sequence for example, any one of the amino acid sequences described herein
- nucleic acid sequence for example, any one of the nucleic acid sequences described herein.
- such a sequence is at least 60%, more preferably 80% or 85%, and more preferably 90%, 95% or even 99% identical at the amino acid level or nucleic acid to the sequence used for comparison.
- Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e-3 and e-100 indicating a closely related sequence.
- sequence analysis software for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center
- subject is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline.
- Ranges provided herein are understood to be shorthand for all of the values within the range.
- a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
- the terms “treat,” treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
- the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
- compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
- FIGS. 1 A- 1 C show the aortic phenotype of pure C57BL/6J (BL6) and 129S6/SvEvTac (129) mice.
- FIG. 1 A Aortic root size (mm
- FIG. 1 B Representative parasternal long axis echocardiograms at 6 months of the aortic root (yellow arrow) and ascending aorta (red arrow) in WT and MFS mice on BL6 and 129 strains;
- FIG. 1 C Survival curve to 10 months for WT and MFS mice on pure BL6 and 129 strains. * ⁇ 0.05, ** ⁇ 0.01, ⁇ 0.001, ⁇ 0.0001, ⁇ 0.00001, NS non-significant.
- FIGS. 2 A- 2 E show the molecular mechanisms driving aortic disease in MFS mice.
- FIG. 2 A Western blot analysis of the aortic root of 4 WT and 4 MFS mice on BL6 and 129 strains at 10 months of age;
- FIG. 2 A Western blot analysis of the aortic root of 4 WT and 4 MFS mice on BL6 and 129 strains at 10 months of age;
- FIG. 2 E Western blot analysis of the aortic root of 3 placebo- and 3 RDEA119-treated 129 WT and MFS mice at 4 months of age. Plac: placebo; Los: losartan; RDEA: RDEA119. * ⁇ 0.05, ** ⁇ 0.01, ⁇ 0.001, ⁇ 0.0001, ⁇ 0.00001, NS non-significant.
- FIGS. 3 A- 3 G show the mapping modifier loci of aortic aneurysm in MFS mice.
- FIG. 3 C Aortic root size (mm) at 6 months of age in MFS mice lacking either one or two functional Mmp17 and Map2k6 alleles (n>10 per group);
- FIG. 3 D Western blot analysis of the aortic root at 10 months of age in 3 WT mice, 3 pure 129 MFS mice, 3 pure BL6 MFS mice, and 3 MFS mice either retaining (+/+) or lacking ( ⁇ / ⁇ ) functional Mmp17 and Map2k6 alleles;
- FIG. 3 C Aortic
- FIG. 3 E Western blot analysis of Egfr activation in the aortic root at 10 months of age in 4 pure BL6 and pure 129 WT and MFS mice, as well as 3 MFS mice either retaining (+/+) or lacking ( ⁇ / ⁇ ) functional Mmp17 and Map2k6 alleles;
- FIG. 3 E Western blot analysis of Egfr activation in the aortic root at 10 months of age in 4 pure BL6 and pure 129 WT and MFS mice, as well as 3 MFS mice either retaining (+/+) or lacking ( ⁇ / ⁇ ) functional Mmp17 and Map2k6 alleles;
- FIG. 3 F Aortic root growth (mm) from 2 to 4
- 3 G Western blot analysis at 4 months of age in 3 placebo- and 3 erlotinib-treated 129 WT and MFS mice. Chr: Chromosome; M17: Mmp17; M2: Map2k6; Plac: placebo; Erlo: erlotinib. * ⁇ 0.05, ** ⁇ 0.01, ⁇ 0.001, ⁇ 0.0001, NS non-significant.
- FIGS. 4 A- 4 E show the identification of a modifier locus for aortic aneurysm in MFS patients.
- FIG. 4 A Pedigrees of 5 MFS families recruited for genome wide linkage analysis; yellow indicates MFS patients with mild aortic disease, black indicates MFS patients with severe aortic disease, grey indicates patients with indeterminate data, and white indicates family members who do not have MFS;
- FIG. 4 B Parametric linkage analysis revealed 1 locus that surpassed a genome wide significance LOD score of 3.3, which is indicated by the red line;
- FIG. 4 A Pedigrees of 5 MFS families recruited for genome wide linkage analysis; yellow indicates MFS patients with mild aortic disease, black indicates MFS patients with severe aortic disease, grey indicates patients with indeterminate data, and white indicates family members who do not have MFS;
- FIG. 4 B Parametric linkage analysis revealed 1 locus that surpassed a genome wide significance LOD score of 3.3, which is indicated by the red line;
- FIG. 4 C Quantitative PCR analysis of MAP3K4 mRNA expression from cultured dermal fibroblasts of 2 controls, 2 MFS patients from family B with mild aortic disease and 2 MFS patients from family B with severe aortic disease; all biological samples were run in experimental triplicate and normalized to ⁇ -actin;
- FIG. 4 D Aortic root growth from 2 to 6 months of age in W
- AA Ascending aorta; * ⁇ 0.05, ** ⁇ 0.01, ⁇ 0.001, ⁇ 0.0001, NS non-significant.
- FIG. 7 shows the weight (in grams) at 2 months of age in female and male WT and MFS mice on pure BL6 and 129 strains (n>10 per group). NS non-significant.
- FIG. 11 shows the Mmp17 C-terminal DNA and amino acid sequences, illustrating the 9 amino acid truncation in the BL6 mouse strain (SEQ ID NO: 24) relative to the 129 strain (SEQ ID NO: 25).
- the human MMP17 sequences (SEQ ID NO: 26) are displayed for comparison.
- the DNA sequence highlighted in red identifies the 129 codon that corresponds to the BL6 stop codon.
- the amino acid highlighted in red represents the predicted start site of the GPI anchor in each sequence.
- the instant disclosure is based, at least in part, upon the discovery that upregulation of expression and/or activity of certain MAP kinase pathway components drives Marfan Syndrome (MFS) development in a mouse model of Marfan Syndrome.
- MFS Marfan Syndrome
- Genetic backcrosses were performed between mice of an MFS model and a non-MFS-afflicted strain of mice, thereby identifying genetic loci associated with MFS.
- loci that caused elevated expression and/or activity of MMP17, MAP2K6 or MAP3K4, or of gene products thereof, were identified as contributing to MFS and related conditions in such mice.
- Modulation of MAP kinase pathway signaling, and particularly inhibition and/or gene replacement of MMP17, MAP2K6 and/or MAP3K4, or of gene products thereof, is thereby discovered to be a therapeutic approach for MFS.
- MFS diagnosis is also aided by this identification of MAP kinase pathway signaling components/loci indicative of development of MFS in a subject.
- Marfan syndrome is an autosomal dominant connective tissue disorder that includes a predisposition for aortic root aneurysm and aortic rupture. MFS is caused by a deficiency of the microfibrillar constituent protein fibrillin 1 that is imposed by heterozygous mutations in FBN1.
- Marfan syndrome is a systemic disorder with autosomal dominant inheritance and a prevalence of approximately 1 per 5,000 population (Pyeritz, R. E. & McKusick, V. A. (1979) N Engl J Med. 300, 772-777). The syndrome shows no racial preference and both sexes are affected equally. It has been estimated that 25% of cases occur due to spontaneous mutations. While this condition shows high penetrance, marked interfamilial clinical variability is the rule (Pyeritz, R. E. et al. (1979) birth Defects Orig Artic Ser. 15, 155-178).
- Historic lack of a specific biochemical or genetic marker of disease, coupled with the variability in clinical presentation, has frustrated diagnosis of equivocal cases and has likely contributed to a significant underestimation of the prevalence of disease.
- Cardiovascular pathology including aortic root dilatation, dissection, and rupture, pulmonary artery dilatation, myxomatous valve changes with insufficiency of the mitral and aortic valves, and progressive myocardial dysfunction, is the leading cause of mortality in the MFS.
- MFS cardiovascular pathology
- the majority of fatal events associated with untreated MFS occur in early adult life.
- the average age of death was 32 years (Murdoch, J. L. et al. (1972) N Engl J Med. 286, 804-808).
- Marfan syndrome Many of the features of Marfan syndrome are common in the general population and represent a tremendous public health burden. These include aortic aneurysm (1-2% of the population at large), mitral valve prolapse ( ⁇ 7%), emphysema (11%), scoliosis (0.5%), cataract (30%), arthritis (very common), and myopathy (many common genetic and acquired forms).
- MFS mice Fbn1 C1039G/+ mice
- TGF ⁇ NAb TGF ⁇ neutralizing antibody
- Ang-II angiotensin-II type 1 receptor blocker
- Smad2/3 activation Habashi et al., Science 312, 117; Neptune et al., Nature Genetics 33, 407; Ng et al., Journal Clinical Investigation 114, 1586; Cohn et al., Nature Medicine 13, 204.
- a mitogen-activated protein kinase is a type of protein kinase that is specific to the amino acids serine, threonine, and tyrosine (i.e., a serine/threonine-specific protein kinase).
- MAPKs are involved in directing cellular responses to a diverse array of stimuli, such as mitogens, osmotic stress, heat shock and proinflammatory cytokines. They regulate cell functions including proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis (Pearson G, et al. (April 2001). Endocrine Reviews. 22 (2): 153-83).
- MAP kinases are found in eukaryotes only, but they are fairly diverse and encountered in all animals, fungi and plants, and even in an array of unicellular eukaryotes.
- MAPKs belong to the CMGC (CDK/MAPK/GSK3/CLK) kinase group.
- the closest relatives of MAPKs are the cyclin-dependent kinases (CDKs; Manning G, et al. (December 2002). Science. 298 (5600): 1912-34)).
- ERK1 mitogen-activated protein kinase to be discovered was ERK1 (MAPK3) in mammals. Since ERK1 and its close relative ERK2 (MAPK1) are both involved in growth factor signaling, the family was termed “mitogen-activated”. With the discovery of other members, even from distant organisms (e.g. plants), it has become increasingly clear that the name is a misnomer, since most MAPKs are actually involved in the response to potentially harmful, abiotic stress stimuli (hyperosmosis, oxidative stress, DNA damage, low osmolarity, infection, etc.). Because plants cannot “flee” from stress, terrestrial plants have the highest number of MAPK genes per organism ever found. Thus the role of mammalian ERK1/2 kinases as regulators of cell proliferation is not a generic, but a highly specialized function.
- MAPKs have a number of shared characteristics, such as the activation dependent on two phosphorylation events, a three-tiered pathway architecture and similar substrate recognition sites. These are the “classical” MAP kinases. But there are also some ancient outliers from the group as sketched above, that do not have dual phosphorylation sites, only form two-tiered pathways, and lack the features required by other MAPKs for substrate binding. These are usually referred to as “atypical” MAPKs (Coulombe P, Meloche S (March 2007). Biochimica et Biophysica Acta. 1773 (8): 1376-87). It is yet unclear if the atypical MAPKs form a single group as opposed to the classical ones.
- Mitogen-activated protein kinases are catalytically inactive in their base form. In order to become active, they require (potentially multiple) phosphorylation events in their activation loops. This is conducted by specialized enzymes of the STE protein kinase group.
- the activation loop contains a characteristic TxY (threonine-x-tyrosine) motif (TEY in mammalian ERK1 and ERK2, TDY in ERK5, TPY in JNKs, TGY in p38 kinases) that needs to be phosphorylated on both the threonine and the tyrosine residues in order to lock the kinase domain in a catalytically competent conformation.
- TxY threonine-x-tyrosine motif
- This tandem activation loop phosphorylation (that was proposed to be either distributive or processive, dependent on cellular environment) is performed by members of the Ste7 protein kinase family, also known as MAP2 kinases.
- MAP2 kinases are also activated by phosphorylation, by a number of different upstream serine-threonine kinases (MAP3 kinases).
- MAP3 kinases Because MAP2 kinases display very little activity on substrates other than their cognate MAPK, classical MAPK pathways form multi-tiered, but relatively linear pathways. These pathways can effectively convey stimuli from the cell membrane (where many MAP3Ks are activated) to the nucleus (where only MAPKs may enter) or to many other subcellular targets.
- MAPK6 MAPK6
- MAPK4 ERK4
- PAK kinases related to other MAP3 kinases; Deleris P, et al. (February 2011). The Journal of Biological Chemistry. 286 (8): 6470-8).
- these atypical MAPKs require only a single residue in their activation loops to be phosphorylated.
- NLK and ERK7 (MAPK15) activation remain unknown.
- MAPKs Inactivation of MAPKs is performed by a number of phosphatases.
- a very conserved family of dedicated phosphatases is the so-called MAP kinase phosphatases (MKPs), a subgroup of dual-specificity phosphatases (DUSPs; Theodosiou A, Ashworth A (June 2002). Genome Biology. 3 (7): reviews3009.1-reviews3009.10).
- MKPs MAP kinase phosphatases
- DUSPs dual-specificity phosphatases
- tyrosine phosphatases are also involved in inactivating MAP kinases (e.g. the phosphatases HePTP, STEP and PTPRR in mammals).
- MAPKs typically form multi-tiered pathways, receiving input several levels above the actual MAP kinase.
- MAP3Ks have stunningly complex regulation.
- Many of the better-known MAP3Ks, such as c-Raf, MEKK4 or MLK3 require multiple steps for their activation. These are typically allosterically-controlled enzymes, tightly locked into an inactive state by multiple mechanisms.
- the first step en route to their activation consists of relieving their auto-inhibition by a smaller ligand (such as Ras for c-Raf, GADD45 for MEKK4 (Miyake Z, et al. (April 2007).
- this dimerization event also forces the MAP3 kinase domains to adopt a partially active conformation. Full activity is only achieved once these dimers transphosphorylate each other on their activation loops. The latter step can also be achieved or aided by auxiliary protein kinases (MAP4 kinases, members of the Ste20 family). Once a MAP3 kinase is fully active, it may phosphorylate its substrate MAP2 kinases, which in turn will phosphorylate their MAP kinase substrates.
- MAP4 kinases auxiliary protein kinases
- the ERK1/2 pathway of mammals is probably the best-characterized MAPK system.
- the most important upstream activators of this pathway are the Raf proteins (A-Raf, B-Raf or c-Raf), the key mediators of response to growth factors (EGF, FGF, PDGF, etc.); but other MAP3Ks such as c-Mos and Tpl2/Cot can also play the same role. All these enzymes phosphorylate and thus activate the MKK1 and/or MKK2 kinases, that are highly specific activators for ERK1 and ERK2. The latter phosphorylate a number of substrates important for cell proliferation, cell cycle progression, cell division and differentiation (RSK kinases, Elk-1 transcription factor, etc.).
- mammalian p38 and JNK kinases have most of their activators shared at the MAP3K level (MEKK1, MEKK4, ASK1, TAK1, MLK3, TAOK1, etc.).
- some MAP2K enzymes may activate both p38 and JNK (MKK4), while others are more specific for either JNK (MKK7) or p38 (MKK3 and MKK6). Due to these interlocks, there are very few if any stimuli that can elicit JNK activation without simultaneously activating p38 or reversed (Cargnello M, Roux P P (March 2011). Microbiology and Molecular Biology Reviews. 75 (1): 50-83).
- JNK and p38 signaling pathways are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in adaptation to stress, apoptosis or cell differentiation.
- stress stimuli such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock
- JNKs have a number of dedicated substrates that only they can phosphorylate (c-Jun, NFAT4, etc.), while p38s also have some unique targets (e.g. the MAPKAP kinases MK2 and MK3), ensuring the need for both in order to respond to stressful stimuli.
- ERK5 is part of a fairly well-separated pathway in mammals. Its sole specific upstream activator MKK5 is turned on in response to the MAP3 kinases MEKK2 and MEKK3. The specificity of these interactions are provided by the unique architecture of MKK5 and MEKK2/3, both containing N-terminal PB1 domains, enabling direct hetero-dimerization with each other (Nakamura K, Johnson G L (September 2003). The Journal of Biological Chemistry. 278 (39): 36989-92).
- the PB1 domain of MKK5 also contributes to the ERK5-MKK5 interaction: it provides a special interface (in addition to the D-motif found in MKK5) through which MKK5 can specifically recognize its substrate ERK5 (Glatz G, et al. (March 2013). The Journal of Biological Chemistry. 288 (12): 8596-609). Although the molecular-level details are poorly known, MEKK2 and MEKK3 respond to certain developmental cues to direct endothelial formation and cardiac morphogenesis. While also implicated in brain development, the embryonic lethality of ERK5 inactivation due to cardiac abnormalities underlines its central role in mammalian vasculogenesis (Regan C P, et al. (July 2002).
- MAP kinases As typical for the CMGC kinase group, the catalytic site of MAP kinases has a very loose consensus sequence for substrates. Like all their relatives, they only require the target serine/threonine amino acids to be followed by a small amino acid, preferably proline (“proline-directed kinases”). But as SP/TP sites are extremely common in all proteins, additional substrate-recognition mechanisms have evolved to ensure signaling fidelity (Garai ⁇ , et al. (October 2012). Science Signaling. 5 (245): ra74).
- CDKs cyclin-dependent kinases
- MAPKs associate with their substrates via auxiliary binding regions on their kinase domains.
- the most important such region consists of the hydrophobic docking groove and the negatively charged CD-region.
- MAPK docking or D-motifs also called kinase interaction motif/KIM.
- D-motifs essentially consist of one or two positively charged amino acids, followed by alternating hydrophobic residues (mostly leucines), typically upstream of the phosphorylation site by 10-50 amino acids (Reményi A, et al. (December 2005). Mol. Cell. 20 (6): 951-62).
- MAP2 kinases also contain such motifs on their N-termini that are absolutely required for MAP2K-MAPK interaction and MAPK activation (Bardwell A J, et al. (May 2009). The Journal of Biological Chemistry. 284 (19): 13165-73).
- both dual-specificity MAP kinase phosphatases and MAP-specific tyrosine phosphatases bind to MAP kinases through the same docking site (Goldsmith E J (December 2011). Science Signaling.
- D-motifs can even be found in certain MAPK pathway regulators and scaffolds (e.g. in the mammalian JIP proteins).
- substrate-binding sites also exist.
- One such site is formed by the activation loop (when in the active conformation) and the MAP kinase-specific insert below it.
- This site can accommodate peptides with an FxFP consensus sequence, typically downstream of the phosphorylation site (Sheridan D L, et al. (July 2008). The Journal of Biological Chemistry. 283 (28): 19511-20). Note that the latter site can only be found in proteins that need to selectively recognize the active MAP kinases, thus they are almost exclusively found in substrates.
- Different motifs may cooperate with each other, as in the Elk family of transcription factors, that possess both a D-motif and an FxFP motif.
- the presence of an FxFP motif in the KSR1 scaffold protein also serves to make it an ERK1/2 substrate, providing a negative feedback mechanism to set the correct strength of ERK1/2 activation.
- ERK1/2 inhibitors would represent a desirable class of antineoplastic agents. Indeed, many of the proto-oncogenic “driver” mutations are tied to ERK1/2 signaling, such as constitutively active (mutant) receptor tyrosine kinases, Ras or Raf proteins. Although no MKK1/2 or ERK1/2 inhibitors were developed for clinical use, kinase inhibitors that also inhibit Raf kinases (e.g. Sorafenib) are successful antineoplastic agents against various types of cancer (Kim D H, Sim T (March 2012). Arch. Pharmacol Res. 35 (4): 605-15; Matsuda Y, Fukumoto M (December 2011). Medical Molecular Morphology. 44 (4): 183-9).
- the MMP17 gene encodes a member of the peptidase M10 family and membrane-type subfamily of matrix metalloproteinases (MMPs). Proteins in this family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Members of this subfamily contain a transmembrane domain suggesting that these proteins are expressed at the cell surface rather than secreted.
- the encoded preproprotein is proteolytically processed to generate the mature protease. This protein is unique among the membrane-type matrix metalloproteinases in that it is anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor. Elevated expression of the encoded protein has been observed in osteoarthritis and multiple human cancers.
- GPI glycosylphosphatidylinositol
- An illustrative amino acid sequence (SEQ ID NO: 1) of human Mmp17 is NP_057239.4: MRRRAARGPGPPPPGPGLSRLPLPLLLLLALGTRGGCAAPAPAPRAEDLS LGVEWLSRFGYLPPADPTTGQLQTQEELSKAITAMQQFGGLEATGILDEA TLALMKTPRCSLPDLPVLTQARRRRQAPAPTKWNKRNLSWRVRTFPRDSP LGHDTVRALMYYALKVWSDIAPLNFHEVAGSAADIQIDFSKADHNDGYPF DGPGGTVAHAFFPGHHHTAGDTHFDDDEAWTFRSSDAHGMDLFAVAVHEF GHAIGLSHVAAAHSIMRPYYQGPVGDPLRYGLPYEDKVRVWQLYGVRESV SPTAQPEEPPLLPEPPDNRSSAPPRKDVPHRCSTHFDAVAQIRGEAFFFK GKYFWRLTRDRHLVSLQPAQMHRFWRGLPLHLDSVDAVYERTSDHKIVFF
- MMP17 inhibitors include those recited in Table 1.
- MMP17 Inhibitors Compound Action Cas Number Batimastat Potent, broad spectrum 130370-60-4 MMP inhibitor GI 254023X Selective ADAM10 260264-93-5 metalloprotease inhibitor GM 6001 Broad spectrum MMP 142880-36-2 inhibitor TMI 1 Adam 17 (TACE) and MMP 287403-39-8 inhibitor; orally bioavailable WAY 170523 Potent and selective inhibitor 307002-73-9 of MMP-13
- Dual specificity mitogen-activated protein kinase kinase 6 also known as MAP kinase kinase 6 (MAPKK 6) or MAPK/ERK kinase 6 is an enzyme that in humans is encoded by the MAP2K6 gene, on chromosome 17 (Han J, et al. (February 1996). The Journal of Biological Chemistry. 271 (6): 2886-91).
- MAPKK 6 is a member of the dual specificity protein kinase family, which functions as a mitogen-activated protein (MAP) kinase kinase.
- MAP kinases also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals. This protein phosphorylates and activates p38 MAP kinase in response to inflammatory cytokines or environmental stress.
- this gene As an essential component of p38 MAP kinase mediated signal transduction pathway, this gene is involved in many cellular processes such as stress-induced cell cycle arrest, transcription activation and apoptosis (Entrez Gene: MAP2K6 mitogen-activated protein kinase kinase 6′′.).
- An illustrative amino acid sequence (SEQ ID NO: 3) of human Map2k6 is NP_002749.2: MSQSKGKKRNPGLKIPKEAFEQPQTSSKACISIGNQNFEVKADDLEPIME LGRGAYGVVEKMRHVPSGQIMAVKRIRATVNSQEQKRLLMDLDISMRTVD CPFTVTFYGALFREGDVWICMELMDTSLDKFYKQVIDKGQTIPEDILGKI AVSIVKALEHLHSKLSVIHRDVKPSNVLINALGQVKMCDFGISGYLVDSV AKTIDAGCKPYMAPERINPELNQKGYSVKSDIWSLGITMIELAILRFPYD SWGTPFQQLKQVVEEPSPQLPADKFSAEFVDFTSQCLKKNSKERPTYPEL MQHPFFTLHESKGTDVASFVKLILGD
- the corresponding nucleic acid sequence (SEQ ID NO: 4) encoding human Map2k6 is NM
- MAP2K6 inhibitors include those recited in Table 3.
- Mitogen-activated protein kinase kinase kinase 4 is an enzyme that in humans is encoded by the MAP3K4 gene (Takekawa M, et al. (October 1997). EMBO J 16 (16): 4973-82; Entrez Gene: MAP3K4 mitogen-activated protein kinase kinase kinase 4′′).
- each mitogen-activated protein kinase (MAPK) pathway is a conserved cascade of 3 protein kinases: an activated MAPK kinase kinase (MAPKKK) phosphorylates and activates a specific MAPK kinase (MAPKK), which then activates a specific MAPK.
- MAPKKK mitogen-activated protein kinase
- MAPKKK activated MAPK kinase kinase
- MAPKK MAPK kinase kinase
- MAPKK MAPK kinase
- MAPKK mitogen-activated protein kinase
- the N-terminal nonkinase domain may contain a regulatory domain.
- Expression of MEKK4 in mammalian cells activated the CSBP2 (p38 ⁇ ) and JNK MAPK pathways, but not the ERK pathway.
- MKK6 PRKMK6
- MKK4 SERKI1
- MAPKKs that activate CSBP2 (p38 ⁇ ) and JNK, respectively but cannot phosphorylate PRKMK1 (MKK1), an MAPKK that activates ERKs.
- MEKK4 is a major mediator of environmental stresses that activate the p38 MAPK pathway, and a minor mediator of the JNK pathway. Two alternatively spliced transcripts encoding distinct isoforms have been described (Entrez Gene: MAP3K4 mitogen-activated protein kinase kinase kinase 4′′).
- An illustrative amino acid sequence (SEQ ID NO: 7) of human Map3k4 is NP_005913.2: MREAAAALVPPPAFAVTPAAAMEEPPPPPPPPPPPPEPETESEPECCLAA RQEGTLGDSACKSPESDLEDFSDETNTENLYGTSPPSTPRQMKRMSTKHQ RNNVGRPASRSNLKEKMNAPNQPPHKDTGKTVENVEEYSYKQEKKIRAAL RTTERDHKKNVQCSFMLDSVGGSLPKKSIPDVDLNKPYLSLGCSNAKLPV SVPMPIARPARQTSRTDCPADRLKFFETLRLLLKLTSVSKKKDREQRGQE NTSGFWLNRSNELIWLELQAWHAGRTINDQDFFLYTARQAIPDIINEILT FKVDYGSFAFVRDRAGFNGTSVEGQCKATPGTKIVGYSTHHEHLQRQRVS FEQVKRIMELLEYIEALYPSLQALQKDYEKYAAKDFQDRVQALCL
- the disclosure provides agents to modulate the expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof.
- the agent is an inhibitor or antagonist of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, that selectively blocks MAP kinase pathway signaling.
- the agent is an inhibitor of MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof.
- Non-limiting illustrative examples include small molecules (e.g., of Tables 1 and 3), antibodies, antisense and/or siRNA molecules directed to inhibit MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof.
- Agents useful in the methods of the disclosure can be nucleic acid molecules, e.g., antisense, ribozyme, or RNA interference technology, e.g., siRNA molecules corresponding to a portion of the nucleotide sequence encoding a component member of the MAP kinase pathway (e.g., a nucleic acid encoding Mmp17, Map2k6 and/or Map3k4).
- nucleic acid molecules e.g., antisense, ribozyme, or RNA interference technology, e.g., siRNA molecules corresponding to a portion of the nucleotide sequence encoding a component member of the MAP kinase pathway (e.g., a nucleic acid encoding Mmp17, Map2k6 and/or Map3k4).
- Antisense polynucleotides may act by directly blocking translation by hybridizing to mRNA transcripts or degrading such transcripts of a gene.
- the antisense molecule may be recombinantly made using at least one functional portion of a gene in the antisense orientation as a region downstream of a promoter in an expression vector. Chemically modified bases or linkages may be used to stabilize the antisense polynucleotide by reducing degradation or increasing half-life in the body (e.g., methyl phosphonates, phosphorothioate, peptide nucleic acids).
- the sequence of the antisense molecule may be complementary to the translation initiation site (e.g., between ⁇ 10 and +10 of the target's nucleotide sequence).
- Ribozymes catalyze specific cleavage of an RNA transcript or genome. The mechanism of action involves sequence-specific hybridization to complementary cellular or viral RNA, followed by endonucleolytic cleavage. Inhibition may or may not be dependent on ribonuclease H activity.
- the ribozyme includes one or more sequences complementary to the target RNA as well as catalytic sequences responsible for RNA cleavage (e.g., hammerhead, hairpin, axehead motifs).
- potential ribozyme cleavage sites within a subject RNA are initially identified by scanning the subject RNA for ribozyme cleavage sites which include the following trinucleotide sequences: GUA, GUU and GUC.
- an oligonucleotide of between about 15 and about 20 ribonucleotides corresponding to the region of the subject RNA containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render candidate oligonucleotide sequences unsuitable.
- the suitability of candidate sequences can then be evaluated by their ability to hybridize and cleave target RNA.
- the ribozyme may be recombinantly produced or chemically synthesized.
- siRNA refers to double-stranded RNA of at least 20-25 basepairs which mediates RNA interference (RNAi).
- Duplex siRNA corresponding to a target RNA may be formed by separate transcription of the strands, coupled transcription from a pair of promoters with opposing polarities, or annealing of a single RNA strand having an at least partially self-complementary sequence.
- duplexed oligoribonucleotides of at least about 21 to about 23 basepairs may be chemically synthesized (e.g., a duplex of 21 ribonucleotides with 3′ overhangs of two ribonucleotides) with some substitutions by modified bases being tolerated.
- RNA interference should be transcribed, preferably as a coding region of the gene. Interference appears to be dependent on cellular factors (e.g., ribonuclease III) that cleave target RNA at sites 21 to 23 bases apart; the position of the cleavage site appears to be defined by the 5′ end of the guide siRNA rather than its 3′ end. Priming by a small amount of siRNA may trigger interference after amplification by an RNA-dependent RNA polymerase.
- ribonuclease III e.g., ribonuclease III
- inhibition of MAP kinase components can be achieved by administration of inhibitory nucleic acids (e.g., dsRNAs, siRNAs, antisense oligonucleotides, etc.).
- inhibitory nucleic acids e.g., dsRNAs, siRNAs, antisense oligonucleotides, etc.
- CRISPR-Cas e.g., CRISPR-Cas9
- Such variant alleles include the variant alleles identified in mice, for at least MMP17 and MAP2K6 herein, and further including similar human alleles of these genes, as well as of MAP3K4.
- Such methods can be performed upon the cells of a subject in vivo or ex vivo. Use of any combination of the above and/or other known MAP kinase component modulators is also contemplated.
- the CRISPR-Cas system is known in the art. Non-limiting aspects of this system are described in U.S. Pat. No. 8,697,359, issued Apr. 15, 2014, the entire content of which is incorporated herein by reference.
- Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas 10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof.
- the amino acid sequence of S. pyogenes Cas9 protein may be found in the SwissProt database under accession number Q99ZW2.
- the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9.
- the CRISPR enzyme is Cas9, and may be Cas9 from S. pyogenes or S. pneumoniae .
- the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence.
- the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence.
- a vector encodes a CRISPR enzyme that is mutated with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence.
- D10A aspartate-to-alanine substitution
- pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand).
- Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A.
- nickases may be used for genome editing via homologous recombination.
- a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence.
- the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
- Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn; Ruiqiang Li, Yingrui Li, Karsten Kristiansen, Jun Wang; SOAP: short oligonucleotide alignment program, Bioinformatics , Volume 24, Issue 5, 1 Mar.
- any suitable algorithm for aligning sequences non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal
- a guide sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay.
- the components of a CRISPR system sufficient to form a CRISPR complex may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein.
- cleavage of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions.
- Other assays are possible, and will occur to those skilled in the art.
- a method for treating a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition comprises administering to the subject an effective amount of an agent that modulates the activity of MAP kinase pathway signaling and/or expression, function or activity of epidermal growth factor receptor (EGFR); thereby treating the subject.
- the agent that modulates the activity of MAP kinase pathway signaling is an inhibitor of the MAP kinase pathway.
- the agent that modulates the activity of MAP kinase pathway signaling is an inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof.
- the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof is an antisense agent or a double-stranded nucleic acid, optionally a siRNA or shRNA specific for MMP17, MAP2K6 or MAP3K4.
- the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof is specific for a nucleic acid molecule set forth as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8.
- the agent that modulates the activity of MAP kinase pathway signaling comprise Batimastat, GI 254023X, GM 6001, TMI 1, WAY 170523, WX-554 or combinations thereof. Any combination of inhibitors can be used, for example, an siRNA and a compound, e.g. GI 254023X, and/or an antibody.
- the agent that modulates expression, function or activity of epidermal growth factor receptor is an EGFR inhibitor comprising: an antibody, interfering RNAs microRNAs, shRNA, small molecule or combinations thereof.
- the EGFR inhibitor comprises: gefitinib, erlotinib, lapatinib, Brigatinib (AP26113), Afatinib (BIBW2992), Neratinib (HKI-272), AZD3759, AZ5104, CL-387785 (EKI-785), Canertinib (CI-1033), Poziotinib (HM781-36B), Osimertinib (AZD-9291), PD168393, CNX-2006, Rociletinib (CO-1686, AVL-301), WZ4002, Pelitinib (EKB-569), AC480 (BMS-599626), TAK-285, CUDC-101, AEE788 (NVP-AEE788), CP-724714, Dacomitinib (PF299804, PF299), AG-490 (Tyrphostin B42), AST-1306, OSI-420, WHI-P154,
- An anti-EGFR antibody comprises cetuximab, matuzumab, panitumumab, nimotuzumab or mAb 806 and a small molecule EGFR inhibitor comprises gefitinib, lapatinib, canertinib, erlotinib HCL, pelitinib, PKI-166, PD158780, or AG 1478.
- combinations of agents e.g. antibody or small molecules, can be administered as part of the therapy.
- an inhibitor of transforming growth factor ⁇ (TGF ⁇ ) is also administered.
- a pharmaceutical composition comprises a therapeutically effective amount of at least one agent that modulates expression, function or activity of MMP17, MAP2K6, MAP3K4, epidermal growth factor receptor (EGFR), or combinations thereof.
- An exemplary anti-EGFR antibody is cetuximab (ERBITUXTM). Cetuximab is commercially available from ImClone Systems Incorporated. Other examples of anti-EGFR antibodies include matuzumab (EMD72000), panitumumab (VECTIBIXTM; Amgen); nimotuzumab (THERACIMTM) and mAb 806.
- An exemplary small molecule inhibitor of the EGFR signaling pathway is gefitinib (IRESSATM), which is commercially available from AstraZeneca and Teva.
- small molecule inhibitors of the EGFR signaling pathway include erlotinib HCL (OSI-774; TARCEVATM, OSI Pharma); lapatinib (TYKERBTM, GlaxoSmithKline); canertinib (canertinib dihydrochloride, Pfizer); pelitinib (Pfizer); PKI-166 (Novartis); PD158780; and AG 1478 (4-(3-Chloroanillino)-6,7-dimethoxyquinazoline).
- the EGFR inhibitor may be an EGFR tyrosine kinase inhibitor, or may alternatively target the extracellular domain of the EGFR target.
- the EGFR inhibitor is a tyrosine kinase inhibitor such as Erlotinib, Gefitinib, or Lapatinib, or a molecule that targets the EGFR extracellular domain such as Cetuximab or Panitumumab.
- the EGFR inhibitor is an anti-EGFR antibody, preferably a monoclonal antibody, such as Cetuximab or Panitumumab.
- Cetuximab and Panitumumab are currently the clinically mostly used anti-EGFR monoclonal antibodies.
- further anti-EGFR monoclonal antibodies are in development, such as Nimotuzumab (TheraCIM-h-R3), Matuzumab (EMD 72000), Zalutumumab (HuMax-EGFr), Nimotuzumab and Sym 004.
- Erlotinib, Gefitinib, Lapatinib and Regorafenib are currently the clinically mostly used tyrosine kinase EGFR inhibitors.
- tyrosine kinase EGFR inhibitors are in development, such as Canertinib (CI-1033), Neratinib (HKI-272), Afatinib (BIBW2992), Dacomitinib (PF299804, PF-00299804), TAK-285, AST-1306, ARRY334543, AG-1478 (Tyrphostin AG-1478), AV-412, OSI-420 (DesmethylErlotinib), AZD8931, AEE788 (NVP-AEE788), Pelitinib (EKB-569), CUDC-101, AG 490, PD153035 HCL, XL647, Ruxolitinib, and BMS-599626 (AC480).
- Canertinib CI-1033
- Neratinib HKI-272
- Afatinib BW2992
- Dacomitinib PF299804, PF-00299804
- the method according to the invention may also be used to predict response to these tyrosine kinase EGFR inhibitors or any other tyrosine kinase EGFR inhibitors that might be further developed, in particular if the patient is suffering from of lung cancer (in particular non-small cell lung cancer, NSCLC), pancreatic cancer, or head and neck cancer (in particular squamous cell carcinoma of the head and neck (SCCHN)).
- lung cancer in particular non-small cell lung cancer, NSCLC
- pancreatic cancer in particular squamous cell carcinoma of the head and neck (SCCHN)
- TGF ⁇ Transforming growth factor beta
- MFS Massagu, J., et al. Cell 103, 295-309 (2000).
- the TGF ⁇ family of cytokines influences a diverse repertoire of cellular processes including cell proliferation, survival and synthetic activity.
- the TGF ⁇ ligand isoforms bind to a cell surface complex of type 1 and 2 TGF ⁇ receptor subunits (T ⁇ RI and T ⁇ RII respectively). These in turn phosphorylate the canonical cytoplasmic receptor-activated SMAD (R-SMADs) proteins, SMAD2 or SMAD3.
- R-SMADs canonical cytoplasmic receptor-activated SMAD
- TGF ⁇ receptors can also initiate activation of noncanonical cascades including the mitogen activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK1/2), Jun N-terminal kinase (JNK1/2) and p38.
- MAPKs mitogen activated protein kinases
- ERK1/2 extracellular signal-regulated kinase
- JNK1/2 Jun N-terminal kinase
- p38 mitogen activated protein kinases
- ERK1/2 extracellular signal-regulated kinase
- JNK1/2 Jun N-terminal kinase
- p38 Jun N-terminal kinase
- TGF ⁇ neutralizing antibody NAb
- Ang-II angiotensin-II type 1 receptor blocker
- RDEA119 the inhibitor of ERK1/2 activation RDEA119
- TGF ⁇ inhibitors include ligand traps, antisense oligonucleotides (ASO), small molecule receptor kinase inhibitors and peptide aptamers.
- Ligand traps include anti-ligand neutralizing antibodies and soluble decoy receptor proteins that incorporate the ectodomains from either TGF ⁇ receptor II (T ⁇ RII) or TGF ⁇ receptor III (T ⁇ RIII)/betaglycan protein. Neutralizing antibodies have been raised against individual ligands or may be designed to block all three human isomers TGF ⁇ 1, -2 and -3.
- ASO can also be used to reduce the bioavailability of active TGF ⁇ ligands by blocking de novo synthesis of TGF ⁇ .
- ASOs are single-stranded polynucleotide molecules, usually 13-25 nucleotides in length, that hybridize to complementary RNA, inhibiting mRNA function, and preventing protein synthesis through accelerated mRNA degradation by RNase H or steric blockade.
- Another therapeutic strategy is to block TGF ⁇ receptor I (T ⁇ RI) activity through the use of small molecule receptor kinase inhibitors that act via ATP-competitive inhibition of the catalytic domain of the serine-threonine kinase of the T ⁇ RI (ALK5-Receptor).
- TGF ⁇ receptor I TGF ⁇ receptor I
- ALK5-Receptor small molecule receptor kinase inhibitors that act via ATP-competitive inhibition of the catalytic domain of the serine-threonine kinase of the T ⁇ RI
- T ⁇ signaling molecules such as Smads, is possible with the use of peptide aptamers.
- Aptamers are small peptide, DNA
- an inhibitor of TGF ⁇ or TGF ⁇ signaling is administered as part of a therapeutic regimen.
- TGF ⁇ signaling controls proliferation, cellular differentiation, and other functions in a variety of cell types, and can play a role in cell cycle control, regulation of the immune system, and development in certain cell types.
- TGF ⁇ signaling may include inhibition of any TGF ⁇ signaling pathway and/or member of the TGF ⁇ superfamily including ligands such as TGF ⁇ 1, TGF ⁇ 2, TGF ⁇ 3, inhibins, activin, anti-mullerian hormone, bone morphogenetic protein, decapentaplegic and Vg-1; receptors such as TGF ⁇ type I receptor, TGF ⁇ type II receptor, ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, ALK7 and ALK8; and downstream effectors such as R-SMAD and other SMAD proteins (e.g., SMAD1, SMAD2, SMAD3, SMAD4, SMAD5).
- ligands such as TGF ⁇ 1, TGF ⁇ 2, TGF ⁇ 3, inhibins, activin, anti-mullerian hormone, bone morphogenetic protein, decapentaplegic and Vg-1
- receptors such as TGF ⁇ type I receptor, TGF ⁇ type II receptor, ALK1, ALK2, ALK3, ALK4, ALK5,
- the activity of one or more TGF ⁇ receptors is inhibited. In some embodiments, one or more TGF ⁇ receptor-ligand interactions are inhibited. In some embodiments, a TGF ⁇ type I receptor is inhibited.
- a TGF ⁇ type I receptor may include one or more of ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, ALK7 and ALK8. In some embodiments, the TGF ⁇ receptor is ALK5.
- a TGF ⁇ inhibitor may be an ALK5 inhibitor, in some embodiments.
- An ALK5 inhibitor may bind to ALK5 or one or more ALK5 ligands or both.
- An ALK5 inhibitor may bind to ALK5 or one or more downstream SMAD proteins or both.
- An ALK5 inhibitor may disrupt one or more ALK5-ligand interactions or may disrupt one or more ALK5-SMAD interactions.
- an ALK5 inhibitor blocks phosphorylation of SMAD2.
- ALK5 inhibitors may include one or more small molecule ALK5 inhibitors.
- an ALK5 inhibitor is an ATP analog.
- a TGF ⁇ inhibitor of the present invention interacts with a TGF ⁇ receptor, inhibits the signaling of the receptor, interacts with a TGF ⁇ protein, and/or inhibits the transcription and/or translation of the gene encoding TGF ⁇ -1, -2, and/or -3.
- the TGF ⁇ inhibitor of the present invention inhibits TGF ⁇ 1, TGF ⁇ 2, and/or TGF ⁇ 3; in case an inhibitor inhibits all three TGF ⁇ isotypes, the inhibitor is a pan-specific inhibitor.
- TGF ⁇ inhibitors include: A) a small molecule inhibitor of TGF ⁇ receptor type I kinase (ALK5; an inhibitor is an ALK5 inhibitor), B) a neutralizing anti-TGF ⁇ -1, -2, -3 antibody or TGF ⁇ binding fragments thereof, C) a neutralizing anti-TGF ⁇ receptor type I, type II or type III antibody or TGF ⁇ receptors binding fragments thereof, D) an antisense oligonucleotide specific for mRNA encoding TGF ⁇ 1, -2, and -3 isotypes or other components of TGF ⁇ signaling assembly optionally comprising a modified nucleoside such as 2′-O, 4′-C-methylene linked bicyclic ribonucleotides, known as locked nucleic acids LNA (e.g., oxy-LNA, amino-LNA, thio-LNA), phosphorodiamidate morpholino oligomers (PMO), phosphorothioate (PS), 2′-O-methyl (2
- ASOs are single-stranded polynucleotide molecules comprising 13-25 nucleotides, preferably 15-20 nucleotides, more preferred 15, 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides, that hybridize to complementary RNA, inhibiting mRNA function, and preventing protein synthesis for example through accelerated mRNA degradation by RNase H or steric blockade.
- a TGF ⁇ inhibitor binding to TGF ⁇ receptor type I such as a non-peptide, small molecule inhibitor of ALK-5 kinase from dihydropyrolopyrazole derivatives (e.g., LY2157299, LY21109761, LY580276, LY550410, GW788388), pyrazole derivatives (e.g., LY364947, HTS-466284, SM305, SB525334, A-83-01), quinazoline derivatives (e.g., SD-208), or imidazole derivatives (e.g., SM16, SB431542, or SB505124).
- dihydropyrolopyrazole derivatives e.g., LY2157299, LY21109761, LY580276, LY550410, GW788388
- pyrazole derivatives e.g., LY364947, HTS-466284, SM305, SB525334, A-
- a human pan-anti-TGF ⁇ antibody binding to and neutralizing all three isotypes of TGF ⁇ e.g., TGF ⁇ 1, 2, 3) like GC-1008, a neutralizing high-affinity antibody or antigen-binding immunoglobulin single variable domain or polypeptide thereof, that neutralize mature human TGF ⁇ 1 (like CAT 192), or hTGF ⁇ 2 (like CAT 152), and neutralizing anti-TGF ⁇ receptor type II antibody (like D10) or an antibody fragment thereof which binds and neutralizes human TGF ⁇ receptor type II, a fusion protein comprising a TGF ⁇ type II receptor fusion protein, a small molecule or peptide consisting of, for example, 11-50 amino acid residues blocking assembly of the TGF ⁇ signaling complex extra- and intracellularly.
- compositions for the treatment of the diseases, disorders and conditions disclosed herein.
- pharmaceutical composition includes preparations suitable for administration to mammals, e.g., humans.
- the compounds used in the methods of the present disclosure are administered as pharmaceuticals to mammals, e.g., humans, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
- phrases “pharmaceutically acceptable carrier” is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present disclosure to mammals.
- the carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer'
- wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- antioxidants examples include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (13HT), lecithin, propyl gallate, ⁇ -tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (13HT), lecithin
- Formulations of the present disclosure include those suitable for oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present disclosure with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present disclosure with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the disclosure suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present disclosure as an active ingredient.
- a compound of the present disclosure may also be administered as a bolus, electuary or paste.
- the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostea
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions of the present disclosure may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions that can be used include polymeric substances and waxes.
- the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compounds of the disclosure include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and e
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions of the disclosure for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the disclosure with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- Formulations of the present disclosure which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this disclosure, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present disclosure to the body.
- dosage forms can be made by dissolving or dispersing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
- Ophthalmic formulations are also contemplated as being within the scope of this disclosure.
- compositions of this disclosure suitable for parenteral administration comprise one or more compounds of the disclosure in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
- the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue,
- the preparations of the present disclosure may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred.
- parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracistemally and topically, as by powders, ointments or drops, including buccally and sublingually.
- the compounds of the present disclosure which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present disclosure, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present disclosure employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- the physician or veterinarian could start doses of the compounds of the disclosure employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of a compound of the disclosure will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this disclosure for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 50 mg per kg per day, and still more preferably from about 1.0 to about 100 mg per kg per day. An effective amount is that amount treats a disease, disorder or condition set forth herein.
- the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- a compound of the present disclosure While it is possible for a compound of the present disclosure to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
- Nucleic acid agents can be effectively delivered to a subject as stabilized agents, with such stability often provided via lipid nanoparticle (LNP) encasement of active nucleic acid agents and/or modification of therapeutic nucleic acid agents with one or more stabilizing modifications, including, e.g., 2′-O-alkyl modifications (including 2′-O-methyl), 2′-F modifications, backbone modifications, locked nucleic acid (LNA) configurations, GalNAc modifications, cholesterol conjugates, etc.
- LNP lipid nanoparticle
- stabilizing modifications including, e.g., 2′-O-alkyl modifications (including 2′-O-methyl), 2′-F modifications, backbone modifications, locked nucleic acid (LNA) configurations, GalNAc modifications, cholesterol conjugates, etc.
- LNA locked nucleic acid
- Marfan syndrome or associated diseases, disorders and conditions is intended to mean Marfan syndrome or any one of the multitude of diseases disorders or conditions that is caused or associated with the biochemical events that cause Marfan syndrome, e.g., the aberrant expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof.
- exemplary conditions include aneurysm, an aortic aneurysm, valve disease, emphysema, myopathy, scoliosis, or eye disease.
- Exemplary eye diseases include cataracts, myopia, glaucoma, and retinal detachment.
- Marfan syndrome or associated diseases, disorders and conditions include diseases and disorders that related to muscle growth, maintenance, or regeneration, e.g., muscular dystrophies such as Duchenne muscular dystrophy.
- the disease or disorder can be a lung disease or disorder, e.g., emphysema, pneumothorax, and COPD.
- treatment includes the diminishment or alleviation of at least one symptom associated or caused by Marfan syndrome, or an associated disease, disorder or condition.
- treatment can be diminishment of one or several symptoms of a disease or disorder or complete eradication of the disease or disorder, e.g., Marfan syndrome.
- subject is intended to include organisms, e.g., prokaryotes and eukaryotes, which are capable of suffering from or afflicted with Marfan syndrome, or a disease, disorder or condition related thereto.
- subjects include mammals, e.g., humans, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals.
- the subject is a human, e.g., a human suffering from, at risk of suffering from, or potentially capable of suffering from a Marfan syndrome, or a disease, disorder or condition related thereto.
- the agents and pharmaceutical compositions of the disclosure can be administered to a subject to treat or prevent diseases, disorders and conditions associated with aberrant expression or activity of a MAP kinase pathway component, e.g., MMP7, MAP2K6 and/or MAP3K4, or a gene product thereof.
- a MAP kinase pathway component e.g., MMP7, MAP2K6 and/or MAP3K4, or a gene product thereof.
- the agents and pharmaceutical compositions are used to treat or prevent Marfan syndrome or diseases or disorders associated with Marfan syndrome.
- the agents or pharmaceutical compositions are administered in an effective amount using a dosing schedule determined by a medical provider to treat or prevent a disease or disorder set forth herein.
- the agents or pharmaceutical compositions can be administered in a variety of methods, as described herein and known to one of skill in the art.
- the disclosure provides a method for preventing in a subject, a disease or condition associated with an aberrant expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, by administering to the subject an agent which modulates expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof.
- a MAP kinase pathway component e.g., MMP17, MAP2K6 and/or MAP3K4
- Subjects at risk for a disease which is caused or contributed to by aberrant expression or activity of a MAP kinase pathway component can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.
- Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the aberrancy of expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, such that a disease or disorder is prevented or, alternatively, delayed in its progression.
- the modulatory method of the disclosure involves contacting a cell with an agent that modulates one or more of the activities of a component of a MAP kinase signaling pathway, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof.
- An agent that modulates expression or activity of a MAP kinase pathway component e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof can be an agent as described herein, such as a nucleic acid, a polypeptide, or a small molecule.
- the agent inhibits one or more activities of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, and/or inhibits one or more components of the MAP kinase pathway.
- inhibitory agents include antisense MMP17, MAP2K6 and/or MAP3K4 nucleic acid molecules, anti-Mmp17, -Map2k6 and/or -Map3k4 antibodies, and small molecule inhibitors of Mmp17, Map2k6 and/or Map3k4.
- modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject).
- the present disclosure provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant MAP kinase pathway signaling, e.g., Marfan syndrome or an associated disease or disorder.
- the method involves administering an agent, or combination of agents that modulates MAP kinase pathway signaling.
- kits comprising agents or pharmaceutical compositions of the disclosure and instructions for use.
- the kits of the disclosure are for the treatment of diseases and disorders characterized by aberrant MAP kinase pathway signaling.
- the MAP kinase pathway signaling associated disease or disorder is Marfan syndrome or a disease or disorder related to Marfan syndrome.
- Example 1 Involvement of MAP Kinase Pathway Components Map3k4, Map2k6 and Mmp17 in Marfan Syndrome
- 129 MFS mice exhibited a highly significant increase in aortic root size, post-natal aortic root growth and premature lethality from dissection, compared with BL6 MFS counterparts, in association with increased activation of both Smad2/3 and Erk1/2 cascades. All aortic parameters in 129 MFS mice were fully rescued by both losartan and RDEA119. 129/MFS mice also showed worse lung emphysema and spine kyphosis, with significant correlation between aortic root size and these phenotypes, indicating deleterious systemic genetic modification in 129 MFS mice. Wild type (WT) mice on the two background strains showed no difference in any parameter, indicating MFS disease-specific modification.
- Haploinsufficiency for Map2k6 and Mmp17 rescued aortic root growth in 129 MFS mice by approximately 50%, while knockout of these two genes reduced aortic root growth in 129 MFS mice to a rate indistinguishable from that of their BL6 MFS counterparts.
- mice All mice were cared for under strict compliance with the Animal Care and Use Committee of the Johns Hopkins University School of Medicine.
- the Fbn1 C1039G/+ line was initially maintained in a pure C57BL/6 background (backcrossed for greater than 9 generations), allowing for valid comparisons, prior to backcrosses with Sv29 mice, performed as described above. In order to further accommodate the potential for temporal- or background-specified variation, all comparisons were made between contemporary littermates when possible. Mice were sacrificed with an inhalation overdose of halothane (Sigma-Aldrich, St. Louis).
- mice underwent immediate laparotomy, descending abdominal aortic transection, and PBS (pH 7.4) was infused through the right and left ventricles to flush out the blood.
- Mice that were analyzed for aortic histology had latex injected under low pressure into the left ventricular apex until it was visible in the descending abdominal aorta.
- Mice were fixed for 24 hours in 10% buffered formalin, after which the heart, aorta and lungs were removed and stored in 70% ethanol.
- Echocardiography Nair hair removal cream was used on all mice the day prior to echocardiograms. All echocardiograms were performed on awake, unsedated mice using the Visualsonics Vevo 660 V1.3.6 imaging system and a 30 MHz transducer. Mice were imaged at baseline, and at six months, when also sacrificed. The aorta was imaged using a parasternal long axis view. Three separate measurements of the maximal internal dimension at the sinus of Valsalva and proximal ascending aorta were made from distinct captured images and averaged. All imaging and measurements were performed by a cardiologist who was blinded to genotype.
- Latex-infused ascending aortas were transected just above the level of the aortic valve, and 2-3 mm transverse sections were mounted in 4% agar prior to paraffin fixation.
- Five micrometer aortic sections underwent Verhoeff-van Giesen (VVG) staining and were imaged at 40 ⁇ magnification, using a Nikon Eclipse E400 microscope. Wall thickness of the aortic media was measured by a single blinded observer at 16 different locations around the most proximal ascending aortic ring and averaged.
- VVG Verhoeff-van Giesen
- Wall architecture of 4 representative sections for each mouse was assessed by the same 3 blinded observers and graded on an arbitrary scale of 1 (indicating no breaks in the elastic fiber) to 5 (indicating diffuse fragmentation), and the results were averaged.
- Elastic fiber content was quantified in four separate representative images of each section of the most proximal ascending aorta by a single blinded observer, using NIS Elements Advanced Research (Nikon, Japan). The aortic media and the elastic fibers were individually outlined and their areas calculated. The respective areas were averaged from all the images of a given aortic section and the ratio of elastic fiber content to total aortic media was determined.
- Aortic root size was measured by echocardiography at six months (baseline before treatment).
- Marfan syndrome is an inherited connective tissue disorder caused by heterozygous mutations in the FBN1 gene.
- the major cause of mortality is aortic aneurysm, dissection and/or rupture.
- mice were cared for under compliance with the Animal Care and Use Committee of the Johns Hopkins University School of Medicine.
- Fbn1 C1039G/+ mice on a pure C57BL/6J background were already onsite.
- Mice on a pure 12956/SvEvTac background were obtained from Taconic Biosciences (Rensselaer County, NY, USA).
- the Fbn1 C1039G/+ mice on a pure C57BL/6J background were bred into a pure 12956/SvEvTac background and backcrossed for >10 generations.
- mice haploinsufficient or knockout for Mmp17 (B6.129P2-Mmp17 tm1D g en /J; #005824), Map2k6 (B6.12951-Map2k6 tm1Flv /J; #008382) and Map3k4 (B6.129S6-Map3k4 tm1Flv /J; #008375) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA), and bred to Fbn1C1039G/+ mice. Animals were checked daily for death and all mice found dead were immediately autopsied to assess for evidence of aortic dissection.
- mice that were sacrificed were done so using a lethal dose of ketamine and acepromazine (1 ml of 10 mg/ml acepromazine in 10 mls of 100 mg/ml ketamine; MWI Vet, ID, USA).
- mice underwent immediate laparotomy and descending abdominal aortic transection.
- Phosphate buffered saline (PBS) was infused through the right and left ventricles to flush out the blood.
- Treatment was initiated at 2 months of age and continued for 2 months. 10% 2-hydroxypropyl-beta-cyclodextrin dissolved in PBS was administered as a control.
- Erlotinib was reconstituted in 1% methylcellulose (Sigma-Aldrich) dissolved in PBS, and administered daily by oral gavage at a dose of 50 mg/kg. Treatment was initiated at 2 months of age and continued for 2 months. 1% methylcellulose dissolved in PBS was administered as a control.
- Mouse echocardiography Nair hair removal cream was used on all mice the day prior to echocardiography. All echocardiograms were performed on awake, unsedated mice using the VisualSonics Vevo 2100 imaging system and a 30 MHz transducer (Fujifilm VisualSonics, ON, Canada). The aorta was imaged using a parasternal, long-axis view. Three separate measurements of the maximal internal dimension at the sinus of Valsalva and proximal ascending aorta were made from distinct captured images and averaged. All imaging and measurements were performed blinded to genotype and treatment arm.
- Mouse blood pressure analysis Blood pressures were analyzed by taking 20 tail cuff blood pressures per day over 5 days in each mouse to habituate the mice to the tail cuff blood pressure system (BP-2000, Visitech Systems, USA), and the blood pressures obtained on the last day were averaged.
- BP-2000 tail cuff blood pressure system
- Mouse aorta Western Blot analysis Mice that were sacrificed for Western Blot analysis had their proximal ascending aortas immediately dissected, flash frozen in liquid nitrogen and stored at ⁇ 80° C. until further processing. Protein was extracted using the reagents and protocol from a Total Protein Extraction Kit containing protease inhibitor and Protein Phosphatase Inhibitor Cocktail (Millipore, MA, USA). Aortas were homogenized using a pellet pestle motor (Kimble-Kontes, NJ, USA) as per the extraction kit protocol. Samples were then stored once more at ⁇ 80° C. until Western blot analysis was performed.
- Aortic tissue homogenates were dissolved in sample buffer, run on a NuPAGE Novex 4-12% Bis-Tris Gel (Invitrogen, CA, USA), and transferred to nitrocellulose membranes using the iBlot transfer system (Invitrogen). Membranes were washed in PBS and blocked for 1 hour at room temperature with 5% instant non-fat dry milk dissolved in PBS containing 1% Tween-20 (Sigma-Aldrich; PBS-T). Equal protein loading of samples was determined by a protein assay (Bio-Rad, CA, USA) and confirmed by probing with an antibody against R-Actin (Sigma-Aldrich #A5316).
- Membranes were probed overnight at 4° centigrade with primary antibodies against pSmad2 (Cell Signaling, MA, USA #3108), pSmad3 (Cell Signaling #9250), pErk1/2 (Cell Signaling #4370), pMek1 (Cell Signaling #9154), pp38 (Cell Signaling #4511), pJnk1/2 (Santa Cruz #6254), pPkc ⁇ (Cell Signaling #9371), and pEgfr (Cell Signaling #3777), dissolved in PBS-T containing 5% milk.
- pSmad2 Cell Signaling, MA, USA #3108
- pSmad3 Cell Signaling #9250
- pErk1/2 Cell Signaling #4370
- pMek1 Cell Signaling #9154
- pp38 Cell Signaling #4511
- pJnk1/2 Cell Signaling #9371
- pEgfr Cell Signaling #3777
- Blots were then washed in PBS-T and probed with HRP-conjugated anti-rabbit or anti-mouse secondary antibodies (GE Healthcare, UK #NA934) dissolved in PBS-T containing 5% milk for 1 hour at room temperature. Blots were then washed in PBS-T, developed using SuperSignal West Femto HRP substrate (Pierce Scientific, IL, USA), exposed to BioMax Scientific Imaging Film (Sigma), and quantified using ImageJ analysis software (NIH, MD, USA).
- Mouse skeletal X-ray analysis Mice undergoing spine X-ray were anesthetized using a combination of ketamine and xylazine (1 ml of 100 mg/ml ketamine and 100 ⁇ l of 100 mg/ml xylazine in 10 mls of PBS; MWI Vet). They were placed in the left lateral decubitus position on a radiolucent platform with adjacent scale bar and imaged at 1 ⁇ magnification using a Faxitron MX20 (Faxitron, AZ, USA). The output electronic file was processed using ImageJ analysis software (NIH). Spine kyphosis was quantified using a modified kyphosis index (Laws, N., Hoey, A. J. Appl.
- a line was drawn from the anterior superior iliac spine to the point of maximal lordosis of the cervical spine.
- a line was then drawn perpendicular from this line to the anterior aspect of the vertebral body at the point of maximal thoracic kyphosis.
- SNPs were selected from the Illumina mouse medium density linkage panel array that were divergent between the C57BL/6J and 12956/SvEvTac background strains. Genotyping was performed using an Illumina mouse medium density linkage panel, and was run using standard GoldenGate chemistry on an iScan microarray scanner (Illumina, CA, USA). Genotypes were called using Illumina GenomeStudio software (GenomeStudio 2011.1, Genotyping Module 1.9.4 and Gentrain version 1.0). The average physical coverage was 2.9 Mb, the maximum gap was 22.4 Mb and there were 10 gaps >12 Mb. The genotype quality score cut-off for a “no call” genotype was 0.25.
- the “scanone” function calculated the genome-wide LOD significance threshold for this dataset as 3.82.
- the “scantwo” function was used to perform a two-dimensional genome scan with a two-QTL model utilizing a binary model.
- the recommended significance threshold for a mouse intercross using this function was a MfLOD >9.1. Since the “scantwo” function does not compute a p-value, we performed ANOVA plus a post-hoc linear trend test of the raw continuous data to generate a p-value for the 129 allele dose-response graph.
- DNeasy blood and tissue kit Qiagen, CA, USA.
- individuals harboring an FBN1 mutation were classified as affected; they were assigned a severe status if they had an aortic root Z score >3.0, a history of aortic root dissection or a history of aortic root surgery; they were assigned a mild status if they had an aortic root Z-score ⁇ 2.0 or had reached age 60 years without prior aortic root dissection or aortic root surgery; those with a Z score 2.0-3.0 were classed as indeterminate. Individuals without an FBN1 mutation were classified as unaffected.
- Genome-Wide Human SNP Nsp/Sty Array 5.0 or 6.0 according to the manufacturer's recommended protocol (Affymetrix, CA, USA).
- the arrays were then scanned using a GeneChip Scanner 3000 7G (Affymetrix).
- the genomic location of each marker was determined from the Affymetrix Genetic Map (Affymetrix).
- SNPs were selected that were present on both the Affymetrix 5.0 and 6.0 Array using PLINK. Allele frequencies for this SNP set were calculated using PLINK. Tests for Hardy-Weinberg equilibrium (HWE) and Mendelian errors were calculated for autosomal SNPs using Pedstats.
- HWE Hardy-Weinberg equilibrium
- Parametric linkage analysis was performed following the maximized maximum LOD score (MMLS) procedure with the restricted set of SNPs using MERLIN/MinX. The analysis was performed twice, once under a dominant model and once under a recessive model, considering a low sporadic rate (0.0002), an arbitrary penetrance (0.50 and 0.80 for one and two alleles respectively), and arbitrary gene frequencies (0.01 for the dominant model and 0.1 for the recessive model). The limits of the regions of interest were defined by the closest neighboring upstream and downstream SNP markers with LOD scores >1 levels below the peak identified by parametric linkage analysis. Haplotypes were established for all genotyped individuals across the regions of interest.
- Candidate genes were cycle sequenced across all exons, exon/intron boundaries and potential non-coding functional variants from the ENCODE dataset (defined as SNPs in regions associated with DNase hypersensitivity, transcription factor occupancy, histone modification and a MAF ⁇ 0.15) in 2 individuals with mild disease and 2 individuals with severe disease from each family. Firstly, targeted segments of DNA were amplified by PCR using a DNA Engine Dyad thermal cycler (Bio-Rad). Next, the samples were purified using QIAquick PCR purification kit (Qiagen). Finally, cycle sequencing was performed using BigDye Terminator v3.1 kit and an ABI 3730xl DNA Analyzer/sequencing machine in accordance with the manufacturer's instructions (Life Technologies, CA, USA).
- Human dermal fibroblast quantitative RT-PCR expression analysis Primary human dermal fibroblasts were derived from forearm skin biopsies from 2 control individuals, 2 patients in family B with severe aortic disease and 2 patients from family B with mild aortic disease. Cells were incubated in T-75 flasks at 37° C. with 95% air and 5% CO2 whilst submerged in Dulbecco's modified eagle medium (Gibco, Life Technologies) containing 10% fetal bovine serum (Sigma-Aldrich), antibiotics and antimycotic (Gibco). Media was replaced every 3 days. Cells were passaged at 95-100% confluence.
- mice were characterized as heterozygous for a disease-causing Fbn1 allele (Fbn1 C1039G/+ ) on a pure C57BL/6J mouse background (hereafter termed BL6 MFS mice). These mice have been shown to recapitulate multiple manifestations of the disease, including aortic root aneurysm, developmental lung emphysema, and skeletal deformity (Neptune, E. R. et al. Nature Genetics 33, 407-11 (2003); Habashi, J. P. et al. Science 312, 117-21 (2006); Judge, D. P. et al. J. Clin. Invest.
- mice were backcrossed greater than 10 generations onto a 129S6/SvEvTac background (hereafter termed 129 MFS mice), to assess the impact of mouse strain on MFS disease phenotype.
- MFS mice were interbred on the 2 pure strains to generate MFS animals on a mixed genetic background.
- the F1 generation MFS mice displayed an aortic root size that was intermediate between the 2 parental strains ( FIG. 10 ).
- Mice from the F1 and later generations were interbred to produce a 7-generation pedigree that contained circa 300 MFS mice possessing a range of aortic aneurysm severity.
- Genome-wide linkage analysis was performed on 35 MFS mice with mild aortic aneurysm (root size ⁇ 2.20 mm at 6 months), and 40 MFS mice with severe aortic aneurysm (root size >2.70 mm at 6 months).
- Table 6 shows candidate functional variants that differed between the BL6 and 129 strains within the regions of interest on chromosomes 5 and 11 identified using the mouse genome project online repository that were disfavored by PROVEAN.
- Candidate functional variants were sort within both loci that differed between the 2 strains using the mouse genome project online repository (Table 6). Only 1 variant at each locus was predicted to be both functional and located in a gene likely to influence TGF3/MAPK signaling. On chromosome 11, a missense point mutation was identified in Map2k6, a known member of the MAPK signaling cascade, which was predicted to significantly alter protein function (rs51129320; n.11:110490856-110490856G>A; c. G227A; p.G76F; PROVEAN score ⁇ 3.66).
- the BL6 strain encodes a premature termination codon in Mmp17 relative to the 129 strain (rs29636438; n.5:129606538-129606538 G>A; c. A1737G; p.X579W), which creates a truncated protein that is missing the terminal 9 amino acids ( FIG. 11 ).
- This hydrophobic sequence at the C-terminus is critical to the protein's ability to anchor to the extracellular side of the cell membrane via a GPI anchor.
- Mmp17 and Map2k6 knockout mice (Mmp17′ and Map2k6 ⁇ / ⁇ ) were obtained from Jackson laboratories on a mixed BL6/129 background. These were crossed to 129 MFS mice to generate MFS animals with predominant but variable 129 strain content that were haploinsufficient or fully deficient for one or both genes. Mice deficient in both genes were born at expected Mendelian ratios and survived to adulthood without apparent deleterious consequence. MFS mice possessing the 129 sequence at the two genes of interest fully recapitulated both the aortic root size and biochemical signaling seen in pure 129 MFS mice ( FIGS. 3 C, 3 D ).
- aortic root size at 6 months was dependent on the number of functional Mmp17 and Map2k6 alleles, with MFS mice lacking both genes having an aortic size that was indistinguishable from that of pure BL6 MFS animals ( FIG. 3 C ).
- Western blot analysis of the aortic root in 10-month old MFS mice showed that knockout of both Mmp17 and Map2k6 led to attenuation of canonical and noncanonical signaling cascades to values at or below those of BL6 MFS mice ( FIG. 3 D ).
- Selective knockout of Mmp17 led to an intermediate suppression of these signaling cascades, indicating that the two genes act in an additive manner.
- MAP3K4 represented the outstanding candidate, based upon the fact that it lies directly upstream and is a direct activator of MAP2K6, one of the two modifier genes identified in MFS mice.
- a role for EGFR activation in MFS has not been recognized previously; whether this relates to a failed regulatory role of fibrillin-1, or represents a more indirect consequence of events in MFS pathogenesis remains to be determined.
- Such mechanisms could include EGFR transactivation via known modulators such as TGF ⁇ (Uchiyama-Tanaka Y., et al. Kidney Int. 62, 799-808 (2002); Vinals F., Pouyssegur J. Mol. Cell Biol. 21, 7218-30 (2001)), and/or Ang-II (Mehta P. K., Griendling K. K. Am. J. Physiol. Cell Physiol. 292, C82-97 (2007); Higuchi S., et al. Clin.
- Mmp2 and 9 are both activated in MFS mice in an Erk1/2-dependent manner (Xiong W., et al. Circ. Res. 110, e92-e101 (2012)), and can also mediate Ang-II-dependent Egfr transactivation and consequent Erk1/2 activation in vascular cells.
- Efgr inhibitor erlotinib can abrogate Ang-II infusion-mediated TGFI3 induction in vascular tissues, all of which suggests that deleterious feedforward loops involving TGF ⁇ , Ang-II and Egfr could influence MFS disease pathogenesis.
Abstract
The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.
Description
- The present application claims the benefit of U.S. Provisional Patent Application No. 62/466,197 filed Mar. 2, 2017, the entire contents of which are incorporated by reference herein.
- This invention was made with government support under Grant No.: R01 122586 awarded by the National Institutes of Health. The government has certain rights in the invention.
- Marfan syndrome (MFS) is a systemic connective tissue disorder with autosomal dominant inheritance, caused by mutations in the FBN1 gene. It has cardinal features involving the ocular, skeletal and cardiovascular systems, with the major cause of mortality resulting from aortic root dilatation, dissection and rupture.
- Many of the features of Marfan syndrome are common in the general population and represent a tremendous public health burden. These include aortic aneurysm (1-2% of the population at large), mitral valve prolapse (˜7%), emphysema (11%), scoliosis (0.5%), cataract (30%), arthritis (very common), and myopathy (many common genetic and acquired forms).
- As described below, the present disclosure features compositions and methods for the treatment of Marfan syndrome diseases and disorders.
- In one aspect, the instant disclosure provides a method for treating a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition involving administering to the subject an effective amount of an agent that modulates the activity of MAP kinase pathway signaling, thereby treating the subject.
- In one embodiment, the agent that modulates the activity of MAP kinase pathway signaling is a MAP kinase pathway inhibitor. In certain embodiments, the agent that modulates the activity of MAP kinase pathway signaling is an inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof. Optionally, the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof, is an antisense agent or a double-stranded nucleic acid, optionally a siRNA or shRNA specific for MMP17, MAP2K6 or MAP3K4.
- In certain embodiments, the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof, is specific for a nucleic acid molecule having at least a 50% sequence identity to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8.
- In certain embodiments, the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof, is specific for a nucleic acid molecule set forth as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8.
- In another embodiment, the agent that modulates the activity of MAP kinase pathway signaling is a small molecule. Optionally, the agent that modulates the activity of MAP kinase pathway signaling comprise Batimastat, GI 254023X, GM 6001, TMI 1, WAY 170523, WX-554 or combinations thereof.
- In certain embodiments, the agent that modulates the activity of MAP kinase pathway signaling is an antibody.
- In some embodiments, the Marfan syndrome-associated disease or disorder is a clinical condition associated with Marfan syndrome. Optionally, the disease or disorder is an aneurysm, an aortic aneurysm, or emphysema. In certain embodiments, the disease or disorder is an aneurysm.
- Another aspect of the disclosure provides a method for treating a subject having Marfan syndrome or a Marfan-associated condition involving identifying a variant allele of MMP17, MAP2K6 or MAP3K4 that produces elevated expression and/or activity of a gene product of the MMP17, MAP2K6 or MAP3K4 gene; and replacing the variant allele of MMP17, MAP2K6 or MAP3K4 with an allele of MMP17, MAP2K6 or MAP3K4 that does not produce elevated expression and/or activity of a gene product of the MMP17, MAP2K6 or MAP3K4 gene, thereby treating the subject.
- In one embodiment, the step of replacing the variant allele is performed via a CRISPR-Cas9 gene replacement process. Optionally, the step of replacing is performed ex vivo. In a related embodiment, re-introduction to the subject of a cell manipulated ex vivo to perform gene replacement treats the subject.
- In certain embodiments, the variant allele of MMP17, MAP2K6 or MAP3K4 that produces elevated expression and/or activity of a gene product of the MMP17, MAP2K6 or MAP3K4 gene comprises a nucleic acid sequence having at least a 50% sequence identity to SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.
- In certain embodiments, the variant allele of MMP17, MAP2K6 or MAP3K4 that produces elevated expression and/or activity of a gene product of the MMP17, MAP2K6 or MAP3K4 gene comprise nucleic acid sequences set forth as SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.
- An additional aspect of the disclosure provides a pharmaceutical composition for the treatment of a disease or disorder characterized by aberrant MAP kinase pathway expression or activity, where the pharmaceutical composition includes an agent that modulates the activity of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof.
- A further aspect of the disclosure provides a kit for identifying a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition that includes primers specific for amplification of MMP17, MAP2K6 and/or MAP3K4; a probe oligonucleotide, optionally fluorescently labeled, that specifically detects the presence of a MMP17, MAP2K6 and/or MAP3K4 amplicon, wherein detection of elevated expression of MMP17, MAP2K6 and/or MAP3K4 identifies the subject as having or at risk of developing Marfan Syndrome or a Marfan-associated condition; and instructions for use.
- In certain embodiments, the kit further includes a pharmaceutical composition of the instant disclosure.
- Another aspect of the disclosure provides a method for identifying and treating a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition involving: isolating a sample from the subject; assessing the expression level of MMP17, MAP2K6 and/or MAP3K4 in the sample, assessing the level of activity of a gene product of MMP17, MAP2K6 and/or MAP3K4 in the sample, and/or genotyping MMP17, MAP2K6 and/or MAP3K4 in the sample; identifying elevated expression of MMP17, MAP2K6 and/or MAP3K4 in the sample, identifying elevated activity of a gene product of MMP17, MAP2K6 and/or MAP3K4 in the sample, and/or identifying a genotype of MMP17, MAP2K6 and/or MAP3K4 in the sample that causes elevated expression and/or activity of MMP17, MAP2K6 and/or MAP3K4, or of a gene product thereof; and administering a therapy for Marfan Syndrome or a Marfan-associated condition to the subject, thereby treating the subject.
- In certain embodiments, a method for treating a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition comprises administering to the subject an effective amount of an agent that modulates the activity of MAP kinase pathway signaling and/or expression, function or activity of epidermal growth factor receptor (EGFR); thereby treating the subject.
- In certain embodiments, the therapy for Marfan Syndrome or a Marfan-associated condition comprises administration of a TGFβ NAb, losartan and/or an inhibitor of MMP17, MAP2K6 and/or MAP3K4, or of a gene product thereof.
- By “agent” is meant any small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide, or fragments thereof.
- By “ameliorate” is meant decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease.
- By “alteration” is meant a change (increase or decrease) in the expression levels or activity of a gene or polypeptide as detected by standard art known methods such as those described herein. As used herein, an alteration includes a 10% change in expression levels, preferably a 25% change, more preferably a 40% change, and most preferably a 50% or greater change in expression levels.
- By the terms “conjugated,” “linked,” “attached,” “fused” and “tethered,” when used with respect to two or more moieties, means that the moieties or domains are physically associated or connected with one another, either directly or via one or more additional moieties that serve as a linking agent, to form a structure that is sufficiently stable so that the moieties remain physically associated under the conditions in which the structure is used, e.g., physiological conditions. The linkage can be based on genetic fusion according to the methods known in the art or can be performed by, e.g., chemical cross-linking. The compounds and targeting agents may be linked by a flexible linker, such as a polypeptide linker or a synthetic linker. The polypeptide linker can comprise plural, hydrophilic or peptide-bonded amino acids of varying lengths. The term “associated” will be used for the sake of brevity and is meant to include all possible methods of physically associating each compound with one or more desired molecules or agents.
- By “detectable label” is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens. The detectable label is associated with a composition of interest by any possible methods of physically associating each compound to a detectable label.
- By “disease” is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include Marfan Syndrome.
- As used herein, the term “EGFR inhibitor” is intended to include therapeutic agents that inhibit, downmodulate, suppress or downregulate EGFR signaling activity. The term is intended to include chemical compounds, such as small molecule inhibitors (e.g., small molecule tyrosine kinase inhibitors) and biologic agents, such as antibodies, interfering RNA (shRNA, siRNA), soluble receptors and the like.
- By “effective amount” is meant the amount of a required to ameliorate the symptoms of a disease relative to an untreated patient. The effective amount of active compound(s) used to practice the present disclosure for therapeutic treatment of a disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an “effective” amount.
- The disclosure provides a number of targets that are useful for the development of highly specific drugs to treat or a disorder characterized by the methods delineated herein. In addition, the methods of the disclosure provide a facile means to identify therapies that are safe for use in subjects. In addition, the methods of the disclosure provide a route for analyzing virtually any number of compounds for effects on a disease described herein with high-volume throughput, high sensitivity, and low complexity.
- By “fragment” is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
- “Hybridization” means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. For example, adenine and thymine are complementary nucleobases that pair through the formation of hydrogen bonds.
- By “inhibitory nucleic acid” is meant a double-stranded RNA, siRNA, shRNA, or antisense RNA, or a portion thereof, or a mimetic thereof, that when administered to a mammalian cell results in a decrease (e.g., by 10%, 25%, 50%, 75%, or even 90-100%) in the expression of a target gene. Typically, a nucleic acid inhibitor comprises at least a portion of a target nucleic acid molecule, or an ortholog thereof, or comprises at least a portion of the complementary strand of a target nucleic acid molecule. For example, an inhibitory nucleic acid molecule comprises at least a portion of any or all of the nucleic acids delineated herein.
- By “marker” is meant any protein or polynucleotide having an alteration in expression level or activity that is associated with a disease or disorder.
- As used herein, “obtaining” as in “obtaining an agent” includes synthesizing, purchasing, or otherwise acquiring the agent.
- “Primer set” means a set of oligonucleotides that may be used, for example, for PCR. A primer set would consist of at least 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30, 40, 50, 60, 80, 100, 200, 250, 300, 400, 500, 600, or more primers.
- By “reduces” is meant a negative alteration of at least 10%, 25%, 50%, 75%, or 100%.
- By “reference” is meant a standard or control condition.
- A “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides or any integer thereabout or therebetween.
- By “siRNA” is meant a double stranded RNA. Optimally, an siRNA is 18, 19, 20, 21, 22, 23 or 24 nucleotides in length and has a 2 base overhang at its 3′ end. These dsRNAs can be introduced to an individual cell or to a whole animal; for example, they may be introduced systemically via the bloodstream. Such siRNAs are used to downregulate mRNA levels or promoter activity.
- By “specifically binds” is meant a compound or antibody that recognizes and binds a polypeptide of the disclosure, but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes a polypeptide of the disclosure.
- Nucleic acid molecules useful in the methods of the disclosure include any nucleic acid molecule that encodes a polypeptide of the disclosure or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity. Polynucleotides having “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the disclosure include any nucleic acid molecule that encodes a polypeptide of the disclosure or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity. Polynucleotides having “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. By “hybridize” is meant pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399; Kimmel, A. R. (1987) Methods Enzymol. 152:507).
- For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and more preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30° C., more preferably of at least about 37° C., and most preferably of at least about 42° C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred: embodiment, hybridization will occur at 30° C. in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37° C. in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42° C. in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.
- For most applications, washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25° C., more preferably of at least about 42° C., and even more preferably of at least about 68° C. In a preferred embodiment, wash steps will occur at 25° C. in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42 C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 68° C. in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.
- By “substantially identical” is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence (for example, any one of the amino acid sequences described herein) or nucleic acid sequence (for example, any one of the nucleic acid sequences described herein). Preferably, such a sequence is at least 60%, more preferably 80% or 85%, and more preferably 90%, 95% or even 99% identical at the amino acid level or nucleic acid to the sequence used for comparison.
- Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e-3 and e-100 indicating a closely related sequence.
- By “subject” is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline.
- Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
- As used herein, the terms “treat,” treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
- Unless specifically stated or obvious from context, as used herein, the term “or” is understood to be inclusive. Unless specifically stated or obvious from context, as used herein, the terms “a”, “an”, and “the” are understood to be singular or plural.
- Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
- The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
- Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
-
FIGS. 1A-1C show the aortic phenotype of pure C57BL/6J (BL6) and 129S6/SvEvTac (129) mice.FIG. 1A : Aortic root size (mm) in BL6 (n=16) and 129 (n=13) wild-type (WT) mice, and BL6 (n=15) and 129 (n=15) Fbn1C1039G/+ (MFS) mice at 2 and 6 months of age, and postnatal aortic root growth (mm) from 2 to 6 months;FIG. 1B : Representative parasternal long axis echocardiograms at 6 months of the aortic root (yellow arrow) and ascending aorta (red arrow) in WT and MFS mice on BL6 and 129 strains;FIG. 1C : Survival curve to 10 months for WT and MFS mice on pure BL6 and 129 strains. *<0.05, **<0.01, †<0.001, ††<0.0001, †††<0.00001, NS non-significant. -
FIGS. 2A-2E show the molecular mechanisms driving aortic disease in MFS mice.FIG. 2A : Western blot analysis of the aortic root of 4 WT and 4 MFS mice on BL6 and 129 strains at 10 months of age;FIG. 2B : Aortic root growth (mm) from 2 to 6 months in placebo- (n=12) and losartan-treated (n=9) 129 WT mice, and placebo- (n=11) and losartan-treated (n=8) 129 MFS mice; Aortic root growth from 2 to 4 months in placebo-(n=13) and RDEA119-treated (n=5) 129 WT mice, and placebo- (n=13) and RDEA119-treated (n=10) 129 MFS mice;FIG. 2C : Survival curve up to 8 months of treatment in placebo- and losartan-treated 129 WT and MFS mice;FIG. 2D : Western blot analysis of the aortic root of 3 placebo- and 3 losartan-treated 129 WT and MFS mice at 10 months of age; -
FIG. 2E : Western blot analysis of the aortic root of 3 placebo- and 3 RDEA119-treated 129 WT and MFS mice at 4 months of age. Plac: placebo; Los: losartan; RDEA: RDEA119. *<0.05, **<0.01, †<0.001, ††<0.0001, †††<0.00001, NS non-significant. -
FIGS. 3A-3G show the mapping modifier loci of aortic aneurysm in MFS mice.FIG. 3A : Single QTL genome scan of intercrossed MFS mice that possessed either a ‘BL6-like’ aortic root size (<2.20 mm; n=35) or a ‘129-like’ aortic root size (>2.70 mm; n=40) at 6 months of age; genome wide significance LOD score of 3.82 is indicated by the red line; 2 loci exceeded this threshold, with individual LOD scores and adjusted p-values indicated; -
FIG. 3B : Aortic root size (mm) at 6 months of age in F2 generation intercrossed BL6/129 MFS mice, stratified by number of 129 alleles in the 2 regions of interest (average n per group=13);FIG. 3C : Aortic root size (mm) at 6 months of age in MFS mice lacking either one or two functional Mmp17 and Map2k6 alleles (n>10 per group);FIG. 3D : Western blot analysis of the aortic root at 10 months of age in 3 WT mice, 3 pure 129 MFS mice, 3 pure BL6 MFS mice, and 3 MFS mice either retaining (+/+) or lacking (−/−) functional Mmp17 and Map2k6 alleles;FIG. 3E : Western blot analysis of Egfr activation in the aortic root at 10 months of age in 4 pure BL6 and pure 129 WT and MFS mice, as well as 3 MFS mice either retaining (+/+) or lacking (−/−) functional Mmp17 and Map2k6 alleles;FIG. 3F : Aortic root growth (mm) from 2 to 4 months of age in placebo-(n=12) and erlotinib-treated (n=6) 129 WT mice, and placebo- (n=11) and erlotinib-treated (n=11) 129 MFS mice;FIG. 3G : Western blot analysis at 4 months of age in 3 placebo- and 3 erlotinib-treated 129 WT and MFS mice. Chr: Chromosome; M17: Mmp17; M2: Map2k6; Plac: placebo; Erlo: erlotinib. *<0.05, **<0.01, †<0.001, ††<0.0001, NS non-significant. -
FIGS. 4A-4E show the identification of a modifier locus for aortic aneurysm in MFS patients.FIG. 4A : Pedigrees of 5 MFS families recruited for genome wide linkage analysis; yellow indicates MFS patients with mild aortic disease, black indicates MFS patients with severe aortic disease, grey indicates patients with indeterminate data, and white indicates family members who do not have MFS;FIG. 4B : Parametric linkage analysis revealed 1 locus that surpassed a genome wide significance LOD score of 3.3, which is indicated by the red line;FIG. 4C : Quantitative PCR analysis of MAP3K4 mRNA expression from cultured dermal fibroblasts of 2 controls, 2 MFS patients from family B with mild aortic disease and 2 MFS patients from family B with severe aortic disease; all biological samples were run in experimental triplicate and normalized to β-actin;FIG. 4D : Aortic root growth from 2 to 6 months of age in WT mice either retaining (+/+; n=12) or haploinsufficient (+/−n=7) for Map3k4, and MFS mice either retaining (n=8) or haploinsufficient (n=7) for Map3k4;FIG. 4E : Western blot analysis of the aortic root at 10 months of age in 3 WT and 3 MFS mice either retaining or haploinsufficient for Map3k4. M3k4: Map3k4; *<0.05, **<0.01, †<0.001, NS non-significant -
FIG. 5 shows the ascending aortic size (mm) in BL6 (n=16) and 129 (n=13) WT mice, and BL6 (n=15) and 129 (n=15) MFS mice at 2 and 6 months of age, and postnatal growth (mm) from 2 to 6 months. AA: Ascending aorta; *<0.05, **<0.01, †<0.001, ††<0.0001, NS non-significant. -
FIG. 6 shows the systolic blood pressure (BP) at 6 months of age in WT and MFS mice on pure BL6 and 129 strains (n=5 per group). NS: non-significant. -
FIG. 7 shows the weight (in grams) at 2 months of age in female and male WT and MFS mice on pure BL6 and 129 strains (n>10 per group). NS non-significant. -
FIG. 8 shows representative sections of lung alveoli, and mean linear intercept (MLI; μm) in 10-month old WT and MFS mice on pure BL6 and 129 strains (n=5 per group). Line: 50 μm. **<0.01, †<0.001, ††<0.0001, NS non-significant. -
FIG. 9 shows representative spine x-rays and mean modified kyphosis index (length of yellow arrow; mm) in 10-month old WT and MFS mice on pure BL6 and 129 strains (n=10 per group). Line: 10 mm. *<0.05, ††<0.0001, †††<0.00001, NS non-significant. -
FIG. 10 shows the aortic root size (mm) at 6 months of age in WT and MFS mice on pure (F0 generation) BL6 and 129 strains (n as perFIG. 1A ), and F1 generation intercrossed WT (n=20) and MFS (n=21) mice. †<0.001, ††<0.0001, NS non-significant. -
FIG. 11 shows the Mmp17 C-terminal DNA and amino acid sequences, illustrating the 9 amino acid truncation in the BL6 mouse strain (SEQ ID NO: 24) relative to the 129 strain (SEQ ID NO: 25). The human MMP17 sequences (SEQ ID NO: 26) are displayed for comparison. The DNA sequence highlighted in red identifies the 129 codon that corresponds to the BL6 stop codon. The amino acid highlighted in red represents the predicted start site of the GPI anchor in each sequence. - A need exists for methods and compositions for the diagnosis and treatment of Marfan syndrome and associated diseases, disorders and conditions.
- The instant disclosure is based, at least in part, upon the discovery that upregulation of expression and/or activity of certain MAP kinase pathway components drives Marfan Syndrome (MFS) development in a mouse model of Marfan Syndrome. Genetic backcrosses were performed between mice of an MFS model and a non-MFS-afflicted strain of mice, thereby identifying genetic loci associated with MFS. In particular, loci that caused elevated expression and/or activity of MMP17, MAP2K6 or MAP3K4, or of gene products thereof, were identified as contributing to MFS and related conditions in such mice. Modulation of MAP kinase pathway signaling, and particularly inhibition and/or gene replacement of MMP17, MAP2K6 and/or MAP3K4, or of gene products thereof, is thereby discovered to be a therapeutic approach for MFS. MFS diagnosis is also aided by this identification of MAP kinase pathway signaling components/loci indicative of development of MFS in a subject.
- Marfan Syndrome (MFS)
- Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder that includes a predisposition for aortic root aneurysm and aortic rupture. MFS is caused by a deficiency of the microfibrillar
constituent protein fibrillin 1 that is imposed by heterozygous mutations in FBN1. - Marfan syndrome (MFS) is a systemic disorder with autosomal dominant inheritance and a prevalence of approximately 1 per 5,000 population (Pyeritz, R. E. & McKusick, V. A. (1979) N Engl J Med. 300, 772-777). The syndrome shows no racial preference and both sexes are affected equally. It has been estimated that 25% of cases occur due to spontaneous mutations. While this condition shows high penetrance, marked interfamilial clinical variability is the rule (Pyeritz, R. E. et al. (1979) Birth Defects Orig Artic Ser. 15, 155-178). Historic lack of a specific biochemical or genetic marker of disease, coupled with the variability in clinical presentation, has frustrated diagnosis of equivocal cases and has likely contributed to a significant underestimation of the prevalence of disease.
- The cardinal features of this disorder involve the ocular, skeletal, and cardiovascular systems. Cardiovascular pathology, including aortic root dilatation, dissection, and rupture, pulmonary artery dilatation, myxomatous valve changes with insufficiency of the mitral and aortic valves, and progressive myocardial dysfunction, is the leading cause of mortality in the MFS. The majority of fatal events associated with untreated MFS occur in early adult life. In a prospective study of 72 patients in 1972, the average age of death was 32 years (Murdoch, J. L. et al. (1972) N Engl J Med. 286, 804-808).
- Skeletal involvement is evident in nearly all people with MFS. Progressive anterior chest deformity or scoliosis can cause cardiopulmonary dysfunction and commonly require surgical correction. Joint instability can cause physical disability and predispose to premature arthritis. Lung disease most commonly manifests with spontaneous pneumothorax and has been identified in 4-11% of MFS patients (Wood, J. R., et al. (1984) Thorax. 39, 780-784; Hall, J. R., et al. (1984) Ann Thorac Surg. 37, 500-504).
- Many of the features of Marfan syndrome are common in the general population and represent a tremendous public health burden. These include aortic aneurysm (1-2% of the population at large), mitral valve prolapse (˜7%), emphysema (11%), scoliosis (0.5%), cataract (30%), arthritis (very common), and myopathy (many common genetic and acquired forms).
- Previous work has implicated enhanced TGFβ signaling in MFS disease pathogenesis. In Fbn1C1039G/+ mice (hereafter termed MFS mice), a well-validated model of MFS, multiple phenotypic manifestations, including aortic aneurysm, developmental emphysema, mitral valve disease and skeletal muscle myopathy, can be attenuated by administration of TGFβ neutralizing antibody (TGFβ NAb) or the angiotensin-II (Ang-II)
type 1 receptor blocker (ARB) losartan, in association with blunted Smad2/3 activation (Habashi et al., Science 312, 117; Neptune et al., Nature Genetics 33, 407; Ng et al., Journal Clinical Investigation 114, 1586; Cohn et al.,Nature Medicine 13, 204). - It is well-recognized that the severity of aortic disease and other systemic manifestations in patients with MFS is highly variable. While the causes for this are not well understood, there is clearly a strong genetic component, since members of the same family often share similar manifestations and outcomes. Despite this, there is very limited correlation between the type or location of a patient's FBN1 mutation and their disease. This implies that there may be other major modifier genes which determine the penetrance and/or severity of a patient's disease.
- A need exists for methods and compositions for the treatment of Marfan syndrome and associated diseases, disorders and conditions, e.g., diseases, disorders and conditions associated with aberrant MAP kinase pathway component expression and/or activity.
- MAP Kinase Pathway Signaling
- A mitogen-activated protein kinase (MAPK or MAP kinase) is a type of protein kinase that is specific to the amino acids serine, threonine, and tyrosine (i.e., a serine/threonine-specific protein kinase). MAPKs are involved in directing cellular responses to a diverse array of stimuli, such as mitogens, osmotic stress, heat shock and proinflammatory cytokines. They regulate cell functions including proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis (Pearson G, et al. (April 2001). Endocrine Reviews. 22 (2): 153-83).
- MAP kinases are found in eukaryotes only, but they are fairly diverse and encountered in all animals, fungi and plants, and even in an array of unicellular eukaryotes.
- MAPKs belong to the CMGC (CDK/MAPK/GSK3/CLK) kinase group. The closest relatives of MAPKs are the cyclin-dependent kinases (CDKs; Manning G, et al. (December 2002). Science. 298 (5600): 1912-34)).
- The first mitogen-activated protein kinase to be discovered was ERK1 (MAPK3) in mammals. Since ERK1 and its close relative ERK2 (MAPK1) are both involved in growth factor signaling, the family was termed “mitogen-activated”. With the discovery of other members, even from distant organisms (e.g. plants), it has become increasingly clear that the name is a misnomer, since most MAPKs are actually involved in the response to potentially harmful, abiotic stress stimuli (hyperosmosis, oxidative stress, DNA damage, low osmolarity, infection, etc.). Because plants cannot “flee” from stress, terrestrial plants have the highest number of MAPK genes per organism ever found. Thus the role of mammalian ERK1/2 kinases as regulators of cell proliferation is not a generic, but a highly specialized function.
- Most MAPKs have a number of shared characteristics, such as the activation dependent on two phosphorylation events, a three-tiered pathway architecture and similar substrate recognition sites. These are the “classical” MAP kinases. But there are also some ancient outliers from the group as sketched above, that do not have dual phosphorylation sites, only form two-tiered pathways, and lack the features required by other MAPKs for substrate binding. These are usually referred to as “atypical” MAPKs (Coulombe P, Meloche S (August 2007). Biochimica et Biophysica Acta. 1773 (8): 1376-87). It is yet unclear if the atypical MAPKs form a single group as opposed to the classical ones.
- Mitogen-activated protein kinases are catalytically inactive in their base form. In order to become active, they require (potentially multiple) phosphorylation events in their activation loops. This is conducted by specialized enzymes of the STE protein kinase group.
- In the case of classical MAP kinases, the activation loop contains a characteristic TxY (threonine-x-tyrosine) motif (TEY in mammalian ERK1 and ERK2, TDY in ERK5, TPY in JNKs, TGY in p38 kinases) that needs to be phosphorylated on both the threonine and the tyrosine residues in order to lock the kinase domain in a catalytically competent conformation. In vivo and in vitro, phosphorylation of tyrosine precedes phosphorylation of threonine, although phosphorylation of either residue can occur in the absence of the other.
- This tandem activation loop phosphorylation (that was proposed to be either distributive or processive, dependent on cellular environment) is performed by members of the Ste7 protein kinase family, also known as MAP2 kinases. MAP2 kinases in turn, are also activated by phosphorylation, by a number of different upstream serine-threonine kinases (MAP3 kinases). Because MAP2 kinases display very little activity on substrates other than their cognate MAPK, classical MAPK pathways form multi-tiered, but relatively linear pathways. These pathways can effectively convey stimuli from the cell membrane (where many MAP3Ks are activated) to the nucleus (where only MAPKs may enter) or to many other subcellular targets.
- In comparison to the three-tiered classical MAPK pathways, some atypical MAP kinases appear to have a more ancient, two-tiered system. ERK3 (MAPK6) and ERK4 (MAPK4) were recently shown to be directly phosphorylated and thus activated by PAK kinases (related to other MAP3 kinases; Deleris P, et al. (February 2011). The Journal of Biological Chemistry. 286 (8): 6470-8). In contrast to the classical MAP kinases, these atypical MAPKs require only a single residue in their activation loops to be phosphorylated. The details of NLK and ERK7 (MAPK15) activation remain unknown.
- Inactivation of MAPKs is performed by a number of phosphatases. A very conserved family of dedicated phosphatases is the so-called MAP kinase phosphatases (MKPs), a subgroup of dual-specificity phosphatases (DUSPs; Theodosiou A, Ashworth A (June 2002). Genome Biology. 3 (7): reviews3009.1-reviews3009.10). As their name implies, these enzymes are capable of hydrolyzing the phosphate from both phosphotyrosine and the phosphothreonine residues. Since removal of either phosphate groups will greatly reduce MAPK activity, essentially abolishing signaling, some tyrosine phosphatases are also involved in inactivating MAP kinases (e.g. the phosphatases HePTP, STEP and PTPRR in mammals).
- As mentioned above, MAPKs typically form multi-tiered pathways, receiving input several levels above the actual MAP kinase. In contrast to the relatively simple, phosphorylation-dependent activation mechanism of MAPKs and MAP2Ks, MAP3Ks have stunningly complex regulation. Many of the better-known MAP3Ks, such as c-Raf, MEKK4 or MLK3 require multiple steps for their activation. These are typically allosterically-controlled enzymes, tightly locked into an inactive state by multiple mechanisms. The first step en route to their activation consists of relieving their auto-inhibition by a smaller ligand (such as Ras for c-Raf, GADD45 for MEKK4 (Miyake Z, et al. (April 2007). Molecular and Cellular Biology. 27 (7): 2765-76) or Cdc42 for MLK3 (Du Y, et al. (December 2005). The Journal of Biological Chemistry. 280 (52): 42984-93)). This commonly (but not always) happens at the cell membrane, where most of their activators are bound (note that small G-proteins are constitutively membrane-associated due to prenylation). That step is followed by side-to-side homo- and hetero-dimerization of their now accessible kinase domains. Recently determined complex structures reveal that the dimers are formed in an orientation that leaves both their substrate-binding regions free (Rajakulendran T, et al. (September 2009). Nature. 461 (7263): 542-5). Importantly, this dimerization event also forces the MAP3 kinase domains to adopt a partially active conformation. Full activity is only achieved once these dimers transphosphorylate each other on their activation loops. The latter step can also be achieved or aided by auxiliary protein kinases (MAP4 kinases, members of the Ste20 family). Once a MAP3 kinase is fully active, it may phosphorylate its substrate MAP2 kinases, which in turn will phosphorylate their MAP kinase substrates.
- The ERK1/2 pathway of mammals is probably the best-characterized MAPK system. The most important upstream activators of this pathway are the Raf proteins (A-Raf, B-Raf or c-Raf), the key mediators of response to growth factors (EGF, FGF, PDGF, etc.); but other MAP3Ks such as c-Mos and Tpl2/Cot can also play the same role. All these enzymes phosphorylate and thus activate the MKK1 and/or MKK2 kinases, that are highly specific activators for ERK1 and ERK2. The latter phosphorylate a number of substrates important for cell proliferation, cell cycle progression, cell division and differentiation (RSK kinases, Elk-1 transcription factor, etc.).
- In contrast to the relatively well-insulated ERK1/2 pathway, mammalian p38 and JNK kinases have most of their activators shared at the MAP3K level (MEKK1, MEKK4, ASK1, TAK1, MLK3, TAOK1, etc.). In addition, some MAP2K enzymes may activate both p38 and JNK (MKK4), while others are more specific for either JNK (MKK7) or p38 (MKK3 and MKK6). Due to these interlocks, there are very few if any stimuli that can elicit JNK activation without simultaneously activating p38 or reversed (Cargnello M, Roux P P (March 2011). Microbiology and Molecular Biology Reviews. 75 (1): 50-83). Both JNK and p38 signaling pathways are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in adaptation to stress, apoptosis or cell differentiation. JNKs have a number of dedicated substrates that only they can phosphorylate (c-Jun, NFAT4, etc.), while p38s also have some unique targets (e.g. the MAPKAP kinases MK2 and MK3), ensuring the need for both in order to respond to stressful stimuli.
- ERK5 is part of a fairly well-separated pathway in mammals. Its sole specific upstream activator MKK5 is turned on in response to the MAP3 kinases MEKK2 and MEKK3. The specificity of these interactions are provided by the unique architecture of MKK5 and MEKK2/3, both containing N-terminal PB1 domains, enabling direct hetero-dimerization with each other (Nakamura K, Johnson G L (September 2003). The Journal of Biological Chemistry. 278 (39): 36989-92). The PB1 domain of MKK5 also contributes to the ERK5-MKK5 interaction: it provides a special interface (in addition to the D-motif found in MKK5) through which MKK5 can specifically recognize its substrate ERK5 (Glatz G, et al. (March 2013). The Journal of Biological Chemistry. 288 (12): 8596-609). Although the molecular-level details are poorly known, MEKK2 and MEKK3 respond to certain developmental cues to direct endothelial formation and cardiac morphogenesis. While also implicated in brain development, the embryonic lethality of ERK5 inactivation due to cardiac abnormalities underlines its central role in mammalian vasculogenesis (Regan C P, et al. (July 2002). Proc. Nat'l Acad. Sci. USA. 99 (14): 9248-53). It is notable, that conditional knockout of ERK5 in adult animals is also lethal, due to the widespread disruption of endothelial barriers (Hayashi M, Lee J D (December 2004). Journal of Molecular Medicine. 82 (12): 800-8). Mutations in the upstream components of the ERK5 pathway (the CCM complex) are thought to underlie cerebral cavernous malformations in humans.
- As typical for the CMGC kinase group, the catalytic site of MAP kinases has a very loose consensus sequence for substrates. Like all their relatives, they only require the target serine/threonine amino acids to be followed by a small amino acid, preferably proline (“proline-directed kinases”). But as SP/TP sites are extremely common in all proteins, additional substrate-recognition mechanisms have evolved to ensure signaling fidelity (Garai Á, et al. (October 2012). Science Signaling. 5 (245): ra74). Unlike their closest relatives, the cyclin-dependent kinases (CDKs), where substrates are recognized by the cyclin subunit, MAPKs associate with their substrates via auxiliary binding regions on their kinase domains. The most important such region consists of the hydrophobic docking groove and the negatively charged CD-region. Together they recognize the so-called MAPK docking or D-motifs (also called kinase interaction motif/KIM). D-motifs essentially consist of one or two positively charged amino acids, followed by alternating hydrophobic residues (mostly leucines), typically upstream of the phosphorylation site by 10-50 amino acids (Reményi A, et al. (December 2005). Mol. Cell. 20 (6): 951-62). Many of the known MAPK substrates contain such D-motifs that can not only bind to, but also provide specific recognition by certain MAPKs. Interestingly, D-motifs are not restricted to substrates: MAP2 kinases also contain such motifs on their N-termini that are absolutely required for MAP2K-MAPK interaction and MAPK activation (Bardwell A J, et al. (May 2009). The Journal of Biological Chemistry. 284 (19): 13165-73). Similarly, both dual-specificity MAP kinase phosphatases and MAP-specific tyrosine phosphatases bind to MAP kinases through the same docking site (Goldsmith E J (December 2011). Science Signaling. 4 (204): pe47; Huang Z, Zhou B, Zhang Z Y (December 2004). The Journal of Biological Chemistry. 279 (50): 52150-9). D-motifs can even be found in certain MAPK pathway regulators and scaffolds (e.g. in the mammalian JIP proteins).
- Other, less well characterized substrate-binding sites also exist. One such site (the DEF site) is formed by the activation loop (when in the active conformation) and the MAP kinase-specific insert below it. This site can accommodate peptides with an FxFP consensus sequence, typically downstream of the phosphorylation site (Sheridan D L, et al. (July 2008). The Journal of Biological Chemistry. 283 (28): 19511-20). Note that the latter site can only be found in proteins that need to selectively recognize the active MAP kinases, thus they are almost exclusively found in substrates. Different motifs may cooperate with each other, as in the Elk family of transcription factors, that possess both a D-motif and an FxFP motif. The presence of an FxFP motif in the KSR1 scaffold protein also serves to make it an ERK1/2 substrate, providing a negative feedback mechanism to set the correct strength of ERK1/2 activation.
- Since the ERK signaling pathway is involved in both physiological and pathological cell proliferation, it is natural that ERK1/2 inhibitors would represent a desirable class of antineoplastic agents. Indeed, many of the proto-oncogenic “driver” mutations are tied to ERK1/2 signaling, such as constitutively active (mutant) receptor tyrosine kinases, Ras or Raf proteins. Although no MKK1/2 or ERK1/2 inhibitors were developed for clinical use, kinase inhibitors that also inhibit Raf kinases (e.g. Sorafenib) are successful antineoplastic agents against various types of cancer (Kim D H, Sim T (March 2012). Arch. Pharmacol Res. 35 (4): 605-15; Matsuda Y, Fukumoto M (December 2011). Medical Molecular Morphology. 44 (4): 183-9).
- MMP17
- The MMP17 gene encodes a member of the peptidase M10 family and membrane-type subfamily of matrix metalloproteinases (MMPs). Proteins in this family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Members of this subfamily contain a transmembrane domain suggesting that these proteins are expressed at the cell surface rather than secreted. The encoded preproprotein is proteolytically processed to generate the mature protease. This protein is unique among the membrane-type matrix metalloproteinases in that it is anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor. Elevated expression of the encoded protein has been observed in osteoarthritis and multiple human cancers.
-
An illustrative amino acid sequence (SEQ ID NO: 1) of human Mmp17 is NP_057239.4: MRRRAARGPGPPPPGPGLSRLPLPLLLLLALGTRGGCAAPAPAPRAEDLS LGVEWLSRFGYLPPADPTTGQLQTQEELSKAITAMQQFGGLEATGILDEA TLALMKTPRCSLPDLPVLTQARRRRQAPAPTKWNKRNLSWRVRTFPRDSP LGHDTVRALMYYALKVWSDIAPLNFHEVAGSAADIQIDFSKADHNDGYPF DGPGGTVAHAFFPGHHHTAGDTHFDDDEAWTFRSSDAHGMDLFAVAVHEF GHAIGLSHVAAAHSIMRPYYQGPVGDPLRYGLPYEDKVRVWQLYGVRESV SPTAQPEEPPLLPEPPDNRSSAPPRKDVPHRCSTHFDAVAQIRGEAFFFK GKYFWRLTRDRHLVSLQPAQMHRFWRGLPLHLDSVDAVYERTSDHKIVFF KGDRYWVFKDNNVEEGYPRPVSDFSLPPGGIDAAFSWAHNDRTYFFKDQL YWRYDDHTRHMDPGYPAQSPLWRGVPSTLDDAMRWSDGASYFFRGQEYWK VLDGELEVAPGYPQSTARDWLVCGDSQADGSVAAGVDAAEGPRAPPGQHD QSRSEDGYEVCSCTSGASSPPGAPGPLVAATMLLLLPPLSPGALWTAAQA LTL The corresponding nucleic acid sequence (SEQ ID NO: 2) encoding human Mmp17 is NM_016155: agtccggcgggggcgccgcggagagcggagggcgccgggctgcggaacgc gaagcggagggcgcgggaccctgcacgccgcccgcgggcccatgtgagcg ccatgcggcgccgcgcagcccggggacccggcccgccgcccccagggccc ggactctcgcggctgccgctgccgctgctgctgctgctggcgctggggac ccgcgggggctgcgccgcgcccgcacccgcgccgcgcgccgaggacctca gcctgggagtggagtggctaagcaggttcggttacctgcccccggctgac cccacaacagggcagctgcagacgcaagaggagctgtctaaggccatcac agccatgcagcagtttggtggcctggaggccaccggcatcctggacgagg ccaccctggccctgatgaaaaccccacgctgctccctgccagacctccct gtcctgacccaggctcgcaggagacgccaggctccagcccccaccaagtg gaacaagaggaacctgtcgtggagggtccggacgttcccacgggactcac cactggggcacgacacggtgcgtgcactcatgtactacgccctcaaggtc tggagcgacattgcgcccctgaacttccacgaggtgggggcagcgccgcc gacatccagatcgacttctccaaggccgaccataacgacggctacccctt cgacggccccggggcaccgtggcccacgccttcttccccggccaccacca caccgccggggacacccactttgacgatgacgaggcctggaccttccgct cctcggatgcccacgggatggacctgtttgcagtggctgtccacgagttt ggccacgccattgggttaagccatgtggccgctgcacactccatcatgcg gccgtactaccagggcccggtgggtgacccgctgcgctacgggctcccct acgaggacaaggtgcgcgtctggcagctgtacggtgtgcgggagtctgtg tctcccacggcgcagcccgaggagcctcccctgctgccggagcccccaga caaccggtccagcgccccgcccaggaaggacgtgccccacagatgcagca ctcactttgacgcggtggcccagatccggggtgaagctttcttcttcaaa ggcaagtacttctggcggctgacgcgggaccggcacctggtgtccctgca gccggcacagatgcaccgcttctggggggcctgccgctgcacctggacag cgtggacgccgtgtacgagcgcaccagcgaccacaagatcgtcttcttta aaggagacaggtactgggtgttcaaggacaataacgtagaggaaggatac ccgcgccccgtctccgacttcagcctcccgcctggcggcatcgacgctgc cttctcctgggcccacaatgacaggacttatttctttaaggaccagctgt actggcgctacgatgaccacacgaggcacatggaccccggctaccccgcc cagagccccctgtggaggggtgtccccagcacgctggacgacgccatgcg ctggtccgacggtgcctcctacttcttccgtggccaggagtactggaaag tgctggatggcgagctggaggtggcacccgggtacccacagtccacggcc cgggactggctggtgtgtggagactcacaggccgatggatctgtggctgc gggcgtggacgcggcagaggggccccgcgcccctccaggacaacatgacc agagccgctcggaggacggttacgaggtctgctcatgcacctctggggca tcctctcccccgggggccccaggcccactggtggctgccaccatgctgct gctgctgccgccactgtcaccaggcgccctgtggacagcggcccaggccc tgacgctatgacacacagcgcgagcccatgagaggacagaggcggtggga cagcctggccacagagggcaaggactgtgccggagtccctgggggaggtg ctggcgcgggatgaggacgggccaccctggcaccggaaggccagcagagg gcactgcccgccagggctgggcaggctcaggtggcaaggacggagctgtc ccctagtgagggactgtgttgactgacgagccgaggggtggccgctccag aagggtgcccagtcaggccgcaccgccgccagcctcctccggccctggag ggagcatctcgggctgggggcccacccctctctgtgccggcgccaccaac cccacccacactgctgcctggtgctcccgccggcccacagggcctccgtc cccaggtccccagtggggcagccctccccacagacgagccccccacatgg tgccgcggcacgtcccccctgtgacgcgttccagaccaacatgacctctc cctgctttgtaaaaaaaaaaaaaaaaaaa - Known MMP17 inhibitors include those recited in Table 1.
-
TABLE 1 MMP17 Inhibitors Compound Action Cas Number Batimastat Potent, broad spectrum 130370-60-4 MMP inhibitor GI 254023X Selective ADAM10 260264-93-5 metalloprotease inhibitor GM 6001 Broad spectrum MMP 142880-36-2 inhibitor TMI 1 Adam 17 (TACE) and MMP 287403-39-8 inhibitor; orally bioavailable WAY 170523 Potent and selective inhibitor 307002-73-9 of MMP-13 -
TABLE 2 dbSNP MMP17 Variants SNP ID Chr 12 pos Sequence Context Type rs7302578 131,831,385(+) GAGGT(C/T)GTGGG intron-variant (SEQ ID NO: 9) rs7312725 131,849,044(+) ggctc(C/T)gccgt (SEQ intron-variant ID NO: 10) rs7314389 131,829,208(+) TGGCC(C/T)TCAGC intron-variant, (SEQ ID NO: 11) upstream-variant- 2KB rs7484461 131,848,633(+) ccatg(C/G)ctctg (SEQ intron-variant ID NO: 12) rs7484577 131,840,427(+) TCGGA(C/T)GACTC intron-variant (SEQ ID NO: 13) - MAP2K6
- Dual specificity mitogen-activated
protein kinase kinase 6 also known as MAP kinase kinase 6 (MAPKK 6) or MAPK/ERK kinase 6 is an enzyme that in humans is encoded by the MAP2K6 gene, on chromosome 17 (Han J, et al. (February 1996). The Journal of Biological Chemistry. 271 (6): 2886-91). -
MAPKK 6 is a member of the dual specificity protein kinase family, which functions as a mitogen-activated protein (MAP) kinase kinase. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals. This protein phosphorylates and activates p38 MAP kinase in response to inflammatory cytokines or environmental stress. As an essential component of p38 MAP kinase mediated signal transduction pathway, this gene is involved in many cellular processes such as stress-induced cell cycle arrest, transcription activation and apoptosis (Entrez Gene: MAP2K6 mitogen-activatedprotein kinase kinase 6″.). -
An illustrative amino acid sequence (SEQ ID NO: 3) of human Map2k6 is NP_002749.2: MSQSKGKKRNPGLKIPKEAFEQPQTSSKACISIGNQNFEVKADDLEPIME LGRGAYGVVEKMRHVPSGQIMAVKRIRATVNSQEQKRLLMDLDISMRTVD CPFTVTFYGALFREGDVWICMELMDTSLDKFYKQVIDKGQTIPEDILGKI AVSIVKALEHLHSKLSVIHRDVKPSNVLINALGQVKMCDFGISGYLVDSV AKTIDAGCKPYMAPERINPELNQKGYSVKSDIWSLGITMIELAILRFPYD SWGTPFQQLKQVVEEPSPQLPADKFSAEFVDFTSQCLKKNSKERPTYPEL MQHPFFTLHESKGTDVASFVKLILGD The corresponding nucleic acid sequence (SEQ ID NO: 4) encoding human Map2k6 is NM_002758.3: agttccaagtttggagcttttagctgccagccctggcccatcatgtagct gcagcacagccttccctaacgttgcaactgggggaaaaatcactttccag tctgttttgcaaggtgtgcatttccatcttgattccctgaaagtccatct gctgcatcggtcaagagaaactccacttgcatgaagattgcacgcctgca gcttgcatctttgttgcaaaactagctacagaagagaagcaaggcaaagt cttttgtgctcccctcccccatcaaaggaaaggggaaaatgtctcagtcg aaaggcaagaagcgaaaccctggccttaaaattccaaaagaagcatttga acaacctcagaccagttccacaccacctcgagatttagactccaaggctt gcatttctattggaaatcagaactttgaggtgaaggcagatgacctggag cctataatggaactgggacgaggtgcgtacggggggtggagaagatgcgg cacgtgcccagcgggcagatcatggcagtgaagcggatccgagccacagt aaatagccaggaacagaaacggctactgatggatttggatatttccatga ggacggtggactgtccattcactgtcaccttttatggcgcactgtttcgg gagggtgatgtgtggatctgcatggagctcatggatacatcactagataa attctacaaacaagttattgataaaggccagacaattccagaggacatct tagggaaaatagcagtttctattgtaaaagcattagaacatttacatagt aagctgtctgtcattcacagagacgtcaagccttctaatgtactcatcaa tgctctcggtcaagtgaagatgtgcgattttggaatcagtggctacttgg tggactctgttgctaaaacaattgatgcaggttgcaaaccatacatggcc cctgaaagaataaacccagagctcaaccagaagggatacagtgtgaagtc tgacatttggagtctgggcatcacgatgattgagttggccatccttcgat ttccctatgattcatggggaactccatttcagcagctcaaacaggtggta gaggagccatcgccacaactcccagcagacaagttctctgcagagtttgt tgactttacctcacagtgcttaaagaagaattccaaagaacggcctacat acccagagctaatgcaacatccatttttcaccctacatgaatccaaagga acagatgtggcatcttttgtaaaactgattcttggagactaaaaagcagt ggacttaatcggttgaccctactgtggattggtgggtttcggggtgaagc aagttcactacagcatcaatagaaagtcatctttgagataatttaaccct gcctctcagagggttttctctcccaattttctttttactccccctcttaa gggggccttggaatctatagtatagaatgaactgtctagatggatgaatt atgataaaggcttaggacttcaaaaggtgattaaatatttaatgatgtgt catatgagtcctcaagcttctcagacttctcttattctttacaaaatgaa tgcattggccctgacaaaaaggtgctacggtagtgatgaaattataagta gatttgtagtttgtcccatttattattttaatatttatgtttaagtgctt ggttgaaaagattccattttatacaagaagggagattcaaaaaaaaaata taaggttgggttagcaatatttatagggcttttattttttaagttcaatt gtgtctgtggtccagaagaaattatttaatatgcatctttgagaatatta taaaaatatcaaaaaggaaaaaaaaaaa Another illustrative amino acid sequence (SEQ ID NO: 5) of human Map2k6 is NP_001317379.1: MELGRGAYGVVEKMRHVPSGQIMAVKRIRATVNSQEQKRLLMDLDISMRT VDCPFTVTFYGALFREGDVWICMELMDTSLDKFYKQVIDKGQTIPEDILG KIAVSIVKALEHLHSKLSVIHRDVKPSNVLINALGQVKMCDFGISGYLVD SVAKTIDAGCKPYMAPERINPELNQKGYSVKSDIWSLGITMIELAILRFP YDSWGTPFQQLKQVVEEPSPQLPADKFSAEFVDFTSQCLKKNSKERPTYP ELMQHPFFTLHESKGTDVASFVKLILGD The corresponding nucleic acid sequence (SEQ ID NO: 6) encoding human Map2k6 is NM_001330450: ttgctgcaatccgaacttgaggagggggtggagtctgttcagttctgttt ctccttgccgaagtgtggtctttggagctaagtgaagaatgacttctgtt aggttttcctctgctggtcttccttgcagcctcgaaaacctcaccagagt cgcctctgctggtctcttactgtgctgctctgtcagagatgggcaagtaa gcgaactgcagagtgttgctgtgtgtgcttgtgatttgtattttatttga tgtaaacgtgaaggcagagtattttctaacactgtaattcaactaggttt tgtgtctcctggatctatttttttttcttgttgttctgaggagctgatat acttggaaatattaggtttaagatatgcagatgtccaacttatatacata gtcaagggtttagagtctggagacaggaggctggcaatttcaactaggag gcagtaaattcagggcaagaagcgaaaccctggccttaaaattccaaaag aagcatttgaacaacctcagaccagttccacaccacctcgagatttagac tccaaggcttgcatttctattggaaatcagaactttgaggtgaaggcaga tgacctggagcctataatggaactgggacgaggtgcgtacggggtggtgg agaagatgcggcacgtgcccagcgggcagatcatggcagtgaagcggatc cgagccacagtaaatagccaggaacagaaacggctactgatggatttgga tatttccatgaggacggtggactgtccattcactgtcaccttttatggcg cactgtttcgggagggtgatgtgtggatctgcatggagctcatggataca tcactagataaattctacaaacaagttattgataaaggccagacaattcc agaggacatcttagggaaaatagcagtttctattgtaaaagcattagaac atttacatagtaagctgtctgtcattcacagagacgtcaagccttctaat gtactcatcaatgctctcggtcaagtgaagatgtgcgattttggaatcag tggctacttggtggactctgttgctaaaacaattgatgcaggttgcaaac catacatggcccctgaaagaataaacccagagctcaaccagaagggatac agtgtgaagtctgacatttggagtctgggcatcacgatgattgagttggc catccttcgatttccctatgattcatggggaactccatttcagcagctca aacaggtggtagaggagccatcgccacaactcccagcagacaagttctct gcagagtttgttgactttacctcacagtgcttaaagaagaattccaaaga acggcctacatacccagagctaatgcaacatccatttttcaccctacatg aatccaaaggaacagatgtggcatcttttgtaaaactgattcttggagac taaaaagcagtggacttaatcggttgaccctactgtggattggtgggttt cggggtgaagcaagttcactacagcatcaatagaaagtcatctttgagat aatttaaccctgcctctcagagggttttctctcccaattttctttttact ccccctcttaagggggccttggaatctatagtatagaatgaactgtctag atggatgaattatgataaaggcttaggacttcaaaaggtgattaaatatt taatgatgtgtcatatgagtcctcaagcttctcagacttctcttattctt tacaaaatgaatgcattggccctgacaaaaaggtgctacggtagtgatga aattataagtagatttgtagtttgtcccatttattattttaatatttatg tttaagtgcttggttgaaaagattccattttatacaagaagggagattca aaaaaaaaatataaggttgggttagcaatatttatagggcttttattttt taagttcaattgtgtctgtggtccagaagaaattatttaatatgcatctt tgagaatattataaaaatatcaaaaaggagctcttcttgtgaaatgtctg ttccagctgttgtgactgctgccatttttgcaaacatctgcccaatcctg ggtgatcaccacatcttttaggggaagtgacaagatgctctggtcatact ctttttcccaactttggaaaacataaaaatcactcatataacagctcaaa gagtaaaacatttggttcttctgacacttgtggtatagtattagtggaaa gtgatttgtaatatgattttatatccacctacctattcatctacctgtgt gtatgtgtgtgtttgtgtgtctatttggcaattcacaagtcctgccaagt ggtttctatgagcatctctgtttggtaaggaggacaattgtcagttttga gggggacatgtgttaaatcacagaaaaaaatggtgccttcttctgcgttt gtccctcctgccatgtgtaagttgtaaggattgcctttgtagttaatgta ctctttggctttgtttgtttgttttcttcttcagtgaagcagccttacta ttcatagaagggctagaataggagaaaatgaaaggtagtgagtaattctt tgataagatgaggaaataatgggaaaggttgaattaattcctgggcatgg actaccagatgaccacaagttgcgttgaggccgcatctttcttcagcagc gtgcaatagctggctcctctataggagatgagcttcattgggagttccta gcaagttgactaaacagcaaaagttctttctcgtgggtaaatatacccac aggttctatgatttgtagctctaggtttcttgatgatcaaggagtgaagt aattgacagggaaaatatagacctatgataaataaccaggaagcattgct tttggacaaggaaggacagagggttttgattttaaaaagaagaaaaaaaa accttattttttctttcttggcctcaagttcaatatggagaggattgctt ccctgaatcctctcttccttccccttttagattttgaagtgcaatcatat gtttttctctgtttgcattttttcctccttgttcttgacaaggaggagtt gctcctgcccagaatgagcgtgacacttccgaacacttcttcatattcag ttccaagatatatctgcttgattaaacatgagcttcctctgctctgaagc tacctctgtcctcattttattctagccagaaaaggagtatcaccctagtg attatggctgttcactttcccatctatcttcctaaatctggaagttcttc tcttggagatcaagagaaaaattacaattgtattccttactttattcacc cacctatgaaaacaggaagcaataggaaaaaaaatccggttactccattt tagcttttggtgaacgatgtagagcaaattgtctctctggtctaggtccg attactcttacctgtttttccactttgagacattctaaacagaatgtgta acttctcatatgtatgcctctcccatctgtgaacctaggccaaagttgca aaaacaatcatattaatagtagagtagagaaaaagttagtctatggttct caaccctcgtgtacattggaaccatctgggagctgtgaacactgtcgctg ccaatgttccagccaccagagatttggatttaactggtggggcctaggaa ttggtgtttttttgttttgttttgttttttacacaccttcatgtgattct gatgtgaagctgggttcagaacacttatctagtaccttctaaagagaact gacttaaatttactttcttttgaacatttgcagggagtaacatgccattg cagaaagtaacaaaaacaggtcctatttctttccctgtcctcatcagtgg aaatctctttgtcactctgagagaaggcatgtacctgggatactgatagg aagtgtagaacaccttttccccagagaagcaatattttgcactgttatta aatatcttacacggtaaagtcaaaagaatgacctgatagcctcacaagac taaattttagagcatggttttgtttttggaaaactgtgttgtaagtgcca atcaaccaacttttgaaaaaatcaagatacctaaactatatataaatggg gagtattctgtacatatagacttatatataaagacatctgtgttcacgga tgaccctcaaaatagttaatgccccaccagcatagaccatctgaatatca gccctgtctacacctatcaatgtattacaaaatcagtatagctctacaaa agagatcatgcttatttccccagatgtatttgattttgtatcatataatt gtccatgttataatttttgaaaatgtttattaaaatagccatcttttttg atattattggtttaagaggtgtgccaaaaaaagtaatatgcataactttt aagactattaccctatgtttgtacgtatgagtgaatattgcccaccagag tagccatcttgagagactacatatttatattcataatgctattaaattat ttttgccactcctctttcagaaaaggctttagaatccactccctcctctg agatgtgtgtcatcatttgagaattcttacttaggttttgttgttgtttg ttttgctttttacaaaaatccttagcagatgtttccctctttgatttacc tgccttgtttatcagattttgcacaaagttgtgtttgacaatttctagaa gttaaatcttccctcagagctggagttttagcatcattgactctttgtaa aacgccatgtcatgggctctgaagataatttcaaatgaagatttccacac cccgcccccaccacccctgcccaaagtgcatgattatttttaaccagagt cattcttccaccagaataagtgtaatctcccaaaatgactactttgaagg agatagaacccccataaaggtatatgtttgttgataaaatatcaggtcat cacggattttgcaagtgaaagtcacctatcttctatgattgaaggtcctg atgtgggggaataatctattttttctaaagactgtgtttggtcacactga tttaatcagaacaaatgggttaaataagcagcttttatcacagttaagcc atctgaaatggaaacgagtatgtatgggcatggcttgaaattgtttgtat tttacagttcttgtatatccttcaagcctaacaaaaaattgtatgtgcca gagattcctaaactttctgtgttcagggtgccattagttgtcttggtact tttttcatggtgccccaggtcaaaatatatacttaatagttcagtgtttt aagtaattaggtcccaacagcttaataatagcagtttgcacagtgtcctg catatatcactatatttcccttaaaaatttccagcattggctgagcatgg tgactcacgcctgtaatcccagcactttgggaggctgaggcaggtggatc acctcaggtcaggaatttgagaccagcctgactaacatgatgaaaccccg tctctactaaaaatacaaaattagctgggcatggtggcacatgcctgtaa tcccagctactcaggaggctgaggcaggagaattgcttgaacccgggagg cggaggttgcagtgagccgacatcgtgtcagtgcactccagcctgggcaa caagagcaaaacttcatctcaaaaaaaaaaaaaaaaaatgtacaacatct tgcttagcctgtgtgtgttctgtggtaccttggaatagctcagtacataa tttggggaccacagatatctattatgccaatgtttgcactgtctgctgtt ggtgaccctcaaaatgaaattcttggccactcaactctccacattatttc actctttgttttgttattattagtattcttcttgcttgccattggctaat tcattttttaactgcaaccctactcttctttgctgttcatcagccctgca atgccgtagtgtcttagtctagaaaaatgcaatactcaaaagccccagca ttggaggaggctggtgctaagatggacagggttcctgatttctctcattg aacttgatttagtgtcttgggaattataatctcaaaggaggcagagaggg gttaatgttgcataatttatcactaaaatgtctttgttgaccaaggggct ttattaattatgctcagagaaacaattctgtttctcttaaaagtgtctaa caaaacacttttttctttggcctgaaaggacaatggatacctagttccta atttcctacccaaatgctgttttggctgtgttactccctctgccctcgaa gctaagatttatatatttacaaaatttattggagctggtagtcagatcta gtaaaatggattaaatgtcaattgtgctgggattttgccttaacatctat ctatgacttgaagagggatttgttggctcaaaggatcttctgcttttaat gaattagcaagtgaaaaggtatttgaataaatgtcaacttcataggactt tttttttttttaacttttcaaatggaaggtgcagttttcaattaggcctc tgaaaatttacatagtcagatggaaaaatgccagagtaaaatctaggaag aaggagctaccagacccgatagaatagaaagaaagctattttattctcgg aggtctatgttcctcttgtgtttgagtgcctctagcactgttaaatgtgc tgacagctaaagatgctctttgggttttttttttggctttaatttgggta ctatggattcttttgggaatttgttgaaagctaggaccttttccccagga aaatttacattgtatatgaagcacataattttgcaaactttttttggttg ttgttggggggggttgcagtttatatactccacggggttagtagctctgt tctgtagaatattgactgtgacatcctagaccacggttggcaaacttttt ctgtataggaccagatagtaaatatttttggctttgtgtgttataccatc tctgtcacagttactcagctctgctgttgtatcatgaaagcatctatacg caatacacaaatgaatgagcctggtggctgtgttccaataaaactttatt tacaaaccaagcaatgggccaaatttggcccacaggccatggtttgccaa caccagtcttagagcattaaatataaaactctgattaactagatatgtag agttcttccattttagtgactattgagctcagctgctgttgaggcagatt aggaagatggacataggaaactggattcagaaaggatgaggactgtttag tcccatgaaagttgcttgttaatgtcctcaggtaagtatgaattgttctg gaagctgatagaacaattttcttcagatcaaactgaagtacttacttttt ccatttctatgcaatcaccaacataatttacttcaatttggaaataaatg tcacagttctcttagttgttaactgtatccttggcttaggttatttgcat tttctttcttttttctgtagtgtggtttatacacaaggagaatcacgaac ccagacactagtcaatctctctattccctgacttgtactgagattgggga atttgggaggtcagacttacctcaaacgtagaagaaggcagatagagttc ttaacctttttcaacttagccacctcaattatttgttcacattttaagga agtaggaaagagtagtttgaagtcacaaaatttgttctcaggtgttctta aagctccctgttctcactgcgacagaagactcaggcctactcattttgtg ctgtcccacaaaagtgagaggagtacttctctttttttaaatcatcagta aatttcaattttaaggggcctatgcaaaatgcctcctttctgatgtgatt ttcttgggttgctggccctagttgaatttatgggccctgaagcctctagt ggaaatcttgtcttccctatagaacgagaacagctatgtaatttgcttca ccttctgttaggacttgcaccctctttgccatacagaatgctataaaaag gacagtctgccagtgaccgaagctttctcatttttttttcttccagaaca atagcacacatcttggttaaagctatagtctccttattattcagaaatat tctttttcctgctgcaccattaggcaaacatacattatgcttagaatgat acttggaaactccttaacagggcatattgaagtatttgatccagcaactt acctaaaagaatgtttgctcttcacctagggaaataaaacctgaatttca gagccttcaaaatgaaattatccttccaggggaagcacattgccaccaaa tacatcactcactacctgttcctggtgactacatagaagatgtgttattt ttctgaggtttagaaagtcactgtttacagctatgcaaatattgtactat tacagatttttctaatgaagtagtttgaaatcaaggctttagtggaaggt aatcttttcagtttctgacccagatttctttttcaagcaaaactcctctg aaagcctctttgctatagaggtgatgaaggcacttgctagcctaagcaga aacataaagtaaaaaattttgtagtagggaatttttgttggtaagaaatc agtatcatcttgtaacacaaacacgtgttaatagaacttaaaaatactca gcctaattccttgggactttcagtatcttgacatcacttgtattatcatt tgaacttggacattgagccctttatttttgggagtttacagttaaatttt ggaagaattgtgttgtatttctttcttagatgttgtcagtatgaacagaa tttttttgtgaacagttaatcttgatgtgctccatagctttctccagttt acacttttgcatttctgagattcagggtctttttcaaggaaggaggctaa tgtttaaggcctggaggctgaattcagggagcgtattggcaagtttaggc acttacttgtgtcttaatgtgggaaacagaactttctaagtaatctctgg agtttgtagcttagaccaggccttcaaaagtcttttctgttttcctttgc tacaatttgcttgttatttctctgccggtcacagatgacctggactgact gaatgcttttgtggtaaggaactgatctggccattttcatataacaaaaa tcaaagtcaacaattttgtatcaggctgcctaaatgaaccctattgtttc cagttcttaaaaatttaagggctatctaagaaaagtttaagcaaaaccct cattccaaacatgcgaccttataataagaacttcctttaaagatgagcag caaggttgggtatctgatttcactaagtaatattctattgtggtcagaaa tgggtaatttgcatcatttggtcactatcaatatttgtgttggagtctgc aagatatttcaacaaagtaagccaaaccactatcttaggggattgttgct ggactttggaatataaggctgaacagtgatgtgaagtcatgtttgggggc tggaagaagtgataaatgcaaaggttggtgctaaattaggaaccccttga aggagcaagctgattaaaaaaaaaagctggcagacaagtatatcttttaa tttatttgcagtgttgctatattatagagatgatttcctatgggaaaacc catcaaaaagccaaacctttattgttatttttccttaaaaatactgagct ataagaagattcagagagtggcattaatttgggcatcagaacattttctt ttgtatccctagtgttattgatttgaaagagttaccttttcagacagatg gctgaacaaaagtaaatgattaacgggaaatttgatggttgagaaaaagg aacgatatgcctaaagcattttgagaatatacccctcatccatcagccac ctctgggtaaagaaacacaaataccaaagcctgagctccttaaccttttg ttccagagggcagacatttttaagaaaggtgaatgttagagaaggttacc tgatgagcaagcttctttcccataattcagagaactgtgaatgtacttag aaatacactacaggtcttcaccagatgaactagattttataattttaaaa tataatactgaaagctagtttgaagtttcagaagccatgaattatgggga aggagtagttttttattttattttatttttctgatctcaagttgtttgtc ctgttgtatgttcaatacttggggagataagagcgaggtacagctgtggt tttcagaccatattcagtggtgcccctgagggtctcttgtgaacagaagg gaaaaagagtgtgatgaaggtgaactctgcctatctgaacctctgtcaac ctccagtcagaatatctggcttctagtattgttccttttaactggaagtc tctgtggccattaaaaacttgggaacgttggattaaatgaccactttagg actttaaacagtctcaaatatgggaaattttatagccaaccacggctgtg agtccctggcttttgccgtactgagtatgctcacagagatagggagatag gtggccagaagacagggtcatttaattttaattgagcataaatcattttg aaagaaaaatgcaaggaattgttgtatgacagccatgcattatagatcct tacatgcgacattttcctaaagtggttgagaatgacctgatctttgttca ccgtctcagtgacaaggcgtggagtgactgggctcttcatatgcagtgga atttttgcatctctaggtttgcagaggcaggagttaccgtttttgttcat tgacctatcagaaaaaagcaaatcctttggacaatgttgacacagacagg ggtacggtctgagactcaagctaacagagctaccccttgctgccttttgc aaaggtgttgtaggtggagaagggtaatggaaacctggtacagcctttag aagttggaagctatggtggtgtatctgtcatgaactgcacacaagggaat gcttaaacaccagctgagtcatatcaggtgccttgtacacacacataaag agtctggtgaattctgacagtgttctgtttgccactagagcaaatttaat agctggggtttcacagcaactgttttagaaaactatatgtgccaaaaatt tacattgggcagcagtttatagtgttcttggccaatctgcataaaagcca cttgaggaggtttgattaagaaaattgtgtttatctcctgtattacctct gtgtttgatttattctttagtctcaaatttattttctgagtggactgatt ttctatatgaactgaaatgatgttttaatagaataataggtatttttaga ggaaaagtatttttttgtgtaatttgcttacacaactaggacatacttcc tatgatactgaatcatcaaattgagtcatttaaagctgaaagaggtgtta ggaatgtagtttcacattatttaaatacatgaacagttttctatatattt tgtgaaaatcttgatgagacactagaatttctttatggaattgaacttta caagaattttaataaaagaggtggatttcttcagctttctttgtgcttca gtttcatagctgaaaatgctgcttccgtttattaatatggactttgtaag gaaacacaacaacacgttttcttaccttctgtaaattttgtgatagacac atgttatttgtatatatgattgattgtttgcctgttgcaccctaaagtta ttttcaaaccatgtttattgcaaagagagcctttgggcaagtggaaaatg ccctgatgctagaatgaggtagttccataagctagttaggagcttgctac ctcttcttggtacctgaaatattctgaaaggatatcggagaggtcctatg cacccctgtctttcaaaacccacctccagcacttcaaagtagtgtctctg gagagtttaaaataaaagaatgaatgctattcagtggattccctcattga ggctcccatctttcctgccaggtgcagctttttctggttggaatcatctc ttctttacggattgccgcattgtctctttgtgaatgaggcaggctgaact gtagagcatgaaactcattagaagtttataaagtaaagacctgtaaagca tgtgggtggaatgtttccatgctcttgaggtgaatattaaatttaaattc tggcctttgggaactctttgcttgtgagctgaagaaggaaagaaggagtt gggggtgtatatctaactgtgtttttctatatggaaatatatgagcatca agtgataacttcaataaggcctcaggattgtatttaaaatacctgttttg tgggacagcatgcctttgttttctttgcctgttggctttggtggctccaa acattttcattttaggctagctttcctgtcacccaggttgtgtgcatttt ttttttcatttgaactattgtttatcattattaatgatgttatctccaaa tcccaaagccaaggaaatagccagtatgcaggacttgcagtagatataag cattggtgttaacataggttaagttttgttagtgttcccagaaatatact gaattgagggataatgtagctttaaagaaattatgtttctttttaacatt tggagaagccacctgtcctgggtccctattcttgagaaattcatcttttc atgcaaataacattgatgggggacaagactggatgattgacttctatcag tcagtagacaaggaagtataataattgccaaaggtgagggtaattttgcc ttacaagtatgtaggtcattctgtggtgggatttcccatcacatctagta aaaaacaaccttttcatttccctcctttctaatccaagatcatattttta aaaagtaggtttctgatgtgccatgaaatatttctgtgaatctgtgtttt tgaccaaggaaacagctgagatattaaaccatgtggttgttccacggttc atctggctaccgttctgggtcccctctgaccacctcaaaaagaaaatgaa attgggagattaaatcaagcttgacctcctcttttaatgaggaactttca cgttgacttcctatctcaggatattcttcagtttcatactgctgaggaga aaggaacaagctgcagacactgtaactggtctccagatgtgtgtatatgc gtgtaaaacttcacaccgtgtgtgttgtgttcaatgttgtgtcaatctac aaactgactcaaacaacagtttaacgatagagaagacagtgataatggca aaaaaaacacccaaccacctttttccgtcaaagtgcttgctatggctttc atagctgggacaagtaacattaagtattcaggagcaaagtgttcttgaaa gaaaatggtgtgttgatctcataagaaaatgtacaaccaataaaagacat tttaaaaagaaaaaaaaaaaaaaaa - Known MAP2K6 inhibitors include those recited in Table 3.
-
TABLE 3 MAP2K6 Inhibitors Compound Action Mechanism of Action WX-554 inhibitor MEK inhibitor -
TABLE 4 dbSNP MAP2K6 Variants SNP ID Chr 17 pos Sequence Context Type rs707247 69,430,471(−) TTCTT(A/T)CAGGC intron- (SEQ ID NO: 14) variant rs707248 69,416,490(−) CTAAA(G/T)GCCAT intron- (SEQ ID NO: 15) variant rs731606 69,430,375(−) TTCCA(A/T)TTGGC intron- (SEQ ID NO: 16) variant rs732322 69,422,847(−) tggcc(C/T)aggag intron- (SEQ ID NO: 17) variant rs739559 69,494,089(−) CCCTT(A/G)TTATT intron- (SEQ ID NO: 18) variant - MAP3K4
- Mitogen-activated protein
kinase kinase kinase 4 is an enzyme that in humans is encoded by the MAP3K4 gene (Takekawa M, et al. (October 1997). EMBO J 16 (16): 4973-82; Entrez Gene: MAP3K4 mitogen-activated proteinkinase kinase kinase 4″). - The central core of each mitogen-activated protein kinase (MAPK) pathway is a conserved cascade of 3 protein kinases: an activated MAPK kinase kinase (MAPKKK) phosphorylates and activates a specific MAPK kinase (MAPKK), which then activates a specific MAPK. While the ERK MAPKs are activated by mitogenic stimulation, the CSBP2 (p38α) and JNK MAPKs are activated by environmental stresses such as osmotic shock, UV irradiation, wound stress, and inflammatory factors. This gene encodes a MAPKKK, the MEKK4 protein, also called MTK1. This protein contains a protein kinase catalytic domain at the C terminus. The N-terminal nonkinase domain may contain a regulatory domain. Expression of MEKK4 in mammalian cells activated the CSBP2 (p38α) and JNK MAPK pathways, but not the ERK pathway. In vitro kinase studies indicated that recombinant MEKK4 can specifically phosphorylate and activate PRKMK6 (MKK6) and SERKI1 (MKK4), MAPKKs that activate CSBP2 (p38α) and JNK, respectively but cannot phosphorylate PRKMK1 (MKK1), an MAPKK that activates ERKs. MEKK4 is a major mediator of environmental stresses that activate the p38 MAPK pathway, and a minor mediator of the JNK pathway. Two alternatively spliced transcripts encoding distinct isoforms have been described (Entrez Gene: MAP3K4 mitogen-activated protein
kinase kinase kinase 4″). -
An illustrative amino acid sequence (SEQ ID NO: 7) of human Map3k4 is NP_005913.2: MREAAAALVPPPAFAVTPAAAMEEPPPPPPPPPPPPEPETESEPECCLAA RQEGTLGDSACKSPESDLEDFSDETNTENLYGTSPPSTPRQMKRMSTKHQ RNNVGRPASRSNLKEKMNAPNQPPHKDTGKTVENVEEYSYKQEKKIRAAL RTTERDHKKNVQCSFMLDSVGGSLPKKSIPDVDLNKPYLSLGCSNAKLPV SVPMPIARPARQTSRTDCPADRLKFFETLRLLLKLTSVSKKKDREQRGQE NTSGFWLNRSNELIWLELQAWHAGRTINDQDFFLYTARQAIPDIINEILT FKVDYGSFAFVRDRAGFNGTSVEGQCKATPGTKIVGYSTHHEHLQRQRVS FEQVKRIMELLEYIEALYPSLQALQKDYEKYAAKDFQDRVQALCLWLNIT KDLNQKLRIMGTVLGIKNLSDIGWPVFEIPSPRPSKGNEPEYEGDDTEGE LKELESSTDESEEEQISDPRVPEIRQPIDNSFDIQSRDCISKKLERLESE DDSLGWGAPDWSTEAGFSRHCLTSIYRPFVDKALKQMGLRKLILRLHKLM DGSLQRARIALVKNDRPVEFSEFPDPMWGSDYVQLSRTPPSSEEKCSAVS WEELKAMDLPSFEPAFLVLCRVLLNVIHECLKLRLEQRPAGEPSLLSIKQ LVRECKEVLKGGLLMKQYYQFMLQEVLEDLEKPDCNIDAFEEDLHKMLMV YFDYMRSWIQMLQQLPQASHSLKNLLEEEWNFTKEITHYIRGGEAQAGKL FCDIAGMLLKSTGSFLEFGLQESCAEFWTSADDSSASDEIRRSVIEISRA LKELFHEARERASKALGFAKMLRKDLEIAAEFRLSAPVRDLLDVLKSKQY VKVQIPGLENLQMFVPDTLAEEKSIILQLLNAAAGKDCSKDSDDVLIDAY LLLTKHGDRARDSEDSWGTWEAQPVKVVPQVETVDTLRSMQVDNLLLVVM QSAHLTIQRKAFQQSIEGLMTLCQEQTSSQPVIAKALQQLKNDALELCNR ISNAIDRVDHMFTSEFDAEVDESESVTLQQYYREAMIQGYNFGFEYHKEV VRLMSGEFRQKIGDKYISFARKWMNYVLTKCESGRGTRPRWATQGFDFLQ AIEPAFISALPEDDFLSLQALMNECIGHVIGKPHSPVTGLYLAIHRNSPR PMKVPRCHSDPPNPHLIIPTPEGFSTRSMPSDARSHGSPAAAAAAAAAAV AASRPSPSGGDSVLPKSISSAHDTRGSSVPENDRLASIAAELQFRSLSRH SSPTEERDEPAYPRGDSSGSTRRSWELRTLISQSKDTASKLGPIEAIQKS VRLFEEKRYREMRRKNIIGQVCDTPKSYDNVMHVGLRKVTFKWQRGNKIG EGQYGKVYTCISVDTGELMAMKEIRFQPNDHKTIKETADELKIFEGIKHP NLVRYFGVELHREEMYIFMEYCDEGTLEEVSRLGLQEHVIRLYSKQITIA INVLHEHGIVHRDIKGANIFLTSSGLIKLGDFGCSVKLKNNAQTMPGEVN STLGTAAYMAPEVITRAKGEGHGRAADIWSLGCVVIEMVTGKRPWHEYEH NFQIMYKVGMGHKPPIPERLSPEGKDFLSHCLESDPKMRWTASQLLDHSF VKVCTDEE The corresponding nucleic acid sequence (SEQ ID NO: 8) NM_005922 encoding human Map3k4 is: gatctgggaggcttgtccctcgccgcccaccgtagccccggcgctcggcc ggtcgccgtttccaagatggccgcggcgcgcacggctcctgcggcggggt agaggcggaggcggagtcgagtcactcccgcacttcggggctccggtgcc ccgcgccaggctgcagcttactgcccgccgcggccatgcggggctccgtg cacggatgagagaagccgctgccgcgctggtccctcctcccgcctttgcc gtcacgcctgccgccgccatggaggagccgccgccaccgccgccgccgcc accaccgccaccggaacccgagaccgagtcagaacccgagtgctgcttgg cggcgaggcaagagggcacattgggagattcagcttgcaagagtcctgaa tctgatctagaagacttctccgatgaaacaaatacagagaatctttatgg tacctctccccccagcacacctcgacagatgaaacgcatgtcaaccaaac atcagaggaataatgtggggaggccagccagtcggtctaatttgaaagaa aaaatgaatgcaccaaatcagcctccacataaagacactggaaaaacagt ggagaatgtggaagaatacagctataagcaggagaaaaagatccgagcag ctcttagaacaacagagcgtgatcataaaaaaaatgtacagtgctcattc atgttagactcagtgggtggatctttgccaaaaaaatcaattccagatgt ggatctcaataagccttacctcagccttggctgtagcaatgctaagcttc cagtatctgtgcccatgcctatagccagacctgcacgccagacttctagg actgactgtccagcagatcgtttaaagttttttgaaactttacgactttt gctaaagcttacctcagtctcaaagaaaaaagacagggagcaaagaggac aagaaaatacgtctggtttctggcttaaccgatctaacgaactgatctgg ttagagctacaagcctggcatgcaggacggacaattaacgaccaggactt ctttttatatacagcccgtcaagccatcccagatattattaatgaaatcc ttactttcaaagtcgactatgggagcttcgcctttgttagagatagagct ggttttaatggtacttcagtagaagggcagtgcaaagccactcctggaac aaagattgtaggttactcaacacatcatgagcatctccaacgccagaggg tctcatttgagcaggtaaaacggataatggagctgctagagtacatagaa gcactttatccatcattgcaggctcttcagaaggactatgaaaaatatgc tgcaaaagacttccaggacagggtgcaggcactctgtttgtggttaaaca tcacaaaagacttaaatcagaaattaaggattatgggcactgttttgggc atcaagaatttatcagacattggctggccagtgtttgaaatcccttcccc tcgaccatccaaaggtaatgagccggagtatgagggtgatgacacagaag gagaattaaaggagttggaaagtagtacggatgagagtgaagaagaacaa atctctgatcctagggtaccggaaatcagacagcccatagataacagctt cgacatccagtcgcgggactgcatatccaagaagcttgagaggctcgaat ctgaggatgattctcttggctggggagcaccagactggagcacagaagca ggctttagtagacattgtctgacttctatttatagaccatttgtagacaa agcactgaagcagatggggttaagaaagttaattttaagacttcacaagc taatggatggttccttgcaaagggcacgtatagcattggtaaagaacgat cgtccagtggagttttctgaatttccagatcccatgtggggttcagatta tgtgcagttgtcaaggacaccaccttcatctgaggagaaatgcagtgctg tgtcgtgggaggagctgaaggccatggatttaccttcattcgaacctgcc ttcctagttctctgccgagtccttctgaatgtcatacatgagtgtctgaa gttaagattggagcagagacctgctggagaaccatctctcttgagtatta agcagctggtgagagagtgtaaggaggtcctgaagggcggcctgctgatg aagcagtactaccagttcatgctgcaggaggttctggaggacttggagaa gcccgactgcaacattgacgcttttgaagaggatctacataaaatgctta tggtgtattttgattacatgagaagctggatccaaatgctacagcaatta cctcaagcatcgcatagtttaaaaaatctgttagaagaagaatggaattt caccaaagaaataactcattacatacggggaggagaagcacaggccggga agcttttctgtgacattgcaggaatgctgctgaaatctacaggaagtttt ttagaatttggcttacaggagagctgtgctgaattttggactagtgcgga tgacagcagtgcttccgacgaaatcaggaggtctgttatagagatcagtc gagccctgaaggagctcttccatgaagccagagaaagggcttccaaagca cttggatttgctaaaatgttgagaaaggacctggaaatagcagcagaatt caggctttcagccccagttagagacctcctggatgttctgaaatcaaaac agtatgtcaaggtgcaaattcctgggttagaaaacttgcaaatgtttgtt ccagacactcttgctgaggagaagagtattattttgcagttactcaatgc agctgcaggaaaggactgttcaaaagattcagatgacgtactcatcgatg cctatctgcttctgaccaagcacggtgatcgagcccgtgattcagaggac agctggggcacctgggaggcacagcctgtcaaagtcgtgcctcaggtgga gactgttgacaccctgagaagcatgcaggtggataatcttttactagttg tcatgcagtctgcgcatctcacaattcagagaaaagctttccagcagtcc attgagggacttatgactctgtgccaggagcagacatccagtcagccggt catcgccaaagctttgcagcagctgaagaatgatgcattggagctatgca acaggataagcaatgccattgaccgcgtggaccacatgttcacatcagaa tttgatgctgaggttgatgaatctgaatctgtcaccttgcaacagtacta ccgagaagcaatgattcaggggtacaattttggatttgagtatcataaag aagttgttcgtttgatgtctggggagtttagacagaagataggagacaaa tatataagctttgcccggaagtggatgaattatgtcctgactaaatgtga gagtggtagaggtacaagacccaggtgggcgactcaaggatttgattttc tacaagcaattgaacctgcctttatttcagctttaccagaagatgacttc ttgagtttacaagccttgatgaatgaatgcattggccatgtcataggaaa accacacagtcctgttacaggtttgtaccttgccattcatcggaacagcc cccgtcctatgaaggtacctcgatgccatagtgaccctcctaacccacac ctcattatccccactccagagggattcagcactcggagcatgccttccga cgcgcggagccatggcagccctgctgctgctgctgctgctgctgctgctg ctgttgctgccagtcggcccagcccctctggtggtgactctgtgctgccc aaatccatcagcagtgcccatgataccaggggttccagcgttcctgaaaa tgatcgattggcttccatagctgctgaattgcagtttaggtccctgagtc gtcactcaagccccacggaggagcgagatgaaccagcatatccaagagga gattcaagtgggtccacaagaagaagttgggaacttcggacactaatcag ccagagtaaagatactgcttctaaactaggacccatagaagctatccaga agtcagtccgattgtttgaagaaaagaggtaccgagaaatgaggagaaag aatatcattggtcaagtttgtgatacgcctaagtcctatgataatgttat gcacgttggcttgaggaaggtgaccttcaaatggcaaagaggaaacaaaa ttggagaaggccagtatgggaaggtgtacacctgcatcagcgtcgacacc ggggagctgatggccatgaaagagattcgatttcaacctaatgaccataa gactatcaaggaaactgcagacgaattgaaaatattcgaaggcatcaaac accccaatctggttcggtattttggtgtggagctccatagagaagaaatg tacatcttcatggagtactgcgatgaggggactttagaagaggtgtcaag gctgggacttcaggaacatgtgattaggctgtattcaaagcagatcacca ttgcgatcaacgtcctccatgagcatggcatagtccaccgtgacattaaa ggtgccaatatcttccttacctcatctggattaatcaaactgggagattt tggatgttcagtaaagctcaaaaacaatgcccagaccatgcctggtgaag tgaacagcaccctggggacagcagcatacatggcacctgaagtcatcact cgtgccaaaggagagggccatgggcgtgcggccgacatctggagtctggg gtgtgttgtcatagagatggtgactggcaagaggccttggcatgagtatg agcacaactttcaaattatgtataaagtggggatgggacataagccacca atccctgaaagattaagccctgaaggaaaggacttcctttctcactgcct tgagagtgacccaaagatgagatggaccgccagccagctcctcgaccatt cgtttgtcaaggtttgcacagatgaagaatgaagcctagtagaatatgga cttggaaaattctcttaatcactactgtatgtaatatttacataaagact gtgctgagaagcagtataagcctttttaaccttccaagactgaagactgc acaggtgacaagcgtcacttctcctgctgctcctgtttgtctgatgtggc aaaaggccctctggagggctggtggccacgaggttaaagaagctgcatgt taagtgccattactactgtacacggaccatcgcctctgtctcctccgtgt ctcgcgcgactgagaaccgtgacatcagcgtagtgttttgacctttctag gttcaaaagaagttgtagtgttatcaggcgtcccataccttgtttttaat ctcctgtttgttgagtgcactgactgtgaaacctttaccttttttgttgt tgttggcaagctgcaggtttgtaatgcaaaaggctgattactgaaattta agaaaaaggttcttttttcaataaatggtttattttaggaaagctcaaaa aaaaaaaaaaaaaa -
TABLE 5 dbSNP MAP3K4 Variants SNP ID Chr 06 pos Sequence Context Type rs1000277 161,105,793(−) ACTAA(C/T)CAAAT intron- (SEQ ID NO: 19) variant rs1001756 161,105,475(+) aaatg(A/G)cgagg intron- (SEQ ID NO: 20) variant rs1001808 161,057,414(+) GAGCT(A/G)TAGAT intron- (SEQ ID NO: 21) variant rs1001809 161,057,478(+) gtttc(C/G)aaacc intron- (SEQ ID NO: 22) variant rs10080366 161,019,422(+) tcttt(C/T)tattt intron- (SEQ ID NO: 23) variant - Agents of the Disclosure
- The disclosure provides agents to modulate the expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof. In one embodiment, the agent is an inhibitor or antagonist of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, that selectively blocks MAP kinase pathway signaling. In a particular embodiment, the agent is an inhibitor of MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof. Non-limiting illustrative examples include small molecules (e.g., of Tables 1 and 3), antibodies, antisense and/or siRNA molecules directed to inhibit MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof.
- Agents useful in the methods of the disclosure can be nucleic acid molecules, e.g., antisense, ribozyme, or RNA interference technology, e.g., siRNA molecules corresponding to a portion of the nucleotide sequence encoding a component member of the MAP kinase pathway (e.g., a nucleic acid encoding Mmp17, Map2k6 and/or Map3k4).
- Antisense polynucleotides may act by directly blocking translation by hybridizing to mRNA transcripts or degrading such transcripts of a gene. The antisense molecule may be recombinantly made using at least one functional portion of a gene in the antisense orientation as a region downstream of a promoter in an expression vector. Chemically modified bases or linkages may be used to stabilize the antisense polynucleotide by reducing degradation or increasing half-life in the body (e.g., methyl phosphonates, phosphorothioate, peptide nucleic acids). The sequence of the antisense molecule may be complementary to the translation initiation site (e.g., between −10 and +10 of the target's nucleotide sequence).
- Ribozymes catalyze specific cleavage of an RNA transcript or genome. The mechanism of action involves sequence-specific hybridization to complementary cellular or viral RNA, followed by endonucleolytic cleavage. Inhibition may or may not be dependent on ribonuclease H activity. The ribozyme includes one or more sequences complementary to the target RNA as well as catalytic sequences responsible for RNA cleavage (e.g., hammerhead, hairpin, axehead motifs). For example, potential ribozyme cleavage sites within a subject RNA are initially identified by scanning the subject RNA for ribozyme cleavage sites which include the following trinucleotide sequences: GUA, GUU and GUC. Once identified, an oligonucleotide of between about 15 and about 20 ribonucleotides corresponding to the region of the subject RNA containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render candidate oligonucleotide sequences unsuitable. The suitability of candidate sequences can then be evaluated by their ability to hybridize and cleave target RNA. The ribozyme may be recombinantly produced or chemically synthesized.
- siRNA refers to double-stranded RNA of at least 20-25 basepairs which mediates RNA interference (RNAi). Duplex siRNA corresponding to a target RNA may be formed by separate transcription of the strands, coupled transcription from a pair of promoters with opposing polarities, or annealing of a single RNA strand having an at least partially self-complementary sequence. Alternatively, duplexed oligoribonucleotides of at least about 21 to about 23 basepairs may be chemically synthesized (e.g., a duplex of 21 ribonucleotides with 3′ overhangs of two ribonucleotides) with some substitutions by modified bases being tolerated. Mismatches in the center of the siRNA sequence, however, abolishes interference. The region targeted by RNA interference should be transcribed, preferably as a coding region of the gene. Interference appears to be dependent on cellular factors (e.g., ribonuclease III) that cleave target RNA at sites 21 to 23 bases apart; the position of the cleavage site appears to be defined by the 5′ end of the guide siRNA rather than its 3′ end. Priming by a small amount of siRNA may trigger interference after amplification by an RNA-dependent RNA polymerase.
- CRISPR-Cas
- In certain aspects inhibition of MAP kinase components can be achieved by administration of inhibitory nucleic acids (e.g., dsRNAs, siRNAs, antisense oligonucleotides, etc.). It is also contemplated that CRISPR-Cas (e.g., CRISPR-Cas9) methods can be used to excise and replace MAP kinase pathway component alleles identified to carry a deleterious mutation and/or variant that predisposes/contributes to MFS. Such variant alleles include the variant alleles identified in mice, for at least MMP17 and MAP2K6 herein, and further including similar human alleles of these genes, as well as of MAP3K4. Such methods can be performed upon the cells of a subject in vivo or ex vivo. Use of any combination of the above and/or other known MAP kinase component modulators is also contemplated.
- The CRISPR-Cas system is known in the art. Non-limiting aspects of this system are described in U.S. Pat. No. 8,697,359, issued Apr. 15, 2014, the entire content of which is incorporated herein by reference.
- Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12),
Cas 10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. These enzymes are known; for example, the amino acid sequence of S. pyogenes Cas9 protein may be found in the SwissProt database under accession number Q99ZW2. In some embodiments, the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9. In some embodiments, the CRISPR enzyme is Cas9, and may be Cas9 from S. pyogenes or S. pneumoniae. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, a vector encodes a CRISPR enzyme that is mutated with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A. In aspects of the invention, nickases may be used for genome editing via homologous recombination. - In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn; Ruiqiang Li, Yingrui Li, Karsten Kristiansen, Jun Wang; SOAP: short oligonucleotide alignment program, Bioinformatics,
Volume 24,Issue - EGFR Inhibitors
- In certain embodiments, a method for treating a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition comprises administering to the subject an effective amount of an agent that modulates the activity of MAP kinase pathway signaling and/or expression, function or activity of epidermal growth factor receptor (EGFR); thereby treating the subject. In certain embodiments, the agent that modulates the activity of MAP kinase pathway signaling is an inhibitor of the MAP kinase pathway. In certain embodiments, the agent that modulates the activity of MAP kinase pathway signaling is an inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof. In certain embodiments, the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof, is an antisense agent or a double-stranded nucleic acid, optionally a siRNA or shRNA specific for MMP17, MAP2K6 or MAP3K4. In certain embodiments, the inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof, is specific for a nucleic acid molecule set forth as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8. In other embodiments, the agent that modulates the activity of MAP kinase pathway signaling comprise Batimastat, GI 254023X, GM 6001,
TMI 1, WAY 170523, WX-554 or combinations thereof. Any combination of inhibitors can be used, for example, an siRNA and a compound, e.g. GI 254023X, and/or an antibody. - In certain embodiments, the agent that modulates expression, function or activity of epidermal growth factor receptor (EGFR) is an EGFR inhibitor comprising: an antibody, interfering RNAs microRNAs, shRNA, small molecule or combinations thereof.
- In certain embodiments, the EGFR inhibitor comprises: gefitinib, erlotinib, lapatinib, Brigatinib (AP26113), Afatinib (BIBW2992), Neratinib (HKI-272), AZD3759, AZ5104, CL-387785 (EKI-785), Canertinib (CI-1033), Poziotinib (HM781-36B), Osimertinib (AZD-9291), PD168393, CNX-2006, Rociletinib (CO-1686, AVL-301), WZ4002, Pelitinib (EKB-569), AC480 (BMS-599626), TAK-285, CUDC-101, AEE788 (NVP-AEE788), CP-724714, Dacomitinib (PF299804, PF299), AG-490 (Tyrphostin B42), AST-1306, OSI-420, WHI-P154, WZ3146, WZ8040, AZD8931 (Sapitinib), PKI-166, PD158780, AG 1478, PD153035 HCl, Icotinib, Varlitinib, AZD-9291, AEE788 (NVP-AEE 788), AG-1478 (NSC 693255), AG-490, Anlotinib, ARRY-380, BIBX 1382, BMS-690514, cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzumab or mAb 806. An anti-EGFR antibody comprises cetuximab, matuzumab, panitumumab, nimotuzumab or mAb 806 and a small molecule EGFR inhibitor comprises gefitinib, lapatinib, canertinib, erlotinib HCL, pelitinib, PKI-166, PD158780, or AG 1478. In certain embodiments, combinations of agents, e.g. antibody or small molecules, can be administered as part of the therapy. In other embodiments, an inhibitor of transforming growth factor β (TGFβ) is also administered.
- In certain embodiments, a pharmaceutical composition comprises a therapeutically effective amount of at least one agent that modulates expression, function or activity of MMP17, MAP2K6, MAP3K4, epidermal growth factor receptor (EGFR), or combinations thereof.
- An exemplary anti-EGFR antibody is cetuximab (ERBITUX™). Cetuximab is commercially available from ImClone Systems Incorporated. Other examples of anti-EGFR antibodies include matuzumab (EMD72000), panitumumab (VECTIBIX™; Amgen); nimotuzumab (THERACIM™) and mAb 806. An exemplary small molecule inhibitor of the EGFR signaling pathway is gefitinib (IRESSA™), which is commercially available from AstraZeneca and Teva. Other examples of small molecule inhibitors of the EGFR signaling pathway include erlotinib HCL (OSI-774; TARCEVA™, OSI Pharma); lapatinib (TYKERB™, GlaxoSmithKline); canertinib (canertinib dihydrochloride, Pfizer); pelitinib (Pfizer); PKI-166 (Novartis); PD158780; and AG 1478 (4-(3-Chloroanillino)-6,7-dimethoxyquinazoline).
- The EGFR inhibitor may be an EGFR tyrosine kinase inhibitor, or may alternatively target the extracellular domain of the EGFR target. In certain embodiments, the EGFR inhibitor is a tyrosine kinase inhibitor such as Erlotinib, Gefitinib, or Lapatinib, or a molecule that targets the EGFR extracellular domain such as Cetuximab or Panitumumab.
- In certain embodiments, the EGFR inhibitor is an anti-EGFR antibody, preferably a monoclonal antibody, such as Cetuximab or Panitumumab.
- Cetuximab and Panitumumab are currently the clinically mostly used anti-EGFR monoclonal antibodies. However, further anti-EGFR monoclonal antibodies are in development, such as Nimotuzumab (TheraCIM-h-R3), Matuzumab (EMD 72000), Zalutumumab (HuMax-EGFr), Nimotuzumab and Sym 004. Similarly, Erlotinib, Gefitinib, Lapatinib and Regorafenib are currently the clinically mostly used tyrosine kinase EGFR inhibitors. However, further tyrosine kinase EGFR inhibitors are in development, such as Canertinib (CI-1033), Neratinib (HKI-272), Afatinib (BIBW2992), Dacomitinib (PF299804, PF-00299804), TAK-285, AST-1306, ARRY334543, AG-1478 (Tyrphostin AG-1478), AV-412, OSI-420 (DesmethylErlotinib), AZD8931, AEE788 (NVP-AEE788), Pelitinib (EKB-569), CUDC-101, AG 490, PD153035 HCL, XL647, Ruxolitinib, and BMS-599626 (AC480). The method according to the invention may also be used to predict response to these tyrosine kinase EGFR inhibitors or any other tyrosine kinase EGFR inhibitors that might be further developed, in particular if the patient is suffering from of lung cancer (in particular non-small cell lung cancer, NSCLC), pancreatic cancer, or head and neck cancer (in particular squamous cell carcinoma of the head and neck (SCCHN)).
- TGFβ Inhibitors
- Transforming growth factor beta (TGFβ) has emerged as a candidate mediator of disease pathology and a key therapeutic target in MFS (Massagu, J., et al. Cell 103, 295-309 (2000)). The TGFβ family of cytokines influences a diverse repertoire of cellular processes including cell proliferation, survival and synthetic activity. The TGFβ ligand isoforms bind to a cell surface complex of
type Nature Medicine 13, 204-10 (2007); Carta, L. et al. J. Biol. Chem. 27, 5630-6 (2009)). Furthermore, therapies that associate with increased TGFβ activation in MFS mice, such as calcium channel blockers, exacerbate aortic disease (Doyle, J. J. et al. eLife 4:e08648 (2015)), while those that attenuate TGFβ signaling and related pathways, such as TGFβ neutralizing antibody (NAb), the angiotensin-II (Ang-II)type 1 receptor blocker (ARB) losartan, or the inhibitor of ERK1/2 activation RDEA119, can suppress aortic disease in MFS mice (Habashi, J. P. et al. Science 312, 117-21 (2006); Holm, T. M. et al.Science 15, 358-61 (2011); Habashi, J. P. et al.Science 15, 361-5 (2011)). - The major classes of TGFβ inhibitors include ligand traps, antisense oligonucleotides (ASO), small molecule receptor kinase inhibitors and peptide aptamers. Ligand traps include anti-ligand neutralizing antibodies and soluble decoy receptor proteins that incorporate the ectodomains from either TGFβ receptor II (TβRII) or TGFβ receptor III (TβRIII)/betaglycan protein. Neutralizing antibodies have been raised against individual ligands or may be designed to block all three human isomers TGFβ1, -2 and -3. ASO can also be used to reduce the bioavailability of active TGFβ ligands by blocking de novo synthesis of TGFβ. ASOs are single-stranded polynucleotide molecules, usually 13-25 nucleotides in length, that hybridize to complementary RNA, inhibiting mRNA function, and preventing protein synthesis through accelerated mRNA degradation by RNase H or steric blockade. Another therapeutic strategy is to block TGFβ receptor I (TβRI) activity through the use of small molecule receptor kinase inhibitors that act via ATP-competitive inhibition of the catalytic domain of the serine-threonine kinase of the TβRI (ALK5-Receptor). Lastly, targeting intracellular TGFβ signaling molecules, such as Smads, is possible with the use of peptide aptamers. Aptamers are small peptide, DNA or RNA molecules containing a target-binding and a scaffolding domain that stabilize and interfere with the function of the target.
- Accordingly, in some embodiments, an inhibitor of TGFβ or TGFβ signaling is administered as part of a therapeutic regimen. TGFβ signaling controls proliferation, cellular differentiation, and other functions in a variety of cell types, and can play a role in cell cycle control, regulation of the immune system, and development in certain cell types. Inhibition of TGFβ signaling may include inhibition of any TGFβ signaling pathway and/or member of the TGFβ superfamily including ligands such as TGFβ1, TGFβ2, TGFβ3, inhibins, activin, anti-mullerian hormone, bone morphogenetic protein, decapentaplegic and Vg-1; receptors such as TGFβ type I receptor, TGFβ type II receptor, ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, ALK7 and ALK8; and downstream effectors such as R-SMAD and other SMAD proteins (e.g., SMAD1, SMAD2, SMAD3, SMAD4, SMAD5).
- In some embodiments, the activity of one or more TGFβ receptors is inhibited. In some embodiments, one or more TGFβ receptor-ligand interactions are inhibited. In some embodiments, a TGFβ type I receptor is inhibited. A TGFβ type I receptor may include one or more of ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, ALK7 and ALK8. In some embodiments, the TGFβ receptor is ALK5.
- A TGFβ inhibitor (e.g., a TGFβ signaling inhibitor) may be an ALK5 inhibitor, in some embodiments. An ALK5 inhibitor may bind to ALK5 or one or more ALK5 ligands or both. An ALK5 inhibitor may bind to ALK5 or one or more downstream SMAD proteins or both. An ALK5 inhibitor may disrupt one or more ALK5-ligand interactions or may disrupt one or more ALK5-SMAD interactions. In some embodiments, an ALK5 inhibitor blocks phosphorylation of SMAD2. ALK5 inhibitors may include one or more small molecule ALK5 inhibitors. In some embodiments, an ALK5 inhibitor is an ATP analog.
- A TGFβ inhibitor of the present invention interacts with a TGFβ receptor, inhibits the signaling of the receptor, interacts with a TGFβ protein, and/or inhibits the transcription and/or translation of the gene encoding TGFβ-1, -2, and/or -3. The TGFβ inhibitor of the present invention inhibits TGFβ1, TGFβ2, and/or TGFβ3; in case an inhibitor inhibits all three TGFβ isotypes, the inhibitor is a pan-specific inhibitor. Examples of TGFβ inhibitors include: A) a small molecule inhibitor of TGFβ receptor type I kinase (ALK5; an inhibitor is an ALK5 inhibitor), B) a neutralizing anti-TGFβ-1, -2, -3 antibody or TGFβ binding fragments thereof, C) a neutralizing anti-TGFβ receptor type I, type II or type III antibody or TGFβ receptors binding fragments thereof, D) an antisense oligonucleotide specific for mRNA encoding TGFβ1, -2, and -3 isotypes or other components of TGFβ signaling assembly optionally comprising a modified nucleoside such as 2′-O, 4′-C-methylene linked bicyclic ribonucleotides, known as locked nucleic acids LNA (e.g., oxy-LNA, amino-LNA, thio-LNA), phosphorodiamidate morpholino oligomers (PMO), phosphorothioate (PS), 2′-O-methyl (2′-Ome), 2′-fluoro (2′-fluoro (2′-F), or 2′-methoxyethyl (2′-MOE) derivatives, E) an antisense RNA molecule specific for TGFβ2-mRNA like belagenpumatucel-L and/or TGFβ1-mRNA or TGFβ3-mRNA or other components of mRNA encoding TGFβ signaling assembly, F) a silencing RNA molecule (siRNA) specific for mRNA encoding TGFβ1, -2, and/or -3 isotypes or other components of TGFβ signaling assembly, G) a short hairpin RNA (shRNA) specific for mRNA encoding TGFβ1, -2, and/or -3 isotypes or other components of TGFβ signaling assembly, H) a miRNA molecule specific for mRNA encoding TGFβ1, -2, and/or -3 isotypes or other components of TGFβ signaling assembly, I) an aptamer and/or spiegelmer molecule specific for TGFβ1, -2, and/or -3 isotypes or other components of the TGFβ signaling assembly, and/or J) a ribozyme molecule specific for mRNA encoding TGFβ1, -2, and/or -3 isotypes or other components of the TGFβ signaling assembly.
- ASOs are single-stranded polynucleotide molecules comprising 13-25 nucleotides, preferably 15-20 nucleotides, more preferred 15, 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides, that hybridize to complementary RNA, inhibiting mRNA function, and preventing protein synthesis for example through accelerated mRNA degradation by RNase H or steric blockade.
- In certain embodiments, a TGFβ inhibitor binding to TGFβ receptor type I, such as a non-peptide, small molecule inhibitor of ALK-5 kinase from dihydropyrolopyrazole derivatives (e.g., LY2157299, LY21109761, LY580276, LY550410, GW788388), pyrazole derivatives (e.g., LY364947, HTS-466284, SM305, SB525334, A-83-01), quinazoline derivatives (e.g., SD-208), or imidazole derivatives (e.g., SM16, SB431542, or SB505124). SD-208 for example is a small molecule inhibitor of type I kinase of TGFβ receptor with IC50=49 nM, which inhibits TGFβ signal transduction in a dose-dependent fashion, as for example measured by p-SMAD2 western blot analysis.
- A human pan-anti-TGFβ antibody binding to and neutralizing all three isotypes of TGFβ (e.g., TGFβ1, 2, 3) like GC-1008, a neutralizing high-affinity antibody or antigen-binding immunoglobulin single variable domain or polypeptide thereof, that neutralize mature human TGFβ1 (like CAT 192), or hTGFβ2 (like CAT 152), and neutralizing anti-TGFβ receptor type II antibody (like D10) or an antibody fragment thereof which binds and neutralizes human TGFβ receptor type II, a fusion protein comprising a TGFβ type II receptor fusion protein, a small molecule or peptide consisting of, for example, 11-50 amino acid residues blocking assembly of the TGFβ signaling complex extra- and intracellularly.
- Pharmaceutical Compositions of the Invention
- The agents described herein can be formulated into pharmaceutical compositions for the treatment of the diseases, disorders and conditions disclosed herein. The language “pharmaceutical composition” includes preparations suitable for administration to mammals, e.g., humans. When the compounds used in the methods of the present disclosure are administered as pharmaceuticals to mammals, e.g., humans, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
- The phrase “pharmaceutically acceptable carrier” is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present disclosure to mammals. The carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.
- Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (13HT), lecithin, propyl gallate, α-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- Formulations of the present disclosure include those suitable for oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present disclosure with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present disclosure with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the disclosure suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present disclosure as an active ingredient. A compound of the present disclosure may also be administered as a bolus, electuary or paste.
- In solid dosage forms of the disclosure for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- The tablets, and other solid dosage forms of the pharmaceutical compositions of the present disclosure, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compounds of the disclosure include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- Besides inert dilutents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions of the disclosure for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the disclosure with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- Formulations of the present disclosure which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
- The ointments, pastes, creams and gels may contain, in addition to an active compound of this disclosure, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present disclosure to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
- Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this disclosure.
- Pharmaceutical compositions of this disclosure suitable for parenteral administration comprise one or more compounds of the disclosure in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the disclosure include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
- In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue,
- The preparations of the present disclosure may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred.
- The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracistemally and topically, as by powders, ointments or drops, including buccally and sublingually.
- Regardless of the route of administration selected, the compounds of the present disclosure, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present disclosure, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present disclosure employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the disclosure employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- In general, a suitable daily dose of a compound of the disclosure will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this disclosure for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 50 mg per kg per day, and still more preferably from about 1.0 to about 100 mg per kg per day. An effective amount is that amount treats a disease, disorder or condition set forth herein.
- If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- While it is possible for a compound of the present disclosure to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
- Certain aspects of the disclosure involve administration of nucleic acid agents. Nucleic acid agents can be effectively delivered to a subject as stabilized agents, with such stability often provided via lipid nanoparticle (LNP) encasement of active nucleic acid agents and/or modification of therapeutic nucleic acid agents with one or more stabilizing modifications, including, e.g., 2′-O-alkyl modifications (including 2′-O-methyl), 2′-F modifications, backbone modifications, locked nucleic acid (LNA) configurations, GalNAc modifications, cholesterol conjugates, etc. Such modifications are known in the art and can be readily employed by the skilled artisan for delivery of the nucleic acid agents of the instant disclosure.
- Methods of Treatment
- As used herein, the term “Marfan syndrome or associated diseases, disorders and conditions” is intended to mean Marfan syndrome or any one of the multitude of diseases disorders or conditions that is caused or associated with the biochemical events that cause Marfan syndrome, e.g., the aberrant expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof. Exemplary conditions include aneurysm, an aortic aneurysm, valve disease, emphysema, myopathy, scoliosis, or eye disease. Exemplary eye diseases include cataracts, myopia, glaucoma, and retinal detachment. Moreover, Marfan syndrome or associated diseases, disorders and conditions include diseases and disorders that related to muscle growth, maintenance, or regeneration, e.g., muscular dystrophies such as Duchenne muscular dystrophy. Further, the disease or disorder can be a lung disease or disorder, e.g., emphysema, pneumothorax, and COPD.
- The term “treated,” “treating” or “treatment” includes the diminishment or alleviation of at least one symptom associated or caused by Marfan syndrome, or an associated disease, disorder or condition. For example, treatment can be diminishment of one or several symptoms of a disease or disorder or complete eradication of the disease or disorder, e.g., Marfan syndrome.
- The term “subject” is intended to include organisms, e.g., prokaryotes and eukaryotes, which are capable of suffering from or afflicted with Marfan syndrome, or a disease, disorder or condition related thereto. Examples of subjects include mammals, e.g., humans, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals. In certain embodiments, the subject is a human, e.g., a human suffering from, at risk of suffering from, or potentially capable of suffering from a Marfan syndrome, or a disease, disorder or condition related thereto.
- The agents and pharmaceutical compositions of the disclosure can be administered to a subject to treat or prevent diseases, disorders and conditions associated with aberrant expression or activity of a MAP kinase pathway component, e.g., MMP7, MAP2K6 and/or MAP3K4, or a gene product thereof. In one embodiment, the agents and pharmaceutical compositions are used to treat or prevent Marfan syndrome or diseases or disorders associated with Marfan syndrome.
- In one embodiment, the agents or pharmaceutical compositions are administered in an effective amount using a dosing schedule determined by a medical provider to treat or prevent a disease or disorder set forth herein. The agents or pharmaceutical compositions can be administered in a variety of methods, as described herein and known to one of skill in the art.
- In one aspect, the disclosure provides a method for preventing in a subject, a disease or condition associated with an aberrant expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, by administering to the subject an agent which modulates expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof. Subjects at risk for a disease which is caused or contributed to by aberrant expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the aberrancy of expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, such that a disease or disorder is prevented or, alternatively, delayed in its progression.
- Another aspect of the disclosure pertains to methods of modulating expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the disclosure involves contacting a cell with an agent that modulates one or more of the activities of a component of a MAP kinase signaling pathway, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof. An agent that modulates expression or activity of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof can be an agent as described herein, such as a nucleic acid, a polypeptide, or a small molecule. In one embodiment, the agent inhibits one or more activities of a MAP kinase pathway component, e.g., MMP17, MAP2K6 and/or MAP3K4, or a gene product thereof, and/or inhibits one or more components of the MAP kinase pathway. Examples of such inhibitory agents include antisense MMP17, MAP2K6 and/or MAP3K4 nucleic acid molecules, anti-Mmp17, -Map2k6 and/or -Map3k4 antibodies, and small molecule inhibitors of Mmp17, Map2k6 and/or Map3k4. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the present disclosure provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant MAP kinase pathway signaling, e.g., Marfan syndrome or an associated disease or disorder. In one embodiment, the method involves administering an agent, or combination of agents that modulates MAP kinase pathway signaling.
- The disclosure further provides kits comprising agents or pharmaceutical compositions of the disclosure and instructions for use. In one embodiment, the kits of the disclosure are for the treatment of diseases and disorders characterized by aberrant MAP kinase pathway signaling. In a related embodiment, the MAP kinase pathway signaling associated disease or disorder is Marfan syndrome or a disease or disorder related to Marfan syndrome.
- It should be appreciated that the invention should not be construed to be limited to the examples that are now described; rather, the invention should be construed to include any and all applications provided herein and all equivalent variations within the skill of the ordinary artisan.
- It has been shown that the C57BL/6 and Sv129 mouse backgrounds exhibit strain-specific modulatory effects on TGFβ deficiency phenotypes, and this may relate to their influence on downstream TGFβ signaling (Bourdeau, et al. American Journal Pathology 158, 2011; Warshamhabashiana et al. Am J Resp Cell Mol Biol 27, 705). With this in mind, it was examined whether the Sv129 background could exacerbate a MFS mouse model phenotype. MFS model mice from a pure C57BL/6J (hereafter termed BL6) background were backcrossed for greater than 10 generations onto a 129S6/SvEvTac (hereafter termed 129) background.
- 129 MFS mice exhibited a highly significant increase in aortic root size, post-natal aortic root growth and premature lethality from dissection, compared with BL6 MFS counterparts, in association with increased activation of both Smad2/3 and Erk1/2 cascades. All aortic parameters in 129 MFS mice were fully rescued by both losartan and RDEA119. 129/MFS mice also showed worse lung emphysema and spine kyphosis, with significant correlation between aortic root size and these phenotypes, indicating deleterious systemic genetic modification in 129 MFS mice. Wild type (WT) mice on the two background strains showed no difference in any parameter, indicating MFS disease-specific modification.
- To map potential modifier loci, a large seven generational pedigree of intercrossed BL6 MFS and 129 MFS mice was generated. The resulting offspring were then classified as either BL6-like, 129-like or indeterminate, based on aortic size and shape at 6 months of age. Genome mapping of forty BL6-like and forty 129-like MFS mice revealed 2 QTLs on
chromosomes - Causative genetic variation was searched for in these QTL regions using the mouse genome project, and one likely causal variant was identified in each locus, that was predicted to be both functionally deleterious and mechanistically linked to Mapk signaling. On
chromosome 5, a missense point mutation in Mmp17 (rs29636438; p.X579W) was predicted to alter the C-terminal region, modify attachment of the GPI anchor, and affect its cell surface expression, causing greater activation of Mapk signaling in 129 MFS mice. Onchromosome 11, a missense point mutation in Map2k6 (rs51129320; p.G76E) was predicted to cause greater activation of Mapk signaling in 129 MFS mice. Haploinsufficiency for Map2k6 and Mmp17 rescued aortic root growth in 129 MFS mice by approximately 50%, while knockout of these two genes reduced aortic root growth in 129 MFS mice to a rate indistinguishable from that of their BL6 MFS counterparts. - Genetic modifiers of disease progression in MFS patients were then investigated. Five exceptional families were identified to possess defined and typical FBN1 mutations, that showed discrete intrafamilial variation in the penetrance of vascular disease. Genome-wide linkage in these five families identified a major modifier locus for vascular disease in MFS, encompassing a 5.5 Mb linkage interval on chromosome 6 (LOD=4.0). While the protective haplotype varied between families, all patients with mild disease (20/20) shared a 3.9 Mb familial haplotype that was only observed in 2/18 severely affected family members (p<0.0001). Interestingly, this region includes MAP3K4, which lies directly upstream of MAP2K6 in the Mapk signaling cascade. Furthermore, haploinsufficiency for Map3k4 led to a full rescue of aortic root growth in MFS mice, to a rate indistinguishable from that of WT littermates.
- Thus, a common pathway of genetic modification in MFS has herein been identified, which provides a rationale for exploration of therapies that target genes of this pathway/these pathways, particularly including MMP17, MAP2K6 and MAP3K4. Given that a number of MFS-related conditions also appear to be driven by increased TGFβ signaling (Gallo et al. J Clin. Investigation 124, 448; Doyle et al. Nature Genetics 44, 1249; Lindsay et al., Nature Genetics 44, 922), these pathways are likely also to hold broader clinical relevance. While losartan has been previously described as providing some degree of rescue of aortic root growth in patients with MFS (Lacro, et al., New England Journal of Medicine 371, 2061), there is still significant room for additional pharmacological interventions that can ameliorate the potentially devastating cardiovascular, skeletal and ocular consequences of the disease. Whilst surgical intervention exists for many complications, these often involve major procedures that have significant morbidity and/or mortality associated with them. Furthermore, they often require ongoing additional treatment (e.g., lifelong use of anticoagulation after aortic root replacement) which too possess risk for significant complications. The instant disclosure therefore seeks to provide a MFS therapy possessing the ability to prevent these deleterious outcomes from ever occurring, thereby negating the need for major surgical intervention.
- Mice: All mice were cared for under strict compliance with the Animal Care and Use Committee of the Johns Hopkins University School of Medicine. The Fbn1C1039G/+ line was initially maintained in a pure C57BL/6 background (backcrossed for greater than 9 generations), allowing for valid comparisons, prior to backcrosses with Sv29 mice, performed as described above. In order to further accommodate the potential for temporal- or background-specified variation, all comparisons were made between contemporary littermates when possible. Mice were sacrificed with an inhalation overdose of halothane (Sigma-Aldrich, St. Louis). Mice underwent immediate laparotomy, descending abdominal aortic transection, and PBS (pH 7.4) was infused through the right and left ventricles to flush out the blood. Mice that were analyzed for aortic histology had latex injected under low pressure into the left ventricular apex until it was visible in the descending abdominal aorta. Mice were fixed for 24 hours in 10% buffered formalin, after which the heart, aorta and lungs were removed and stored in 70% ethanol.
- Echocardiography: Nair hair removal cream was used on all mice the day prior to echocardiograms. All echocardiograms were performed on awake, unsedated mice using the Visualsonics Vevo 660 V1.3.6 imaging system and a 30 MHz transducer. Mice were imaged at baseline, and at six months, when also sacrificed. The aorta was imaged using a parasternal long axis view. Three separate measurements of the maximal internal dimension at the sinus of Valsalva and proximal ascending aorta were made from distinct captured images and averaged. All imaging and measurements were performed by a cardiologist who was blinded to genotype.
- Histological and Morphometric Analysis: Latex-infused ascending aortas were transected just above the level of the aortic valve, and 2-3 mm transverse sections were mounted in 4% agar prior to paraffin fixation. Five micrometer aortic sections underwent Verhoeff-van Giesen (VVG) staining and were imaged at 40× magnification, using a Nikon Eclipse E400 microscope. Wall thickness of the aortic media was measured by a single blinded observer at 16 different locations around the most proximal ascending aortic ring and averaged. Wall architecture of 4 representative sections for each mouse was assessed by the same 3 blinded observers and graded on an arbitrary scale of 1 (indicating no breaks in the elastic fiber) to 5 (indicating diffuse fragmentation), and the results were averaged. Elastic fiber content was quantified in four separate representative images of each section of the most proximal ascending aorta by a single blinded observer, using NIS Elements Advanced Research (Nikon, Japan). The aortic media and the elastic fibers were individually outlined and their areas calculated. The respective areas were averaged from all the images of a given aortic section and the ratio of elastic fiber content to total aortic media was determined. Aortic root size was measured by echocardiography at six months (baseline before treatment).
- Marfan syndrome (MFS) is an inherited connective tissue disorder caused by heterozygous mutations in the FBN1 gene. The major cause of mortality is aortic aneurysm, dissection and/or rupture.
- Materials and Methods
- Mouse lines: Mice were cared for under compliance with the Animal Care and Use Committee of the Johns Hopkins University School of Medicine. Fbn1C1039G/+ mice on a pure C57BL/6J background were already onsite. Mice on a pure 12956/SvEvTac background were obtained from Taconic Biosciences (Rensselaer County, NY, USA). The Fbn1C1039G/+ mice on a pure C57BL/6J background were bred into a pure 12956/SvEvTac background and backcrossed for >10 generations. Mice haploinsufficient or knockout for Mmp17 (B6.129P2-Mmp17tm1Dgen/J; #005824), Map2k6 (B6.12951-Map2k6tm1Flv/J; #008382) and Map3k4 (B6.129S6-Map3k4tm1Flv/J; #008375) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA), and bred to Fbn1C1039G/+ mice. Animals were checked daily for death and all mice found dead were immediately autopsied to assess for evidence of aortic dissection. Mice that were sacrificed were done so using a lethal dose of ketamine and acepromazine (1 ml of 10 mg/ml acepromazine in 10 mls of 100 mg/ml ketamine; MWI Vet, ID, USA). At the time of sacrifice, mice underwent immediate laparotomy and descending abdominal aortic transection. Phosphate buffered saline (PBS) was infused through the right and left ventricles to flush out the blood.
- Mouse drug treatments: Losartan was dissolved in drinking water and filtered to reach a concentration of 0.6 g/L, giving an estimated daily dose of 60 mg/kg/day, as described previously (Habashi, J. P. et al. Science 312, 117-21 (2006)). Mice were started on losartan at 2 months of age and continued for 8 months. Placebo-treated animals received regular drinking water. RDEA119 was reconstituted in 10% 2-hydroxypropyl-beta-cyclodextrin (Sigma-Aldrich, MO, USA) dissolved in PBS, and administered twice daily by oral gavage at a dose of 25 mg/kg, as described previously (Holm, T. M. et al.
Science 15, 358-61 (2011)). Treatment was initiated at 2 months of age and continued for 2 months. 10% 2-hydroxypropyl-beta-cyclodextrin dissolved in PBS was administered as a control. Erlotinib was reconstituted in 1% methylcellulose (Sigma-Aldrich) dissolved in PBS, and administered daily by oral gavage at a dose of 50 mg/kg. Treatment was initiated at 2 months of age and continued for 2 months. 1% methylcellulose dissolved in PBS was administered as a control. - Mouse echocardiography: Nair hair removal cream was used on all mice the day prior to echocardiography. All echocardiograms were performed on awake, unsedated mice using the VisualSonics Vevo 2100 imaging system and a 30 MHz transducer (Fujifilm VisualSonics, ON, Canada). The aorta was imaged using a parasternal, long-axis view. Three separate measurements of the maximal internal dimension at the sinus of Valsalva and proximal ascending aorta were made from distinct captured images and averaged. All imaging and measurements were performed blinded to genotype and treatment arm.
- Mouse blood pressure analysis: Blood pressures were analyzed by taking 20 tail cuff blood pressures per day over 5 days in each mouse to habituate the mice to the tail cuff blood pressure system (BP-2000, Visitech Systems, USA), and the blood pressures obtained on the last day were averaged.
- Mouse aorta Western Blot analysis: Mice that were sacrificed for Western Blot analysis had their proximal ascending aortas immediately dissected, flash frozen in liquid nitrogen and stored at −80° C. until further processing. Protein was extracted using the reagents and protocol from a Total Protein Extraction Kit containing protease inhibitor and Protein Phosphatase Inhibitor Cocktail (Millipore, MA, USA). Aortas were homogenized using a pellet pestle motor (Kimble-Kontes, NJ, USA) as per the extraction kit protocol. Samples were then stored once more at −80° C. until Western blot analysis was performed. Aortic tissue homogenates were dissolved in sample buffer, run on a NuPAGE Novex 4-12% Bis-Tris Gel (Invitrogen, CA, USA), and transferred to nitrocellulose membranes using the iBlot transfer system (Invitrogen). Membranes were washed in PBS and blocked for 1 hour at room temperature with 5% instant non-fat dry milk dissolved in PBS containing 1% Tween-20 (Sigma-Aldrich; PBS-T). Equal protein loading of samples was determined by a protein assay (Bio-Rad, CA, USA) and confirmed by probing with an antibody against R-Actin (Sigma-Aldrich #A5316). Membranes were probed overnight at 4° centigrade with primary antibodies against pSmad2 (Cell Signaling, MA, USA #3108), pSmad3 (Cell Signaling #9250), pErk1/2 (Cell Signaling #4370), pMek1 (Cell Signaling #9154), pp38 (Cell Signaling #4511), pJnk1/2 (Santa Cruz #6254), pPkcβ (Cell Signaling #9371), and pEgfr (Cell Signaling #3777), dissolved in PBS-T containing 5% milk. Blots were then washed in PBS-T and probed with HRP-conjugated anti-rabbit or anti-mouse secondary antibodies (GE Healthcare, UK #NA934) dissolved in PBS-T containing 5% milk for 1 hour at room temperature. Blots were then washed in PBS-T, developed using SuperSignal West Femto HRP substrate (Pierce Scientific, IL, USA), exposed to BioMax Scientific Imaging Film (Sigma), and quantified using ImageJ analysis software (NIH, MD, USA).
- Mouse lung tissue collection and analysis: Mice that were sacrificed for lung histology had their trachea intubated with a 20-gauge blunt needle; 0.5% agar was infused under low and constant pressure using direct manometry to inflate the lungs. The trachea was then tied-off using an 8-0 Vicryl suture and the needle was removed. Samples were fixed for 24 hours in 10% buffered formalin and then stored in 70% ethanol. Individual lobes of the lungs were mounted in 4% agar and fixed in paraffin. Five micrometer lung sections underwent hematoxylin and eosin staining and were imaged at 10× magnification, using a Nikon Eclipse E400 microscope. Five fields were analyzed for each lobe of each lung by a single blinded observer, and a mean linear intercept was calculated as described previously (Neptune, E. R. et al. Nature Genetics 33, 407-11 (2003)).
- Mouse skeletal X-ray analysis: Mice undergoing spine X-ray were anesthetized using a combination of ketamine and xylazine (1 ml of 100 mg/ml ketamine and 100 μl of 100 mg/ml xylazine in 10 mls of PBS; MWI Vet). They were placed in the left lateral decubitus position on a radiolucent platform with adjacent scale bar and imaged at 1× magnification using a Faxitron MX20 (Faxitron, AZ, USA). The output electronic file was processed using ImageJ analysis software (NIH). Spine kyphosis was quantified using a modified kyphosis index (Laws, N., Hoey, A. J. Appl. Physiol. 97, 1970-7 (1985)). In brief, a line was drawn from the anterior superior iliac spine to the point of maximal lordosis of the cervical spine. A line was then drawn perpendicular from this line to the anterior aspect of the vertebral body at the point of maximal thoracic kyphosis.
- Mouse whole genome analysis: SNPs were selected from the Illumina mouse medium density linkage panel array that were divergent between the C57BL/6J and 12956/SvEvTac background strains. Genotyping was performed using an Illumina mouse medium density linkage panel, and was run using standard GoldenGate chemistry on an iScan microarray scanner (Illumina, CA, USA). Genotypes were called using Illumina GenomeStudio software (GenomeStudio 2011.1, Genotyping Module 1.9.4 and Gentrain version 1.0). The average physical coverage was 2.9 Mb, the maximum gap was 22.4 Mb and there were 10 gaps >12 Mb. The genotype quality score cut-off for a “no call” genotype was 0.25. Only SNPs of sufficient quality were used for downstream analysis. R/qtl software (rqtl.org; Broman K. W., Sen Ś. (2009) Introduction. In: A Guide to QTL Mapping with R/qtl. Statistics for Biology and Health. Springer, New York, NY) was utilized to calculate LOD scores for the whole-genome SNP analysis. All of the animals for which there was both genotype and phenotype data were included in the analysis; mice were only included if they were either BL6 or 129 throughout the whole ROI on a given chromosome. First, the “scanone” function was used to perform a single-QTL genome scan utilizing a nonparametric model and 1000 permutations. The results were expressed as a LOD score and p-value. The “scanone” function calculated the genome-wide LOD significance threshold for this dataset as 3.82. Next, the “scantwo” function was used to perform a two-dimensional genome scan with a two-QTL model utilizing a binary model. The recommended significance threshold for a mouse intercross using this function was a MfLOD >9.1. Since the “scantwo” function does not compute a p-value, we performed ANOVA plus a post-hoc linear trend test of the raw continuous data to generate a p-value for the 129 allele dose-response graph.
- Families with Marfan syndrome: The 5 families were recruited from the Connective Tissue Clinic at Johns Hopkins Hospital and Ghent University Hospital. The diagnosis of MFS was made in accordance with the revised Ghent nosology (Loeys, B. L., et al. Revised Ghent criteria for the diagnosis of Marfan syndrome (MFS) and related conditions. J. Med. Genet. 47, 476-485 (2010)). Echocardiograms were performed and interpreted as previously described (Brooke B. S., et al. N. Engl. J. Med. 358, 2787-95 (2008)). Aortic root aneurysm was defined by a maximal aortic root Z score >2.0. All blood samples and skin biopsies were collected in compliance with the Institutional Review Board after informed consent was obtained. DNA was extracted from 5 mL whole blood using a DNeasy blood and tissue kit (Qiagen, CA, USA). For the purposes of genome wide linkage analysis, individuals harboring an FBN1 mutation were classified as affected; they were assigned a severe status if they had an aortic root Z score >3.0, a history of aortic root dissection or a history of aortic root surgery; they were assigned a mild status if they had an aortic root Z-score <2.0 or had reached
age 60 years without prior aortic root dissection or aortic root surgery; those with a Z score 2.0-3.0 were classed as indeterminate. Individuals without an FBN1 mutation were classified as unaffected. - Human whole genome analysis: The DNA was digested, amplified, and hybridized to either a Genome-Wide Human SNP Nsp/Sty Array 5.0 or 6.0 according to the manufacturer's recommended protocol (Affymetrix, CA, USA). The arrays were then scanned using a GeneChip Scanner 3000 7G (Affymetrix). The genomic location of each marker was determined from the Affymetrix Genetic Map (Affymetrix). SNPs were selected that were present on both the Affymetrix 5.0 and 6.0 Array using PLINK. Allele frequencies for this SNP set were calculated using PLINK. Tests for Hardy-Weinberg equilibrium (HWE) and Mendelian errors were calculated for autosomal SNPs using Pedstats. Tests for HWE were calculated for sex chromosome SNPs using PLINK, and Mendelian errors using Pedstats. Subsequently, the following quality control filters were applied using PLINK; <1% missing data, minor allele frequency (MAF) >0.2, no Mendelian errors and HWE p>0.05. Statistically unlikely genotypes were then filtered using the error-checking algorithm in MERLIN/MinX. As a last step, SNPs that were in complete linkage disequilibrium with a proximate SNP (r2=1) were excluded using PLINK to produce a list of SNPs of outstanding quality. Prior to genome wide linkage analysis, the dataset was simplified whilst maintaining uniform coverage across the genome by only including every 10th consecutive SNP. Parametric linkage analysis was performed following the maximized maximum LOD score (MMLS) procedure with the restricted set of SNPs using MERLIN/MinX. The analysis was performed twice, once under a dominant model and once under a recessive model, considering a low sporadic rate (0.0002), an arbitrary penetrance (0.50 and 0.80 for one and two alleles respectively), and arbitrary gene frequencies (0.01 for the dominant model and 0.1 for the recessive model). The limits of the regions of interest were defined by the closest neighboring upstream and downstream SNP markers with LOD scores >1 levels below the peak identified by parametric linkage analysis. Haplotypes were established for all genotyped individuals across the regions of interest. Since the mode of inheritance and the penetrance of the modifier region were uncertain, the segregation of haplotypes between individuals classified as affected with mild disease was examined first. Next individuals classified as affected with severe disease were incorporated into this analysis. The NCBI mapviewer (cbi.nlm.nih.gov/projects/mapview; Wolfsberg, T. G. 2010. Using the NCBI Map Viewer to Browse Genomic Sequence Data. Current Protocols in Bioinformatics. 29:1.5:1.5.1-1.5.25.) was used to identify candidate genes contained within haplotypes of interest.
- Human DNA sequencing analysis: Candidate genes were cycle sequenced across all exons, exon/intron boundaries and potential non-coding functional variants from the ENCODE dataset (defined as SNPs in regions associated with DNase hypersensitivity, transcription factor occupancy, histone modification and a MAF <0.15) in 2 individuals with mild disease and 2 individuals with severe disease from each family. Firstly, targeted segments of DNA were amplified by PCR using a DNA Engine Dyad thermal cycler (Bio-Rad). Next, the samples were purified using QIAquick PCR purification kit (Qiagen). Finally, cycle sequencing was performed using BigDye Terminator v3.1 kit and an ABI 3730xl DNA Analyzer/sequencing machine in accordance with the manufacturer's instructions (Life Technologies, CA, USA).
- Human dermal fibroblast quantitative RT-PCR expression analysis: Primary human dermal fibroblasts were derived from forearm skin biopsies from 2 control individuals, 2 patients in family B with severe aortic disease and 2 patients from family B with mild aortic disease. Cells were incubated in T-75 flasks at 37° C. with 95% air and 5% CO2 whilst submerged in Dulbecco's modified eagle medium (Gibco, Life Technologies) containing 10% fetal bovine serum (Sigma-Aldrich), antibiotics and antimycotic (Gibco). Media was replaced every 3 days. Cells were passaged at 95-100% confluence. Cells were collected using TRIzol (Life Technologies) and immediately stored at −80° C. RNA was extracted using a miRNeasy mini kit according to the manufacturer's instructions (Qiagen). Quantitative RT-PCR was performed using a RNA-to-CT 1-step Kit and an ABI 7900HT Fast Real-Time PCR System in accordance with the manufacturer's instructions (Life Technologies). The following pre-validated probes were used for analysis: Hs01060665 (β-ACTIN) and Hs00245958_m1 (MAP3K4) (Life Technologies).
- Statistical analysis: All quantitative data are shown as bar graphs produced using Excel (Microsoft, WA, USA).
Mean± 2 standard errors of the mean (SEM) are displayed. Statistical analyses were performed using two-tailed t tests. A p-value <0.05 was considered statistically significant for all tests. - Results
- Mice were characterized as heterozygous for a disease-causing Fbn1 allele (Fbn1C1039G/+) on a pure C57BL/6J mouse background (hereafter termed BL6 MFS mice). These mice have been shown to recapitulate multiple manifestations of the disease, including aortic root aneurysm, developmental lung emphysema, and skeletal deformity (Neptune, E. R. et al. Nature Genetics 33, 407-11 (2003); Habashi, J. P. et al. Science 312, 117-21 (2006); Judge, D. P. et al. J. Clin. Invest. 114, 172-81 (2004)), although the severity of the manifestations is on the milder end of the human phenotypic spectrum. In the present study, these Fbn1C1039G/+ mice were backcrossed greater than 10 generations onto a 129S6/SvEvTac background (hereafter termed 129 MFS mice), to assess the impact of mouse strain on MFS disease phenotype. Aortic root size at 2 and 6 months of age, and post-natal aortic root growth from 2 to 6 months, were greater in 129 MFS mice, compared to their BL6 MFS counterparts (
FIGS. 1A, 1B yellow arrows). This strain-dependent modification of aortic size was absent in wild-type (WT) littermates, showing it to be a MFS disease-specific effect. Furthermore, the 129 strain did not exacerbate growth of the more distal ascending aorta in MFS mice (FIGS. 5, 1B red arrows), indicating that this strain-specific exacerbation only occurs at sites of underlying disease predisposition, as opposed to a more generalized loss of arterial homeostasis. - Compared to BL6 MFS mice, 129 MFS animals died prematurely secondary to aortic dissection and/or rupture (
FIG. 1C ). This was independent of hemodynamic status, weight or gender (FIGS. 6, 7 ). Compared to BL6 MFS animals, 129 MFS mice also had worse lung disease as measured by mean linear intercept (MLI;FIG. 8 ; Neptune, E. R. et al. Nature Genetics 33, 407-11 (2003)), and worse spine kyphosis as measured by a modified kyphosis index (KI;FIG. 9 ; Laws, N., Hoey, A. J Appl. Physiol. 97, 1970-7 (1985)). Of note, in 129 MFS mice there was an individual correlation between aortic root size and both lung MLI (r2=0.75, p=0.012) and spine KI (r2=0.30, p=0.013). - To assess the mechanism driving disease exacerbation, Western blot analysis was performed on the aortic root of 10-month old animals. Compared to BL6 MFS mice, 129 MFS animals showed greatly enhanced activation of pathways previously shown to be operative in MFS mice, including Smad2/3, Erk1/2 and its upstream activator Mek1, p38, and PKCI3 (
FIG. 2A ). Jnk1/2 activation remained unaffected, suggesting selective, rather than global modulation of MAPK signaling. There were no differences in activation of any of these pathways in WT animals on the two backgrounds, indicating MFS disease-specific modification. Treatment of 129 MFS mice with either the ARB losartan or the inhibitor of Erk1/2 activation RDEA119, reduced aortic root growth to a rate equal to that of WT animals (FIG. 2B ). Furthermore, losartan ameliorated premature lethality in 129 MFS mice (FIG. 2C ). This correlated with a reduction in both canonical (Smad2) and noncanonical (Erk1/2, p38) TGFI3 signaling cascades in losartan-treated 129 MFS mice (FIG. 2D ), and a selective reduction in noncanonical (Erk1/2, p38) cascades in RDEA119-treated 129 MFS animals (FIG. 2E ). Taken together, these data illustrate that the 129 strain exacerbates signaling cascades known to be upregulated in BL6 MFS mice, and therapies targeting these pathways are highly efficacious even against the more severe disease seen in 129 MFS animals. - To identify modifier loci for the MFS aortic phenotype, MFS mice were interbred on the 2 pure strains to generate MFS animals on a mixed genetic background. The F1 generation MFS mice displayed an aortic root size that was intermediate between the 2 parental strains (
FIG. 10 ). Mice from the F1 and later generations were interbred to produce a 7-generation pedigree that contained circa 300 MFS mice possessing a range of aortic aneurysm severity. Genome-wide linkage analysis was performed on 35 MFS mice with mild aortic aneurysm (root size <2.20 mm at 6 months), and 40 MFS mice with severe aortic aneurysm (root size >2.70 mm at 6 months). Two loci were identified that strongly linked with aortic severity onchromosomes FIG. 3A ), with evidence of epistasis between the loci (MfLOD=12.8). The regions of interest (ROI) were defined as those flanked by individual markers that surpassed genome wide significance; these included 14.7 Mb on chromosome 5 (128,433,315-143,149,098 bp) and 8.9 Mb on chromosome 11 (106,799,515-115,722,120 bp). When 129 allele dose at these ROI was plotted against aortic root size at 6 months of age in the F2 generation interbred mice, there was a clear dose-response, with more 129 alleles (0 to 4) correlating with increased aortic size (p=0.0006;FIG. 3B ). - Table 6 shows candidate functional variants that differed between the BL6 and 129 strains within the regions of interest on
chromosomes -
TABLE 6 Chr Gene Residue Score Prediction 5 Mmp17 p.X579W 9aa deletion Stop- Loss 5 Tfr2 p.G42V −3 Disfavored 5 Zkscan p.R246W −3 Disfavored 5 Fzd10 p.S389R −1 Disfavored 5 Rimbp2 p.D1062H −1 Disfavored 11 Map2k6 p.G76E −2 Disfavored 11 Bptf p.R2360C −3 Disfavored 11 Helz p.L1498P −3 Disfavored 11 Sdk2 p.L1501P −3 Disfavored 11 Ccdc46 p.E507G −2 Disfavored 11 Grin2c p.P1098H −2 Disfavored 11 Slc9a3r1 p.P182S −1 Disfavored 11 Grin2c p.P970L −1 Disfavored - Candidate functional variants were sort within both loci that differed between the 2 strains using the mouse genome project online repository (Table 6). Only 1 variant at each locus was predicted to be both functional and located in a gene likely to influence TGF3/MAPK signaling. On
chromosome 11, a missense point mutation was identified in Map2k6, a known member of the MAPK signaling cascade, which was predicted to significantly alter protein function (rs51129320; n.11:110490856-110490856G>A; c. G227A; p.G76F; PROVEAN score −3.66). Onchromosome 5, the BL6 strain encodes a premature termination codon in Mmp17 relative to the 129 strain (rs29636438; n.5:129606538-129606538 G>A; c. A1737G; p.X579W), which creates a truncated protein that is missing theterminal 9 amino acids (FIG. 11 ). This hydrophobic sequence at the C-terminus is critical to the protein's ability to anchor to the extracellular side of the cell membrane via a GPI anchor. Loss of theterminal 9 amino acids in BL6 mice was predicted to significantly alter the hydrophobicity profile of the C-terminal segment, reducing the efficiency of GPI attachment and decreasing the amount of functional protein at the cell surface compared to the 129 strain (Galian C., et al. J. Biol. Chem. 287, 16399-409 (2012); Yan W., et al. J. Mol. Biol. 275, 25-33 (1998)). Given that both Map2k6 and Mmp17 are expressed in the vasculature and are reported to be positive effectors of TGF3/MAPK signaling (Paye, A., et al. Cancer Res. 74, 6758-70 (2014); Han, J., et al. J. Biol. Chem. 271, 2886-91 (1996)), it was hypothesized that both variants would likely induce a loss of function on the BL6 background. - Mmp17 and Map2k6 knockout mice (Mmp17′ and Map2k6−/−) were obtained from Jackson laboratories on a mixed BL6/129 background. These were crossed to 129 MFS mice to generate MFS animals with predominant but variable 129 strain content that were haploinsufficient or fully deficient for one or both genes. Mice deficient in both genes were born at expected Mendelian ratios and survived to adulthood without apparent deleterious consequence. MFS mice possessing the 129 sequence at the two genes of interest fully recapitulated both the aortic root size and biochemical signaling seen in pure 129 MFS mice (
FIGS. 3C, 3D ). Furthermore, aortic root size at 6 months was dependent on the number of functional Mmp17 and Map2k6 alleles, with MFS mice lacking both genes having an aortic size that was indistinguishable from that of pure BL6 MFS animals (FIG. 3C ). Western blot analysis of the aortic root in 10-month old MFS mice showed that knockout of both Mmp17 and Map2k6 led to attenuation of canonical and noncanonical signaling cascades to values at or below those of BL6 MFS mice (FIG. 3D ). Selective knockout of Mmp17 led to an intermediate suppression of these signaling cascades, indicating that the two genes act in an additive manner. - Consistent with prior work showing that Mmp17 can potentiate MAPK signaling by enhancing EGFR activation independent of catalytic activity (Galian C., et al. J. Biol. Chem. 287, 16399-409 (2012)), it was found that increased Egfr phosphorylation in the aortic root of 129 MFS mice relative to BL6 MFS animals, which was fully normalized by Mmp17 knockout, was independent of Map2k6 status (
FIG. 3E ). Furthermore, treatment with the EGFR inhibitor erlotinib abrogated aortic root growth in 129 MFS mice (FIG. 3F ), in association with reduced activation of Egfr, Erk1/2, and p38 (FIG. 3G ). Hence EGFR inhibition may represent a novel, clinically-available, therapeutic strategy that can help ameliorate aortic growth in MFS. - In parallel, 5 MFS families were recruited that showed discrete intrafamilial variation in the severity of vascular disease among age- and gender-matched FBN1 mutation carriers (
FIG. 4A ). Parametric linkage analysis was performed to identify variation conferring a mild aortic disease phenotype. This revealed a single locus harboring protective genetic variation onchromosome 6 that exceeded the genome-wide significance LOD score of 4.0 (FIG. 4B ). While there was no common haplotype across families, all 5 families showed a positive LOD score in this region, with all 20 individuals classified as having mild disease sharing a 3.9 Mb familial haplotype between markers rs676017 and rs6455736. The association between the presence of the protective haplotype and disease status (mildaortic disease 20/20; severeaortic disease 1/18) was statistically significant (p<0.0001). Of the 32 genes in this region, MAP3K4 represented the outstanding candidate, based upon the fact that it lies directly upstream and is a direct activator of MAP2K6, one of the two modifier genes identified in MFS mice. - While direct sequencing of all exons, exon/intron boundaries and potential non-coding functional variants from the ENCODE dataset in the 5 MFS pedigrees did not yield a candidate variant in MAP3K4, we did observe a significant reduction in MAP3K4 expression in dermal fibroblasts of patients with mild disease compared to those with severe disease (
FIG. 4D ). Next, MFS mice to mice haploinsufficient for Map3k4 (Map3k4) were bred to test for genetic interaction. Aortic root growth from 2 to 6 months was reduced in MFS mice haploinsufficient for Map3k4, compared to MFS littermates that retained both alleles (FIG. 4D ). Western blot analysis of the aortas of 10-month old mice confirmed that Map3k4 levels were reduced in these animals, as was activation of both Erk1/2 and p38 (FIG. 4E ). - Taken together, this confluence of discovery-based and hypothesis-driven methodologies has informed disease pathogenesis in MFS and should provide confidence regarding the potential of therapeutic strategies directed against these novel target proteins. It demonstrates the power of harnessing nature's ability to generate phenotypic variability in pathological disease states through modifying genetic variation. It also highlights the utility of using mouse models to inform human disease modifier studies, since the latter can be limited by a paucity of families with discrete intrafamilial phenotypic variation, small pedigrees, allelic heterogeneity at the primary disease locus, and late onset declaration of phenotypic variation. Such issues can be mitigated by concomitant utilization of robust, validated animal models.
- A role for EGFR activation in MFS has not been recognized previously; whether this relates to a failed regulatory role of fibrillin-1, or represents a more indirect consequence of events in MFS pathogenesis remains to be determined. Such mechanisms could include EGFR transactivation via known modulators such as TGFβ (Uchiyama-Tanaka Y., et al. Kidney Int. 62, 799-808 (2002); Vinals F., Pouyssegur J. Mol. Cell Biol. 21, 7218-30 (2001)), and/or Ang-II (Mehta P. K., Griendling K. K. Am. J. Physiol. Cell Physiol. 292, C82-97 (2007); Higuchi S., et al. Clin. Sci. 112, 417-28 (2007)). Interestingly, Mmp2 and 9 are both activated in MFS mice in an Erk1/2-dependent manner (Xiong W., et al. Circ. Res. 110, e92-e101 (2012)), and can also mediate Ang-II-dependent Egfr transactivation and consequent Erk1/2 activation in vascular cells. Furthermore the Efgr inhibitor erlotinib can abrogate Ang-II infusion-mediated TGFI3 induction in vascular tissues, all of which suggests that deleterious feedforward loops involving TGFβ, Ang-II and Egfr could influence MFS disease pathogenesis.
- This work supports the observations that both Smad2/3 and Erk1/2 signaling cascades are activated in MFS mice, with a direct correlation between the extent of activation of these proteins and phenotypic severity. It also illustrates prominent activation of p38 in this MFS mouse model, recapitulating prior observations in fibrillin-1 null mice (Carta, L. et al. J. Biol. Chem. 27, 5630-6 (2009)); this may relate to a hypomorphic Map2k6 allele on the BL6 background previously preventing its robust activation. Interestingly, Ang-II mediated Egfr transactivation has been shown to drive dual Erk1/2 and p38 activation in VSMCs, in the absence of Jnk1/2 upregulation, a direct recapitulation of our findings. In contrast, prior work has suggested that Map3k4 modulates p38 and Jnk1/2 activation without affecting Erk1/2 (Yan W., et al. J Mol. Biol. 275, 25-33 (1998)).
- Finally, this work highlights a role for Mmp17 in the modulation of aortic disease in MFS mice. It may achieve this effect through modulation of Egfr, as the data herein evidences.
- The contents of all references, patents, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (14)
1. A method for treating a subject having or at risk of developing Marfan Syndrome or a Marfan-associated condition comprising:
administering to the subject an effective amount of an agent that modulates the activity of MAP kinase pathway signaling; thereby treating the subject.
2. The method of claim 1 , wherein the agent that modulates the activity of MAP kinase pathway signaling is an inhibitor of the MAP kinase pathway.
3. The method of claim 1 , wherein the agent that modulates the activity of MAP kinase pathway signaling is an inhibitor of MMP17, MAP2K6 or MAP3K4, or of a gene product thereof.
4-5. (canceled)
6. The method of claim 1 , wherein the agent that modulates the activity of MAP kinase pathway signaling is a small molecule.
7. The method of claim 1 , wherein the agent that modulates the activity of MAP kinase pathway signaling comprise Batimastat, GI 254023X, GM 6001, TMI 1, WAY 170523, WX-554 or combinations thereof.
8. (canceled)
9. The method of claim 1 , wherein the Marfan syndrome-associated disease or disorder is a clinical condition associated with Marfan syndrome.
10. The method of claim 9 , wherein the disease or disorder is an aneurysm, an aortic aneurysm, or emphysema.
11. The method of claim 9 , wherein the disease or disorder is an aneurysm.
12-39. (canceled)
40. The method of claim 1 , further comprising an inhibitor of transforming growth factor β (TGFβ).
41. (canceled)
42. The method of claim 3 , wherein the agent that modulates the activity of MAP kinase pathway signaling is a small molecule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/202,066 US20240025982A1 (en) | 2017-03-02 | 2023-05-25 | Map kinase pathway targets for the treatment of marfan syndrome |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762466197P | 2017-03-02 | 2017-03-02 | |
PCT/US2018/020692 WO2018160987A1 (en) | 2017-03-02 | 2018-03-02 | Map kinase pathway targets for the treatment of marfan syndrome |
US202016490546A | 2020-02-21 | 2020-02-21 | |
US18/202,066 US20240025982A1 (en) | 2017-03-02 | 2023-05-25 | Map kinase pathway targets for the treatment of marfan syndrome |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/490,546 Division US11692028B2 (en) | 2017-03-02 | 2018-03-02 | Map kinase pathway targets for the treatment of Marfan syndrome |
PCT/US2018/020692 Division WO2018160987A1 (en) | 2017-03-02 | 2018-03-02 | Map kinase pathway targets for the treatment of marfan syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240025982A1 true US20240025982A1 (en) | 2024-01-25 |
Family
ID=63371185
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/490,546 Active US11692028B2 (en) | 2017-03-02 | 2018-03-02 | Map kinase pathway targets for the treatment of Marfan syndrome |
US18/202,066 Pending US20240025982A1 (en) | 2017-03-02 | 2023-05-25 | Map kinase pathway targets for the treatment of marfan syndrome |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/490,546 Active US11692028B2 (en) | 2017-03-02 | 2018-03-02 | Map kinase pathway targets for the treatment of Marfan syndrome |
Country Status (2)
Country | Link |
---|---|
US (2) | US11692028B2 (en) |
WO (1) | WO2018160987A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020081741A2 (en) * | 2018-10-16 | 2020-04-23 | The Johns Hopkins University | Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders |
CN110029158B (en) * | 2019-02-01 | 2021-03-30 | 北京大学第三医院 | Marfan syndrome detection panel and application thereof |
WO2022051685A2 (en) * | 2020-09-04 | 2022-03-10 | The Johns Hopkins University | Treatment of vascular ehlers-danlos syndrome and related syndromes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4706193B2 (en) | 2004-05-27 | 2011-06-22 | 国立大学法人 長崎大学 | Use of probes, screening methods and kits for the analysis of Marfan syndrome |
US8597646B2 (en) | 2005-10-25 | 2013-12-03 | The Johns Hopkins University | Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders |
WO2013003360A1 (en) | 2011-06-29 | 2013-01-03 | Janssen Pharmaceutica Nv | Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases |
WO2014037316A1 (en) | 2012-09-07 | 2014-03-13 | Université de Liège | Combination treatment of cancer |
-
2018
- 2018-03-02 US US16/490,546 patent/US11692028B2/en active Active
- 2018-03-02 WO PCT/US2018/020692 patent/WO2018160987A1/en active Application Filing
-
2023
- 2023-05-25 US US18/202,066 patent/US20240025982A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018160987A1 (en) | 2018-09-07 |
US11692028B2 (en) | 2023-07-04 |
US20200247881A1 (en) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240025982A1 (en) | Map kinase pathway targets for the treatment of marfan syndrome | |
US10767178B2 (en) | Compositions and methods of using piRNAS in cancer diagnostics and therapeutics | |
JP6212107B2 (en) | Methods for treating hair loss disorders | |
US11512309B2 (en) | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors | |
CN104011208B (en) | MiRNA-212/132 family as therapeutic targets | |
EP3119406B1 (en) | Methods for improving cognitive function via modulation of quinone reductase 2 | |
US20210363527A1 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING MIR-324 and TUT4/7 EXPRESSION MODULATORS | |
US9187787B2 (en) | Method of diagnosing and treating cancer | |
EP3658157B1 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
JP2010507595A (en) | Inhibition of SOX9 function in the treatment of pathophysiological conditions associated with proteoglycans | |
US20140148498A1 (en) | Methods and compositions for the treatment of marfan syndrome and associated disorders | |
US20230383292A1 (en) | Targeting xist and rna methylation for x reactivation therapy | |
US9127273B2 (en) | UNC-45A splice variants based cancer diagnostics and therapeutics | |
EP2992112B1 (en) | Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis | |
US11845989B2 (en) | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors | |
WO2010050328A1 (en) | Tumor metastasis inhibitor | |
WO2012106404A2 (en) | Diagnosis and treatment of neurological disorders through vipr2 and vpac2r | |
RU2812912C2 (en) | Treatment of ophthalmological pathological conditions with angiopoetin-like protein 7 (angptl7) inhibitors | |
US11225661B2 (en) | Methods for controlling seizures by manipulating the levels of microRNA-211 (miR-211) in the brain | |
CN108752453B (en) | LEMD3 and application of mutation thereof in BAVM diagnosis and treatment | |
US20150104870A1 (en) | Neuronal differentiation promoter | |
US20210220471A1 (en) | Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer | |
US20190336579A1 (en) | Compositions and methods to induce targeted apoptosis by modulating protein tyrosine phosphatase 13 (ptpn13) | |
WO2024033467A2 (en) | Allele specific sirna therapy for dynamin 2-related diseases | |
WO2010013231A2 (en) | Modulation of coagulation factors and effectors of same for control of transplant organ size |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |